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1. Introduction 
1.1 Background 
 
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone 
marrow, leading to bone destruction and marrow failure. It accounts for approximately 1.8% of 
all hematologic and solid cancers and slightly > 15% of hematologic malignancies in the United 
States1. MM is most frequently diagnosed among people aged 65 to 74 years (median age 69 
years)2. During 2016, the American Cancer Society estimated that 30.330 new cancer cases 
occurred in USA, with 12.650 deaths1.  Over the past decade, statistical analysis show that the 
rates for new MM cases have been increasing an average of 0.8% each year2. However, these 
analysis also reveal that death rates have been declining an average of 0.8% each year (period 
2004-2013) thanks to the availability of newer and more effective treatment options2. MM is 
typically sensitive to different classes of cytotoxic drugs, both as frontline treatment and as 
treatment for relapsed disease. Unfortunately, even if responses are typically durable, nowadays 
MM is not considered curable with current approaches. However, treatment of MM has been 
rapidly evolving, due to the introduction of new classes of drugs, such as proteasome inhibitors, 
immunomodulatory drugs (IMIDs), histone deacetylase inhibitors and monoclonal antibodies 
and new indications for old classes of drugs, such as alkylating agents3-5. Moreover, there is 
increasing understanding of MM tumor biology, creating the rational for new combinations of 
drugs and new therapies development6,7. Discover of the associated cytogenetic abnormalities 
confirm the hypothesis that MM is a heterogeneous disease, suggesting that risk-adapted 
therapies and individualizing treatment will further help to improve patient management. 
Bendamustine is a molecule largely adopted in the past as effective chemotherapeutic agent in 
several types of hematological and non-hematological malignancies. Its unique mechanism of 
action, both as alkylating agent and antimetabolite, probably accounts for its wide efficacy 
profile also in the treatment of relapsing/refractory multiple myeloma. In this specific clinical 
setting, in which patients experience several therapy lines and have poor prognosis, 
bendamustine combined with bortezomib and dexamethasone, is emerging as an effective 
salvage therapy, also in the era of new drugs. In fact, despite the introduction of so-called novel 
agents, such as second generation proteasome inhibitors (carfilzomib) or third generation 
immunomodulatory drugs (pomalidomide), many trials have demonstrated that bendamustine in 
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combination with other agents is also a valid therapeutic option as these mentioned above. This 
retrospective, observational study aimed to evaluate, in a real-life setting, a cohort of heavily pre-
treated patients affected by relapsing/refractory multiple myeloma, whose salvage therapy 
consisted in courses of bendamustine-bortezomib-dexamethasone. Efficacy and safety data were 
evaluated, focusing especially on effectiveness of this regimen on previously bortezomib-
refractory patients and on its tolerability. Data on efficacy and safety of our real-life experience 
were highly comparable to those of major trials adopting the same regimen in the same clinical 
setting, demonstrating how it is a feasible salvage therapeutic option, in a context of poor 
treatment choices. Moreover, our data revealed how bendamustine addition could overcome a 
previous pharmacological refractoriness to bortezomib, leading to clinical response also those 
patients already treated with this proteasome inhibitor. 
 
1.2 Initial Diagnostic Workup 
 
Initial diagnostic workup in all patients should include detailed history and physical examination 
and baseline blood studies and biological assessments to differentiate symptomatic and 
asymptomatic MM: complete blood count with differential and platelet counts, evaluation of 
kidney function and serum electrolytes, lactate dehydrogenase (LDH), serum calcium, albumin, 
and beta-2 microglobulin. Increased creatinine levels and blood urea nitrogen levels indicate 
decreased kidney function, whereas increased LDH and beta-2 microglobulin levels reflect 
tumor cell burden. 
The monoclonal protein (M-protein) components in serum and urine are evaluated by the urine 
and serum analyses. Urine analysis as a part of the initial diagnostic workup should include 
evaluating urine protein electrophoresis, urine immunofixation electrophoresis and 24-hour urine 
for total protein. Serum analysis should include quantitative immunoglobulin levels (IgG, IgA, 
and IgM), serum protein electrophoresis, and serum immunofixation electrophoresis in order to 
obtain more specific information about the type of M-protein present. Evaluating changes and 
proportions of proteins, in particular the M-protein, helps track disease progression and response 
to treatments. Serum free light chain (FLC) assay along with serum protein electrophoresis and 
serum immunofixation electrophoresis yields high sensitivity while screening for MM and 
related plasma cell disorders8. Serum FLC assay also has prognostic value in plasma cell 
disorders, including monoclonal gammopathy of undetermined significance (MGUS), 
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smoldering myeloma, active myeloma, immunoglobulin light chain amyloidosis, and solitary 
plasmacytoma8,9. The serum FLC assay is also important for quantitative monitoring of patients 
with oligosecretory myeloma and light chain amyloidosis. In particular, the FLC ratio is 
mandatory for documenting stringent complete response (CR), according to the International 
Myeloma Working Group (IMWG) Uniform Response Criteria10. The FLC assay cannot replace 
the 24-hour urine protein electrophoresis for monitoring patients with measurable urinary M-
proteins. 
Most patients present serum M-protein with or without associated urinary M-protein. In the 
Mayo Clinic review of 1,027 MM newly diagnosed patients, 20% had secretory urinary M-
proteins; however, 3% had neither serum nor urine M-protein and therefore had nonsecretory 
myeloma11.Serum FLC assay is useful to monitor disease response and progression in a 
proportion of patients with nonsecretory myeloma. After the MM or M-protein is quantified, it is 
very important to use the same test for serial studies to ensure accurate relative quantification. At 
diagnosis, bone marrow aspiration and biopsy is recommended to evaluate bone marrow plasma 
cell infiltration and to detect quantitative and/or qualitative abnormalities of bone marrow 
plasma cells. To evaluate osteolysis (lytic bone lesions), full skeleton radiographic survey (Rx) 
or whole-body, low-dose CT is recommended, but also the importance of role of FDG PET/CT 
scan is increasing. 
Although MM may be morphologically similar, cytogenetic and molecular biology differences 
confirm that several subtypes of the disease can be identified. Bone marrow aspiration, 
performed at initial diagnosis, should include chromosome analysis by metaphase cytogenetics 
and FISH (fluorescence in situ hybridization) should be performed with the plasma cells 
obtained from the bone marrow aspiration. Specific chromosomal abnormalities have been 
identified in patients with MM involving translocations, deletions, or amplifications. 
In particular, deletion of 17p13 (the locus for the tumor-suppressor gene, p53) leads to loss of 
heterozygosity of TP53 and is considered a high-risk feature in MM12-14. Other high-risk 
chromosomal aberrations are characterized by structural changes that include specific 
rearrangements involving the IGH gene (encoding immunoglobulin heavy chain) located at 
14q32, whose alteration identifies several subgroups of patients. The MM main translocations 
are t(11;14) (q13;q32), t(4;14) (p16;q32), and t(14;16) (q32;q23). In particular, t(4;14) and 
t(14;16) have a poor prognosis, although t(11;14) seems to impart no increased risk15-17. Del13q 
is a common abnormality observed on FISH studies, but is can be considered a negative 
prognostic factor only when observed on metaphase cytogenetics. 
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Abnormalities of chromosome 1 are also among the frequent chromosomal alterations in MM18; 
the long arm is most often associated with amplifications while short arm is most often 
associated with deletions19. Gains/amplification of 1q21 increases the risk of progression of 
disease and amplification incidence is higher in relapsed patients than in newly diagnosed 
disease18,20. 
The important of patients’ stratification into various risk groups, based on chromosomal markers, 
is important for prognostic evaluation, selection, and sequencing of therapy approaches21,22. 
In addition to prognostic role of cytogenetic analysis, biological factors or gene expression 
signatures may help for discerning prognosis and rational therapeutic decisions23,24. In particular, 
the application of high-throughput genomic tools such as gene expression profiling (GEP) helps 
to understand the molecular subtypes of MM 25. Thanks to the novel agents for treatment 
approaches, a majority of patients can now anticipate long-term disease control. However, high-
risk disease patients do not receive the same benefit from certain approaches as low-risk patients 
and need alternative treatments. Gene expression profiling is a fast and powerful with the 
potential to provide additional prognostic value to improve risk stratification and to help 
therapeutic decisions. Recently,15-gene, 70-gene, and 92-gene models based on GEP signatures 
of MM cells have been identified and developed 26-28. It has been demonstrated that patients in 
the high-risk group based on the 15-gene26, 70-gene27, or 92-gene28 models had shorter survival 
compared with the low-risk group. GEP is not currently routinely used in clinical practice during 
diagnostic workup, even if it can be considered a useful tool and may be helpful in selected 
patients to estimate disease aggressiveness and individualize treatment. 
Bone marrow immunohistochemistry may be useful in some cases to confirm presence of 
monoclonal plasma cells and to more accurately quantify plasma cell involvement; bone marrow 
flow cytometry can help in certain situations. 
 
1.3 Additional Diagnostic Tests 
 
Active MM is positive on PET scan31,32. FDG PET/CT and MRI scans are more sensitive than 
total body Rx and are particularly indicated when symptomatic areas show no abnormality on 
routine radiographs. FDG PET/CT results after induction therapy and autologous stem cell 
transplant (Auto-SCT) help in predicting the prognosis of patients with symptomatic MM33,34. 
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To confirm the presence of plasmacytomas a tissue biopsy may also be necessary. Plasma cell 
proliferation assays may be helpful to identify the fraction of proliferating myeloma cell 
population35. Also, if amyloidosis is suspected, bone marrow and fat pad staining for the 
presence of amyloid should be considered and serum viscosity should be evaluated, particularly 
in those with high levels of M-protein. Considered that bisphosphonate therapy is a possibility in 
supportive care of patients with MM, a baseline bone densitometry test may be recommended. 
In selected MM patients, allogeneic stem cells transplantation (allo-SCT) may be considered. In 
this approach, myeloablative or nonmyeloablative/reduced-intensity therapy is administered with 
an infusion of stem cells (peripheral blood or bone marrow) obtained from a donor, preferably an 
HLA-identical sibling. In such cases, the patient will need to be HLA-typed. 
 
1.4 Diagnostic Categories 
 
As seen above, patients are initially classified as either having smoldering/asymptomatic disease 
or active/symptomatic disease. 
In addition to existing requirements of CRAB features, IMWG recently updated the disease 
definition of MM to include biomarkers36; the CRAB criteria include hypercalcemia (>11.5 
mg/dL), renal insufficiency (creatinine >2 mg/dL or creatinine clearance <40 mL/min), anemia 
(hemoglobin <10 g/dL or 2 g/dL < normal), and the presence of bone lesions. The IMWG has 
also clarified that presence of ≥1 osteolytic lesions seen on skeletal radiography, whole-body 
MRI, or whole-body PET/CT fulfills the criteria for bone disease36. The MM-defining 
biomarkers identified by the IMWG include ≥1 of the following: ≥60% clonal plasmacells in the 
bone marrow; involved/uninvolved FLC ratio of ≥100 with the involved FLC being ≥100 mg/L; 
or MRI with ≥1 focal lesion (involving bone or bone marrow)36. 
The IMWG criteria for a diagnosis of smoldering (asymptomatic) myeloma include serum M-
protein (IgG or IgA) ≥30 g/L or 3.0 g/dL and/or clonal bone marrow plasma cells 10% to 60% 
and absence of myeloma-defining events or amyloidosis36. The updated IMWG diagnostic 
criteria allow initiation of therapy before end-organ damage on the basis of specific biomarkers, 
and also allow the use of sensitive imaging criteria to diagnose MM, including PET/CT and 
MRI36. 
Active myeloma can be staged using either the Durie-Salmon staging system or the International 
Staging System (ISS) (Table 1)37. The ISS is based on easily obtained laboratory measures 
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(serum beta-2 microglobulin and serum albumin) and is easier to use than the Durie-Salmon 
staging system for patients with previously untreated MM. The ISS has been recently revised to 
incorporate the serum LDH and high-risk FISH abnormalities [t(4;14), t(14;16), 17p13 
deletion]38. 
 
Table 1: International Staging System (ISS) 
 
 
1.5 Response Criteria 
 
Assessing the response to treatment is a key determinant of MM. The IMWG response criteria 
were developed from the EBMT (European Society for Blood and Marrow 
Transplantation)/IBMTR (International Bone Marrow Transplant Registry)/ABMTR 
(Autologous Blood and Marrow Transplant Registry) response criteria39, with revisions and 
improvements to help uniform reporting. 
The updated IMWG response criteria definitions10,40-43 for stringent CR, immunophenotypic CR, 
molecular CR, CR, VGPR (very good partial response), PR (partial response), MR (minimal 
response) for relapsed/refractory myeloma, SD (stable disease), and PD (progressive disease) are 
outlined on table 242,43. In order to include measures of minimal residual disease (MRD) 
assessments, the response criteria has recently been updated, and it is recommended that the 
IMWG uniform response criteria should be used in future clinical trials. 
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Table 2: Updated IMWG Response Criteria 
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2. Multiple Myeloma Treatment 
2.1 Frontline treatment 
 
MM patients presenting with active/symptomatic disease are initially treated with frontline 
treatment and, in selected patients, it is followed by high-dose chemotherapy with autologous 
stem cell transplantation. The recent aims are to improve the response rates and depth of 
response in both transplant and non-transplant candidates. It should be important to assess for 
response to frontline therapy after 1 to 2 cycles of therapy. 
Stem cell toxins, such as alkylating or nitrosoureas agents, may compromise stem cell reserve, 
and regimens with these agents (in particular melphalan) should be avoided in patients who are 
potential candidates for SCT. In patients with advanced MM is really important to determine 
whether they are candidates for high-dose therapy and transplant, based on age and co-
morbidities: advanced age and renal dysfunction are not absolute contraindications to transplant. 
All patients also need careful attention to supportive care: 80% of patients have bone disease and 
up to 33% have renal compromise. Frontline proteosome inhibitor–based regimens may be 
indicated in patients with renal failure and in those with certain adverse cytogenetic features44. 
Appropriate adjunctive measures should be used in order to manage renal dysfunction, bone 
disease, and other complications such as hypercalcemia, hyperviscosity, and 
coagulation/thrombosis. So, supportive care is critical to avoid early complications that may 
compromise seriously therapeutic outcome. 
3-drug regimens over 2-drug regimens is actually preferred as the standard of care for primary 
treatment of MM. This is based on improved response rates, depth of response, and rates of 
progression-free survival (PFS) and overall survival (OS) seen with 3-drug regimens in clinical 
trials. However, the panel notes that doublets could be used in elderly and/or frail patients, who 
could be unable to tolerate a 3-drug regimen. 
In patients receiving an IMiD-based therapy, prophylaxis with full-dose aspirin is recommended 
and an anticoagulation agent is recommended for patients receiving an IMiD-based therapy and 
who are at high risk for thrombosis.  
In patients receiving proteosome inhibitor–based therapies, prophylactic antiviral therapy is 
recommended45-46, because of risk of reactivation of herpes simplex infection or herpes zoster, 
due to impaired lymphocyte function that results from MM and/or its treatment-related 
myelosuppression46-49. 
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Regarding carfilzomib, second generation proteosome inhibitor, careful assessment should be 
performed before initiating treatment close monitoring during treatment is recommendedbecause 
it can potentially cause cardiac and pulmonary toxicities50. 
 
2.2 Therapy Regimens for newly-diagnosed Transplant Candidates 
 
Bortezomib is the first proteosome inhibitor (PI) active in MM (Figure 1). Bortezomib-based 3-
drug regimens have been listed as preferred primary therapy options for patients who are SCT 
eligible; these regiments include bortezomib/thalidomide/dexamethasone, 
bortezomib/lenalidomide/dexamethasone, bortezomib/doxorubicin/dexamethasone, and 
bortezomib/cyclophosphamide/dexamethasone. 
Considering results ofthe MMY-3021 trial51, subcutaneous administration is the preferred route 
for bortezomib.  
In this trial, a randomization of 222 patients to single-agent bortezomib administered either by 
the conventional intravenous route or by subcutaneous route was performed, and it was 
demonstrated non-inferior efficacy with subcutaneous versus intravenous bortezomib with regard 
to the primary end point (ORR, overall response rate after 4 cycles of single-agent bortezomib). 
Moreover, consistent results were shown with regard to secondary end points, with a significant 
reduction in peripheral neuropathy, and there were no significant differences in terms of time to 
progression or in one-year OS between groups51-52. Herpes prophylaxis in patients receiving 
bortezomib therapy should be mandatory. During frontline triplet treatment, it is recommended 
to harvest peripheral blood early in the course of primary treatment, preferably after 3 to 4 cycles 
of initial therapy. 
 
 
Figure 1: Bortezomib structure. Bortezomib is a modified dipeptide boronic acid from 
leucine and phenylalanine 
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2.2.1 Bortezomib/Thalidomide/Dexamethasone 
 
Thalidomide has an important role in treatment of MM, thanks to its efficacy in attacking 
multiple targets in the microenvironment of the myeloma cell, producing apoptosis, inhibition of 
angiogenesis, and cytokine circuits, among others (Figure 2).  
 
 
Figure 2: Thalidomide structure 
 
The most important phase III trial regarding a comparison between bortezomib, thalidomide, and 
dexamethasone (n=241) versus thalidomide and dexamethasone (n=239) as frontline therapy 
followed by tandem autologous SCT with high-dose melphalan and then consolidation therapy 
with the same primary regimen was presented by GIMEMA Italian Multiple Myeloma 
Network53. ORR significantly improved after primary treatment, thanks to the addition of 
bortezomib to thalidomide and dexamethasone. In fact, after frontline therapy, CR/nCR (near 
CR) was achieved in 73 patients (31%; 95% CI, 25.0–36.8) receiving 
bortezomib/thalidomide/dexamethasone, and 27 patients (11%; 95% CI, 7.3–15.4) on 
thalidomide/dexamethasone53. Rates of CR/nCR and VGPR or better continued to be 
significantly higher in the VTD group than in the TD group after the first and second autologous 
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SCT, and subsequent consolidation treatment. However, patients receiving the bortezomib-
containing regimen experienced grade 3/4 PN. 
A single-institution retrospective study shows similar data to the interim data from the GIMEMA 
trial54. However, the findings of this analysis confirm that ORR after primary therapy with 
bortezomib, thalidomide, and dexamethasone was 94% of the patients (32 of 34 patients showed 
some response, including a VGPR rate ≥56%)54. 
The Spanish Myeloma Group (PETHEMA/GEM) also demonstrated in a phase III trial a 
significantly higher CR rate with bortezomib/thalidomide/dexamethasone as primary therapy 
overall (35% vs 14%; P=.001) and in patients with high-risk cytogenetics (35% vs 0%; 
P=.002)55. In particular, the CR rate continued to be significantly higher after autologous SCT 
(46% vs 24%) in patients treated with VTD versus TD as primary therapy55. 
The phase III IFM 2013-04 trial is comparing 4 cycles of CyBorD versus 4 cycles of VTD as 
induction therapy before autologous SCT in newly diagnosed MM patients (N=340)56. The 
preliminary results show that patients who received VTD as induction therapy experienced 
higher ORR (92.3%) compared with those who received CyBorD (84%). In particular, those who 
received VTD had significantly greater VGPR (P=.04) and PR (P=.02) rates56. 
Moreover, the hematologic toxicity was greater in CyBorD arm, however, in the VTD arm 
higher rates of PN were reported56. 
Nowadays, in Italy, VTD is the preferred regimen for newly diagnosed MM patients eligible to 
autologous SCT, with a recommendation of appropriate thromboprophylaxis. 
 
2.2.2 Bortezomib/Dexamethasone 
 
In the IFM cooperative group trial, 482 transplant-eligible patients were randomized to one of 
the 4 frontline treatment arms: 121 in VAD alone, 121 in VAD plus consolidation therapy with 
DCEP (dexamethasone/cyclophosphamide/etoposide/cisplatin); 121 in 
bortezomib/dexamethasone, and 119 in bortezomib/dexamethasone plus consolidation with 
DCEP57. Primary end-point was to assess response rate after frontline treatment, according to 
modified EBMT criteria39, including nCR (CR but immunofixation-positive)58 and VGPR (serum 
M-protein reduction ≥90%; urine light chain <100 mg/24 hours)10. After frontline treatment, 
ORR (78.5% vs 62.8%) and rates of CR/nCR (14.8% vs 6.4%) and VGPR (37.7% vs 15.1%) 
were significantly higher with VD versus VAD57. At a median follow-up of 32.2 months, median 
PFS was modestly, but not statistically significantly, prolonged compared with VAD (36.0 vs 
17 
 
29.7 months)57. Use of DCEP as consolidation therapy after primary therapy did not have a 
significant impact on the rates of response57. Bortezomib/dexamethasone regimen was equally 
effective in patients with high-risk MM, including those with ISS stage III disease and poor-risk 
cytogenetic abnormalities. Severe adverse events incidence was similar between the 2 groups. 
Hematologic toxicity and deaths related toxicity were more frequent with VAD versus VD. 
Bortezomib/dexamethasone showed a rate of PN during induction through first transplantation 
significantly higher than VAD57. 
A phase III randomized trial, conducted by IFM, compared bortezomib/dexamethasone with a 
combination of reduced doses of bortezomib and thalidomide plus dexamethasone59. Response 
rates in this study match those described in previous trials comparing VAD with bortezomib and 
dexamethasone57. 
High-risk patients [with either t(4;14) or del(17p)] are known to have a short EFS (event-free 
survival) and OS. A trial analyzed a large series of newly diagnosed transplant-eligible MM 
patients (aged <65 years) with and t(4;14) or del(17p) treated with bortezomib/dexamethasone 
versus VAD as frontline treatment58-59. The analysis demonstrated that bortezomib, compared 
with patients treated with VAD primary therapy, improves the prognosis (in terms of both EFS 
and OS; p<.001 and p<.001, respectively) of patients with t(4;14).  
 
2.2.3 Lenalidomide/Dexamethasone 
 
Lenalidomide is a potent analogue of thalidomide, believed to attack multiple targets in the 
microenvironment of the myeloma cell, producing apoptosis and inhibition of angiogenesis and 
cytokine circuits. It was approved from the FDA for the treatment of relapsed/refractory MM in 
combination with dexamethasone (Figure 3). 
 
 
Figure 3: Lenalidomide structure. 
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However, lenalidomide and dexamethasone have more recently also been investigated as 
frontline treatment. S0232, by SWOG, a phase III randomized controlled study, compared 
dexamethasone single agent with dexamethasone plus lenalidomide for newly diagnosed MM 
patients60. At interim analysis, this trial was halted and patients on dexamethasone alone arm 
were allowed to switch to lenalidomide/dexamethasone arm. Moreover, based on the preliminary 
results from the ECOG phase III study (E4A03), the SWOG data and safety monitoring 
committee based its recommendation to permanently close enrollment61. At the end of first year, 
the time the SWOG trial was halted, lenalidomide plus dexamethasone arm showed improved 
CR rate compared with dexamethasone alone (22.1% vs 3.8%)60. 
In another open-label trial, 445 newly diagnosed MM patients were randomly assigned to high-
dose or low-dose regimens. High-dose dexamethasone showed a superior response, with 169 
(79%) of 214 patients receiving high-dose therapy and 142 (68%) of 205 patients on low-dose 
therapy with a CR or PR within 4 cycles62. However, the higher response rates did not result in 
statistical superior time to progression, PFS, or OS compared with low-dose dexamethasone, and 
this trial was stopped after 1 year. Considered that the OS rate was significantly higher in low-
dose arm, patients on high-dose therapy were allowed to cross-over. The OS rate in the low-dose 
dexamethasone group was 96% compared with 87% in the high-dose group (P=.0002), at 1-year 
interim analysis; 2-year OS was 87% versus 75%, respectively. 
Inferior OS with high-dose dexamethasone seemed to be related to increased deaths caused by 
toxicity. 52% of patients on the high-dose had grade 3-4 toxic effects in the first 4 months, 
versus 35% on the low-dose regimen, including DVT (26% vs 12%), infections including 
pneumonia (16% vs 9%), and fatigue (15% vs 9%). Patients who had received 4 cycles of 
primary treatment with either dose followed by autologous SCT showed a 3-year OS rate of 
92%, suggesting that lenalidomide and dexamethasone is a reasonable option for primary therapy 
before auto-SCT. However, a limit of this trial was that the choice to proceed to SCT was not 
randomized but based on physician and patient preference. 
Extra-hematologic adverse events showed an incidence of DVT lower with single-agent 
lenalidomide or lenalidomide plus low-dose dexamethasone than when it is combined with high-
dose dexamethasone. Recently, a report showed that patients treated with lenalidomide and high-
dose dexamethasone that developed during therapy a venous thromboembolism did not 
experience shorter OS or time to progression63. Prophylactic anticoagulation is recommended in 
patients receiving this therapy45,64. 
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However, it has been reported a decrease in CD34-positive cells collected after prolonged 
lenalidomide treatment has been reported65,66.  IMWG guidelines suggest that patients managed 
with lenalidomide and dexamethasone should have their stem cells collected within the first 4 
cycles of therapy67. It has also been demonstrated that chemomobilization could overcome this 
inability to collect stem cells68. In particular, there are data showing the efficacy of addition of 
plerixafor when conventional mobilization methods fails for successful stem cell harvest69,70. 
Lenalidomide/dexamethasone can be considered one of the best options in frontline treatment, 
with a recommendation together with an appropriate thromboprophylaxis. 
 
2.2.4 Bortezomib/Cyclophosphamide/Dexamethasone (CyBorD) 
 
CyBorD as primary treatment was evaluated in three phase II studies involving newly diagnosed 
MM, demonstrating high response rates71-73. 
In particular, Reeder et al (USA and Canada)72 showed an ORR of 88%, including rates of 
VGPR or greater of 61% and CR/near CR of 39%. The depth of response seen after frontline 
treatment was maintained, in those who underwent transplantation, after transplant, with 70% 
rates of CR/near CR; rate of at least VGPR or better was 74%. According to the long-term 
follow-up analysis, the 5-year PFS and OS rates were 42% (95% CI, 31–57) and 70% (95% CI, 
59–82)74. 
German DSMM XIa study also demonstrated high responses with frontline CyBorD (ORR, 84%; 
PR, 74%; CR, 10%), with high response rates also in patients with unfavorable cytogenetics73. In 
updated results of EVOLUTION study, frontline treatment with CyBorD demonstrated an ORR 
of 75% (CR, 22%; ≥VGPR, 41%) and the 1-year PFS rate was 93%71. 
Twice-weekly bortezomib can be associated with toxicities that may limit efficacy caused by 
treatment delays or discontinuation. So, Reeder et al75 modified the regimen to a once-weekly 
schedule. In the study, patients treated with weekly bortezomib achieved responses similar to the 
twice-weekly schedule (ORR, 93% vs 88%; VGPR, 60% vs 61%, respectively), showing fewer 
grade 3/4 adverse events (37%/3% vs 48%/12%). Fewer dose reductions of 
bortezomib/dexamethasone were required in the modified schedule and neuropathy rates were 
the same in both cohorts, even though the total bortezomib dose per cycle was higher in the 
weekly versus the twice-weekly schedule (6.0 mg/m2 vs 5.2 mg/m2)75. 
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2.2.5 Bortezomib/Doxorubicin/Dexamethasone (PAD) 
 
HOVON-65/GMMG-HD4 group phase III trial of newly diagnosed patients with stage II/III MM 
update results demonstrated high response rates after primary therapy with 
bortezomib/doxorubicin/dexamethasone (PAD) versus VAD. This superior response rate (CR + 
near CR, 31% vs 15%; P<.001) was also maintained after SCT, with a significantly higher 
ORR76. Del(13q) did not have a significant impact on response and no unexpected toxicities 
occurred. In particular, response rates improved with bortezomib maintenance (34% vs 49%; 
P<.001)76. PFS in patients treated with PAD as frontline therapy followed by SCT and 
bortezomib maintenance, after a median follow-up of 41 months, was 35 versus 28 months in 
patients treated with VAD followed by SCT and maintenance with thalidomide. Patients treated 
with PAD had also a significantly better PFS (HR, 0.75; 95% CI, 0.62–0.90; P=.002), and OS 
was also found to be improved in PAD arm (HR, 0.77; 95% CI, 0.60–1.00; P=.049). In high-risk 
patients, presenting with increased creatinine >2 mg/dL, bortezomib-containing regimen 
significantly improved PFS from a median of 13 to 30 months (HR, 0.45; 95% CI, 0.26–0.78; 
P=.004) and OS from a median of 21 to 54 months (HR, 0.33; 95% CI, 0.16–0.65; P<.001). 
In patients with deletion of 17p13 also a benefit in terms of increased PFS was evaluated76. 
Peripheral neuropathy (PN)-rate (grade 2 to 4) was higher in those treated with the bortezomib-
containing regimen versus VAD (40% vs 18%). Moreover, newly developed grade 3 to 4 PN 
occurred in 8% of patients during thalidomide maintenance and 5% of patients during 
bortezomib maintenance76. 
 
2.2.6 Bortezomib/Lenalidomide/Dexamethasone (VRD) 
 
Bortezomib/lenalidomide/dexamethasone is active and well-tolerated in all newly diagnosed pa- 
tients with MM, transplant eligible, and transplant ineligible, as demonstrated in phase II and III 
studies71,77,78. 
In particular, the first phase I/II prospective study of bortezomib/lenalidomide/dexamethasone in 
newly diagnosed MM patients, the rate of ≥ PR was 100%, with 74% VGPR or better and 52% 
CR/nCR77. Trials of phase II EVOLUTION71 and phase II IFM2008 trial78 also confirmed the 
benefits of bortezomib/lenalidomide/dexamethasone as frontline treatment. In IFM2008 trial, 
patients received bortezomib/lenalidomide/dexamethasone as induction therapy followed by 
SCT78, and they subsequently received 2 cycles of bortezomib/lenalidomide/dexamethasone as 
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consolidation cycles and 1-year lenalidomide maintenance. Responses ≥ VGPR at the 
completion of induction was 58%, while after transplantation and consolidation therapy it was 
70% and 87%, respectively78.  
EVOLUTION was a really interesting trial, designed to assess the efficacy and tolerability of 
combining bortezomib/cyclophosphamide/lenalidomide/dexamethasone versus 
bortezomib/lenalidomide/dexamethasone versus bortezomib/cyclophosphamide/dexamethasone 
(CyBorD) in a randomized multicenter setting71. The ORR after primary treatment with 
bortezomib/lenalidomide/dexamethasone followed by maintenance with bortezomib was 85% 
(51% ≥VGPR; 24% CR) and corresponding 1-year PFS was 83% in the 
bortezomib/lenalidomide/dexamethasone arm71. 
Bortezomib/lenalidomide/dexamethasone triplet was compared to lenalidomide and 
dexamethasone in SWOG S077, a multicenter phase III79, where 525 previously untreated MM 
patients were randomly assigned to receive 6 months of induction therapy with either 
bortezomib/lenalidomide/dexamethasone versus lenalidomide/dexamethasone each followed by 
maintenance therapy with lenalidomide/dexamethasone until progression or unacceptable 
toxicity. At a median follow-up of 55 months, treatment with 
bortezomib/lenalidomide/dexamethasone compared with lenalidomide/dexamethasone resulted 
in higher rates of ORR (82% vs 72%) and CR (16% vs 8%), superior median PFS (median, 43 vs 
30 months; hazard ratio [HR], 0.71; 95% CI, 0.56–0.91), and improved OS (median, 75 vs 64 
months; HR, 0.71; 95% CI, 0.52–0.97). As expected, grade 3 or higher neuropathy was more 
frequent in the bortezomib-containing arm (24% vs 5%; P<.0001). 
Nowadays, considering these data, bortezomib/lenalidomide/dexamethasone regimen can be 
considered the preferred primary treatment of transplant-eligible patients with newly-diagnosed 
MM, even if this regimen is not yet available in Italy. 
 
2.2.7 Carfilzomib/Lenalidomide/Dexamethasone 
 
Carfilzomib is a second-generation proteasome inhibitor that binds highly selectively and 
irreversibly to the proteasome (Figure 4).  
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Figure 4: Chemical structure of Carfilzomib 
 
It is administered intravenously. Moreover, preclinical studies with carfilzomib have shown lack 
of neurodegeneration in vitro80 and less neurotoxicity in animal studies81. Moreover, Carfilzomib 
has demonstrated important antimyeloma activity in patients with relapsed and/or refractory MM 
with an acceptable tolerability profile, including limited neuropathy after prolonged treatment82-
84. 
In particular, the efficacy and safety of carfilzomib in combination with lenalidomide and 
dexamethasone, as primary therapy for MM patients, were evaluated in 2 single‐arm trials. 
First, the combination of carfilzomib/lenalidomide/dexamethasone (KRD) in newly diagnosed 
MM patients was evaluated in a multicenter phase I/II trial85. In this trial, patients (n=53) 
received KRD, and, after 4 cycles, stem cells were collected from eligible patients (n=35)85, 7 of 
whom proceeded to autologous SCT, while the remainder continued with KRD85. With median 
follow-up of 13 months, 24-month PFS was estimated at 92%. Considering safety, the most 
common grade 3 and 4 toxicities in ≥10% of patients included hypophosphatemia (25%), 
hyperglycemia (23%), anemia (21%), thrombocytopenia (17%), and neutropenia (17%). In 
particular, PN was limited to grade 1/2 (23%)85. 
The second phase II trial also KRD in newly diagnosed MM patients (n=45). After 8 cycles of 
treatment, patients with SD (stable disease) received up to 24 cycles of lenalidomide, 10 mg/day 
(days 1 to 21)86; with 38 patients who were evaluable for response and toxicity. PFS was 83.3%, 
after a median follow-up of 10 months. A total of 25 patients completed 8 cycles of KRD, of 
which 24 continued to lenalidomide therapy and 1 patient opted to exit the study after initial 
therapy. Considering safety, the most common extra-hematologic and hematologic toxicities 
(≥grade 3) in more than 10% of patients included electrolyte disturbances (18%), liver function 
test elevation (13%), rash/pruritus (11%), fatigue (11%), lymphopenia (63%), anemia (16%), 
leukopenia (13%), and thrombocytopenia (11%)87. 
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Based on the above data, nowadays, in USA, KRD is an option for frontline primary treatment of 
MM transplant-eligible patients. However, it is not yet available in Italy in this setting. 
 
2.2.8 Ixazomib/Lenalidomide/Dexamethasone 
 
Ixazomib is a new-generation oral proteosome inhibitor that was approved by the FDA in 
combination with lenalidomide and dexamethasone (IRD) for MM patients with who have 
received at least one prior therapy (Figure 5). 
 
 
Figure 5: Ixazomib structure 
 
However, in a phase I/II trial, Kumar et al88 studied an all oral combination of 
ixazomib/lenalidomide/dexamethasone in newly diagnosed MM patients. This trial showed that 
IRD was well tolerated and active in the study population. In particular, of the 64 patients in 
whom the response could be evaluated, 37 (58%; 95% CI, 45–70) had a VGPR or better. 
Considering safety, grade 3 or higher adverse events related to any drug in the combination were 
reported in 41 (63%) patients. These included extrahematological toxicity, skin and 
subcutaneous tissue disorders (11 patients, 17%), and hematological toxicity including 
neutropenia (8 patients, 12%), and   thrombocytopenia (5 patients, 8%); drug-related PN of grade 
3 or higher occurred in only 4 (6%) patients. 
Based on these phase II results and the efficacy of the combination of other proteosome 
inhibitors (bortezomib or carfilzomib) in combination with lenalidomide/dexamethasone as 
primary therapy in newly diagnosed MM56,85-87,89, IRD could be considered an option (at the 
moment not yet in Italy) for the treatment of newly diagnosed MM patients. 
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2.3 Preferred Primary Therapy Regimens for Non-Transplant Candidates 
 
Many of the described regimens for transplant candidates are also options for non-transplant 
candidates. As in transplant-eligible patients, three-drug regimens are preferred because have 
been shown to induce higher response rates and better depth of response in clinical trials.  
However, the two-drug regimens are reserved for elderly and/or frail patients. In particular, the 
best options for non-transplant candidates include 
bortezomib/cyclophosphamide/dexamethasone, bortezomib/lenalidomide/dexamethasone, and 
lenalidomide/low-dose dexamethasone.  
Melphalan-containing regimens should be no longer considered the standard of care in this 
setting in the era of novel agents. 
 
2.3.1 Bortezomib/Melphalan/Prednisone 
 
The role of bortezomib/melphalan/prednisone (VMP) as frontline treatment for inelegible-SCT 
MM patients was studied in a phase III trial, evaluating nine 6-week cycles of VMP versus MP, 
randomly assigning 682 patients90. The median age of patients in this study was 71 years, and 
patients with serum creatinine higher than 2 mg/dL were excluded. ORR (at least PR) was 71% 
in VMP versus 35% in MP, with CR 30% versus 4%, respectively. The median time to 
progression was 24 months versus 16.6 months, and median duration of response was 19.9 
months versus 13.1 months. Considering safety, grade 3 adverse events were higher in the 
bortezomib group than in the control group (53% versus 44%), but there were no significant 
differences in grade 4 events (28% versus 27%, respectively), or treatment-related deaths (1% 
and 2%). 
Considering these findings, VMP can be considered as a primary therapy option for newly 
diagnosed myeloma who are inelegible for high-dose therapy. 
 
2.3.2 Bortezomib/Cyclophosphamide/Dexamethasone 
 
The role of CyBorD as frontline treatment for inelegible-SCT MM patients was studied in a 
small phase II trial (n=20)91. The median age of patients in this study was 76 years (range, 66–90 
years). After a median of 5 cycles, the ORR was 95%, with 70% of patients achieving a VGPR 
or better. Considering safety, 6 patients experienced non-hematologic grade 3/4 adverse events 
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(20%), including muscle weakness, sepsis, and pneumonia. Neutropenia and thrombocytopenia 
were seen in 2 patients (10%)91. 
Considering these findings91, together with the earlier described results from the EVOLUTION 
trial54 and the phase II trials72,73, CyBorD can be considered as a primary therapy option for non-
transplant candidates. 
 
2.3.3 Lenalidomide/Low-Dose Dexamethasone 
 
The results of two trials: SWOG SO23260, which included transplant-ineligible patients, and the 
ECOG E4A0392, which included elderly MM patients, demonstrate that lenalidomide in 
combination with low-dose dexamethasone is a effective and well-tolerated regimen for these 
patients. In the ECOG E4A03 trial, OS rate was significantly higher in the lenalidomide plus 
low-dose dexamethasone arm compared with the lenalidomide plus high-dose dexamethasone 
arm62. The inferior survival outcome seen with high-dose dexamethasone was greatest in patients 
aged ≥65 years. However, at 2 years, patients who did not proceed to transplant had an OS rate 
of 91% with lenalidomide and low-dose dexamethasone62. 
The FIRST trial, an international, multicenter trial, evaluated efficacy and safety of 
lenalidomide/dexamethasone given continuously or for 72 weeks compared with 
melphalan/prednisone/thalidomide (MPT) in elderly (n=1,623) transplantation-ineligible newly 
diagnosed MM patients93. 
The primary end point was PFS, while secondary end points were OS and safety, including the 
incidence of secondary malignancies. After a median of 37 months of follow-up, the risk of 
progression or death was reduced by 28% in patients receiving continuous 
lenalidomide/dexamethasone versus MPT (HR, 0.72; 95% CI, 0.61–0.85; P<.001)93. Moreover, 
continuous lenalidomide/dexamethasone also reduced the risk of progression or death compared 
with 18 cycles of lenalidomide/dexamethasone (HR, 0.70; 95% CI, 0.89–1.20; P=.70). In 
particular, in the interim analysis, also an OS benefit was seen in the 
lenalidomide/dexamethasone arm versus MPT (HR, 0.78; CI, 0.64–0.96; P=.02)93. 
During last years, several reports have shown higher incidences of secondary malignancies when 
lenalidomide is used as a maintenance therapy post-transplantation or in a melphalan-containing 
regimen94-97. In the FIRST trial, the overall incidence of secondary malignancies, including solid 
tumours and hematologic malignancies, was lower in the continuous 
lenalidomide/dexamethasone arm. In particular, the overall rates of second primary cancers were 
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3.0% in the continuous lenalidomide/dexamethasone arm, 6.0% in the arm receiving 18 cycles of 
lenalidomide/dexamethasone, and 5.0% in the MPT arm93. Moreover, regarding renal 
impairment, in an analysis based on renal function of patients enrolled in the FIRST trial, 
continuous lenalidomide/low-dose dexamethasone compared with MPT reduced the risk of 
progression or death in patients with normal, mild, and moderate renal impairment by 33%, 30%, 
and 35%, respectively98. 
So, lenalidomide/low-dose dexamethasone is considered a category one of the best options for 
transplant-ineligible patients with MM, with appropriate thromboprophylaxis for patients 
receiving this therapy. 
Moreover, based on the results of the FIRST trial93, continuous lenalidomide/dexamethasone 
until disease progression should be considered for patients who are not eligible for transplant. 
 
2.3.4 Bortezomib/Dexamethasone 
 
UP-FRONT, a US community-based, randomized, open-label, multicenter phase IIIb, trial 
compared safety and efficacy of 3 highly active bortezomib-based regimens in previously 
untreated elderly ineligible for SCT MM patients99. The patients with symptomatic, measurable 
MM were randomized (1:1:1) to one of the following regimens: VTD (n=167); 
bortezomib/dexamethasone (n=168); or melphalan/prednisone/bortezomib (n=167) followed by 
maintenance therapy with bortezomib. The primary end point was PFS; secondary end points 
included ORR, CR/nCR and VGPR rates, OS, and safety. All three induction regimens exhibited 
substantial activity, with ORR of 80% (VTD), 73% (bortezomib/dexamethasone), and 69% 
(melphalan/prednisone/bortezomib) during the treatment period99. However, after a median 
follow-up of 21.8 months, no significant difference in PFS was observed between the treatment 
arms99. Response rates, including CR and VGPR or better, improved after bortezomib 
maintenance, with no concomitant increase in the incidence of PN. 
So, bortezomib/dexamethasone can be considered as option for frontline treatment for MM 
patients who are ineligible for transplant. 
 
2.3.5 Bortezomib/Lenalidomide/Dexamethasone 
 
Phase II study results, earlier discussed, have shown that primary therapy with VRD is active and 
well tolerated in all newly diagnosed MM patients regardless of autologous SCT status77. 
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The earlier discussed randomized phase III SWOG S0777 trial, comparing VRD versus RD as 
induction therapy without an intent of immediate transplantation, reported superior results with 
the three-drug regimen79. So, VRD can be considered one of the best options for MM patients 
who are ineligible for SCT. However, it is not yet available in Italy. 
 
2.3.6 Ixazomib/Lenalidomide/Dexamethasone 
 
A earlier discussed phase I/II study evaluated the safety and efficacy of the all-oral combination 
of ixazomib with lenalidomide and dexamethasone in newly diagnosed MM patients88. Both 
efficacy and tolerability of this regimen in older patients (≥65 years) was similar to that in 
younger patients in this study. So, also IRD can be considered as option for frontline treatment 
for all patients with newly diagnosed MM, including those who are not eligible for SCT. 
However, it is not yet available in Italy. 
 
2.3.7 Carfilzomib/Lenalidomide/Dexamethasone 
 
The results of a earlier discussed phase I/II trial demonstrated that KRD is well-tolerated and is 
also effective in all patients with newly diagnosed MM85. An updated follow-up analysis of the 
subset of elderly patients (23 patients, age ≥65 years) showed that use of KRD regimen for an 
extended period resulted in deep and durable responses. In particular, all patients experienced at 
least a PR, with a median follow-up of 30.5 months. Moreover, the reported PFS rate was 79.6% 
(95% CI: 53.5–92.0) and OS was 100%89. 
The phase II trial by Korde et al87 also showed that treatment with KRD regimen results in high 
rates of deep remission and no MRD. The results were very similar across age groups, with the 
oldest patient on the trial being 88 years of age87, and the regimen was found to be effective also 
in individuals with high-risk disease100. 
Based on these phase II studies that did not exclude transplant ineligible patients, KRD can be 
considered as an important option for the treatment of all patients with newly diagnosed MM, 
including those who are not eligible for SCT. The only problem is that carfilzomib can 
potentially cause cardiac and pulmonary toxicities in elderly patients101, and that’s why it should 
be recommended adequate monitoring of these patients.  
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3. Stem Cell Transplantation in Multiple Myeloma 
3.1 Monitoring After Primary Myeloma Therapy of Both Transplant and Non-
Transplant Candidates 
 
Patients on treatment should be monitored not only for response to primary therapy but also for 
symptoms related to disease and/or treatment. In particular, it should be recommended to re-
evaluate (after 1–2 cycles) with the laboratory tests, skeletal survey, and bone marrow aspiration 
and biopsy only if indicated, to determine treatment response or whether the primary disease is 
progressive. Patient potentially transplant candidates must undergo a stem cell harvest after 4 to 
6 cycles of therapy, collecting at that enough stem cells for 2 transplants (depending on the 
intended number of transplants and age) in anticipation of a tandem transplant or a second 
transplant as subsequent therapy. Alternatively, all patients may consider continuation of primary 
therapy until the best response is reached. The optimal duration of primary therapy after 
achieving maximal response is actually unknown; hence, maintenance therapy or observation 
could be considered beyond maximal response. 
Follow-up tests after frontline myeloma treatment include those used for initial diagnosis: a 
complete blood count with differential and platelet counts; renal function corrected serum 
calcium; and quantification of M-protein and immunoglobulins. The serum FLC may be assessed 
as clinically indicated, and they have a role especially in patients with oligosecretory or 
nonsecretory MM. Response should be assessed using the IMWG criteria10. 
Other tests, such as skeletal survey, MRI, and PET/CT scan, bone marrow aspiration and biopsy, 
may be performed as indicated by symptoms to detect disease progression. Patients eligible for 
SCT should be referred for evaluation by SCT team and stem cells should be harvested. 
 
3.2 Stem Cell Transplants 
 
High-dose therapy with stem cell support is a critical component in the treatment plan of newly 
diagnosed eligible MM patients. There are different types of SCT: single autologous SCT, a 
tandem SCT (a planned second course of high-dose therapy and SCT within 6 months of the first 
course), or an allogeneic SCT. Moreover, an allogeneic SCT can be performed or after prior 
myeloablative therapy or after non-myeloablative therapy. Non-myeloablative therapy, or “mini 
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transplant,” has been investigated as a technique to decrease toxicity of the allotransplant while 
preserving the alloimmune GvM (graft-versus-myeloma) effect102,103. It is important to note that 
non-myeloablative allogeneic transplant by itself is not adequate therapy and it should be usually 
performed following maximal tumor control through adequate induction therapy or an 
autologous SCT. An allogeneic SCT may also follow an autologous SCT. 
All candidates for pre-SCT high-dose chemotherapy must have sufficient liver, renal, 
pulmonary, and cardiac function. However, renal dysfunction is not an absolute contraindication 
to transplant. Earlier studies of autologous transplant included TBI (total body irradiation) as a 
component of the preparative regimen. Chemotherapy regimens have only recently been shown 
to have equivalent efficacy and less toxicity than TBI, whose regimens have now been 
abandoned104, but newer, potentially less toxic radiation techniques aimed to deliver total 
marrow irradiation while reducing toxicities to non-target organs are currently undergoing 
evaluation in clinical trials105. 
 
3.2.1 Autologous SCTs 
 
Autologous SCT results in high response rates and remains the standard of care after frontline 
treatment for eligible patients. Results of the first randomized trial were reported in 1996, 
demonstrating that autologous SCT is associated with statistically significant higher response 
rates and increased OS and EFS when compared with the response of similar patients treated 
with conventional therapy106. In 2003, a second trial comparing high-dose therapy with standard 
therapy showed an increase in the CR rate and an improvement in OS, 54 months in the high-
dose group vs 42 months for standard therapy107, with a more pronounced benefit was for higher-
risk patients. Barlogie et al108 reported on the results of arandomized American trial comparing 
510 patients to receive high-dose therapy with autologous stem cell support or standard therapy: 
with a median follow-up of 76 months, no differences were seen in response rates, PFS, or OS 
between the groups. The reasons for the discrepant results are not clear, but may be related to 
differences in the specific high-dose and conventional regimens between the American and 
French study. For example, TBI was included as part of the high-dose regimen in the American 
study; then TBI has subsequently been found to be inferior to high-dose melphalan104. 
Another important trial included 190 patients, median age 55 to 65 years, randomized to standard 
or high-dose therapy109. This study was specifically designed to include older patients, with a 
median age in this trial of 61 years compared with the median age of the participants in other 
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trials which ranged from 54 to 57 years. No significant difference was seen in OS, although a 
trend was seen toward improved EFS in the high-dose group (P=.7), after 120 months of follow-
up. Moreover, in the high-dose group the period without symptoms, treatment, or treatment 
toxicity was significantly longer. The study showed that the equivalent survival suggests that the 
treatment choice between high-dose and conventional-dose chemotherapy should be based on 
personal choice in older patients. For example, an early transplant may be favored because 
patients can enjoy a longer interval of symptom-free time. However, this study110 showed also 
that a transplant performed at relapse has a similar OS compared with an early transplant. A 
randomized French trial examined the choice of early versus late transplant and the results in 
both arms are comparable with respect to OS111. However, early SCT was shown to be superior 
in terms of quality of life, assessed as time without symptoms and side effects from therapy111. 
All randomized studies of autologous SCT after primary therapy were designed and 
implemented before the availability of thalidomide, lenalidomide, or bortezomib. Therefore, the 
role of transplant may evolve in the future. The results of the PETHEMA trial strongly support, 
even in the era of novel agents, the use of upfront autologous SCT for MM55, with evaluation of 
responses after induction therapy and after autologous SCT. Considering patients who actually 
underwent the autologous SCT, the CR rates increased in the group treated with VTD from 35% 
pretransplant to 57% posttransplant as induction therapy, and, in the group treated with 
thalidomide and dexamethasone as induction therapy, from 14% to 40%, respectively55. 
A recent phase III study compared high-dose melphalan followed by autologous SCT with MPR 
(melphalan/prednisone/lenalidomide): patients (n=402) were randomly assigned, in a 1:1:1:1 
ratio, to 1 of 4 groups: high-dose therapy and SCT followed by maintenance with lenalidomide; 
high-dose therapy and SCT alone; primary therapy with MPR followed by lenalidomide; and 
primary therapy with lenalidomide alone. The primary study end point was PFS, secondary end 
points included ORR, OS, the time to a response, and safety112. High-dose melphalan therapy 
followed by SCT was associated with a significant reduction in the risk of progression or death 
(HR, 0.44) and prolonged OS (HR for death, 0.55)112. 
Results from the IFM 2005-01 study of symptomatic myeloma patients receiving frontline 
treatment with bortezomib and dexamethasone versus VAD showed a marked improvement in 
ORR with bortezomib and dexamethasone over VAD57. Evaluation of responses was performed 
after primary treatment and post-autologous SCT. After the first autologous SCT, CR/nCR rates 
were 35.0% in the bortezomib plus dexamethasone arm, compared with 18.4% in the VAD 
arm57, VGPR rates were 54.3% versus 37.2%. and median PFS was 36.0 months versus 29.7 
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months (P=.064) with bortezomib plus dexamethasone versus VAD after a median follow-up of 
32.2 months57. Moreover, PFS was also significantly longer in the patients achieving greater than 
or equal to a VGPR after primary treatment than in patients achieving a less than VGPR 
(median, 36 vs 29.7 months)57.  
In another trial, 474 patients were randomized to frontline treatment with VTD (n=236) versus 
TD (n=238) before double autologous SCT113. The three-drug regimen yielded high response 
rates compared with the two-drug regimen, with a CR rate of 19% vs 5% and greater than or 
equal to VGPR of 62% vs 31%. After SCT, improved incremental responses were still seen with 
VTD compared with TD. Considered together, these studies suggest that improved responses 
with the primary regimen result in improved outcomes after SCT. 
Trials have found that PD emerging after frontline treatment does not preclude a good response 
to autologous SCT108,114,115. In particular, Kumar et al115 considered a case series of 50 patients 
with primary progressive MM receiving an autologous SCT, comparing results with those of 100 
patients with responsive disease undergoing autologous SCT. The 1-year PFS from the time of 
SCT was 70% in the primary progressive group compared with 83% in the chemosensitive 
group.  
Nowadays, autologous SCT is the best option after frontline treatment and for treatment of 
primary progressive or refractory disease after primary treatment. 
 
3.2.2 Tandem SCTs 
 
Tandem SCT is defined as a planned second course of high-dose therapy and SCT within 6 
months of the first course. Several randomized trials have evaluated the role of planned tandem 
transplants. In particular, the IFM94 randomized trial reported by Attal et al116 compared newly 
diagnosed MM patients to single or tandem autologous transplants. In tandem transplant group, a 
total of 78% of patients received the second transplant at a median time of 2.5 months after the 
first. There were a variety of options for relapsed disease treatment: for example, patients with 
relapsed disease in either group underwent either no therapy, additional conventional therapy, or 
another SCT. EFS 7 years after diagnosis was 10% in the single transplant group versus 20% in 
the double transplant group.  
Stadtmauer117, in accompanying editorial, questions whether the promising results might be 
related to type of regimens used, rather than to the effect of 2 courses of high-dose therapy. For 
example, patients received 140 mg/m2 of melphalan plus TBI in the single transplant arm, while 
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the same dose without TBI for the initial transplant and with TBI for the second transplant in the 
tandem arm. As earlier noted, TBI has shown more toxicity without providing additional benefit. 
Based on this, Stadtmauer suggests that the increased survival in IFM94’s tandem arm may have 
resulted from greater cumulative exposure to melphalan, 280 vs 140 mg/m2.  
In a subset analysis, the patients who did not achieve a CR or a VGPR within 3 months after the 
first SCT appeared to benefit the most from a second SCT. The investigators suggested that the 
improvement associated with tandem transplant is related not to improved response rates but 
rather to longer durations of response. Four other randomized trials have compared single versus 
tandem SCT109,118-120, with no one showing a significant improvement in OS. However, 
considering that the median follow-up in these trials ranged from 42 to 53 months, it is not 
surprising the lack of significant improvement. Cavo et al118 found that patients not in CR or 
nCR after the first SCT benefited the most from a second SCT, confirming the observations of 
the IFM94 trial using non-TBI-based high-dose regimens. 
In both the Italian and French trials, the benefit of a second autologous SCT was seen in patients 
who do not achieve a CR or VGPR, more than 90% reduction in M-protein level, with the first 
procedure. However, these two trials were not adequately powered to evaluate the equivalence of 
one versus two SCT in patients achieving a CR or VGPR after the first transplantation. 
Barlogie et al121 found in a review of long-term outcomes of several trials of autologous 
transplantation that tandem SCT were superior to both single SCT and standard therapies. Also, 
when EFS was sustained for at least 3.5 years after tandem SCT, post-relapse survival was 
longer. However, at diagnosis, in all eligible patients it’s recommended to collect enough stem 
cells for two transplants. A tandem SCT with or without maintenance therapy can be considered 
for all patients who are eligible for SCT, and it is an option for patients who do not achieve at 
least a VGPR after the first autologous SCT. Palumbo et al112 support for use of lenalidomide 
maintenance therapy after autologous transplantation: although it is associated with more 
frequent grade 3 or 4 neutropenia and infections, lenalidomide maintenance, compared with no 
maintenance, was found to significantly reduce risk of disease progression or death (HR, 0.47) 
after both single and tandem transplantation112. 
The benefit from the second SCT in patients who have CR or VGPR, or in those who achieve 
less than a VGPR after the first SCT, should preferably be determined in a randomized clinical 
trial. In fact, such a randomized prospective Intergroup- and NIH-supported trial is currently 
ongoing. For this group of patients, the other options include observation or maintenance 
therapy. 
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A retrospective case-matched control trial was performed comparing patients who underwent a 
second autologous SCT versus those treated with conventional chemotherapy for relapsed 
MM122. This retrospective analysis demonstrated that a second autologous SCT is associated 
with superior relapse-associated mortality compared with conventional chemotherapy, 68% vs 
78%, along with improved OS, 32% vs 22%, at 4 years, as seen in other published smaller 
studies123-125. In this trial, factors associated with improved OS and PFS included younger age 
(<55 years), beta-2 microglobulin level <2.5 mg/L at diagnosis, a remission duration of more 
than 9 months, and better than a PR to their first autologous SCT. So, a second autologous SCT, 
for relapsed or progressive MM, may be an option for carefully selected patients. Some of these 
patients can achieve durable CR or PR125,126. 
A multicenter, randomized phase III trial compared high-dose melphalan plussecond autologous 
SCT with cyclophosphamide in relapsed MM patients who had received autologous SCT as 
frontline treatment127. The patients included in the study needed treatment for progressive or 
relapsed disease at least 18 months after a previous autologous SCT, and first received PAD 
induction therapy. Then, patients with adequately harvested stem cells were after induction 
randomized to high-dose melphalan plus second autologous SCT (n=89) or oral 
cyclophosphamide (n=85). The primary end-point was time to disease progression127. After a 
median follow-up of 31 months, median time to progression in patients who underwent second 
autologous SCT after induction was 19 months versus 11 months for those treated with 
cyclophosphamide (HR, 0.36; 95% CI, 0.25–0.53; P<.0001). Considering hematologic toxicity, 
grade 3/4 neutropenia (76% vs 13%) and thrombocytopenia (51% vs 5%) were higher in 
autologous SCT versus cyclophosphamide127. 
Moreover, StaMINA trial indicated that a tandem autologous SCT followed by lenalidomide 
maintenance has similar outcomes to a single autologous SCT followed by lenalidomide 
maintenance in frontline treatment of MM128. EMN02/HO95 MM trial, an intergroup, 
multicenter, phase III study, suggests that in newly diagnosed MM tandem autologous SCT, 
compared with single autologous SCT after induction therapy with a bortezomib-based regimen, 
appears to be superior in extending PFS129. 
So, second autologous SCT for relapsed disease may be considered either on or off clinical trial 
considering the interval between the first SCT and documented progression130-133 and 2 to 3 
years is the minimum length of remission for considering second autologous SCT for relapsed 
disease. 
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3.2.3 Allogeneic SCT 
 
Allogeneic SCT includes either myeloablative or non-myeloablative (mini transplant) 
transplants. Allogeneic SCT can be considered as an alternative to autologous SCT to avoid the 
contamination of reinfused autologous tumor cells, but also to take advantage of the beneficial 
graft-versus-tumor (GvT) effect associated with allogeneic transplants. However, older MM 
population, lack of a suitable donor and increased morbidity has limited this approach in MM. 
Non-myeloablative transplants are designed to decrease the morbidity of the high-dose 
chemotherapy but preserve the beneficial GvT effect. Moreover, the principal difference between 
myeloablative and non-myeloablative transplants relates to the chemotherapy regimen used. 
Considered the small candidate pool, it should be not surprising that no randomized clinical trials 
comparing myeloablative allogeneic to autologous SCT have ever been performed, but multiple 
case series have been published describing allogeneic SCT as an initial or as therapy for 
relapsed/refractory MM. Kyle in a review134 reported a mortality rate of 25% within 100 days 
and overall transplant-related mortality of approximately 40% and few patients were cured. In all 
reports it has also reported increased morbidity without convincing proof of improved 
survival114,135. However, SWOG randomized trial of autologous transplant versus conventional 
chemotherapy showed interesting data108. At start, the original trial had an ablative, allogeneic 
transplant group consisting of patients with HLA identical siblings; the allogeneic arm was then 
closed because 36 patients received allograftswith a 6-month mortality of 45%. With 7 years of 
follow-up the OS of the conventional chemotherapy, autologous, and allogeneic arms were all 
identical at 39%. However, the autologous and conventional chemotherapy arms do not 
demonstrate a plateau, while the allogenic curve was flat at 39% and this suggests that a 
proportion of these patients are long-term survivors. So, there is on-going interest in 
myeloablative allogeneic SCT, particularly given the lack of a significant cure rate for single or 
tandem autologous SCT. 
Today, also in era of novel agent, allogeneic SCT should be considered an option, preferably in a 
clinical trial in patients whose disease responds to primary therapy, with primary PD, or with PD 
after an initial autologous SCT. 
Another possibility is first autologous SCT followed by a mini-allogeneic transplant: Bruno et 
al136 showed in a prospective trial that, among patients <65 years with HLA-matched siblings 
who received an autograft-allograft regimen, the CR rate after allografting was 55% compared 
with 26% after double autograft in patients without HLA-matched siblings. Median OS was 
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higher, 80 vs 54 months. In the prospective PETHEMA trial, in patients who did not achieve at 
least a nCR with a first autologous SCT, no significant difference was seen in OS after double 
autologous SCT versus autologous SCT followed by mini-allogeneic transplant. However, a 
trend toward a longer PFS was observed in the group treated with autologous SCT followed by 
mini-allogeneic transplant137. IFM99-03 trial by Garban et al138 and the BMT CTN 0102 trial139 
reportedin patients with high risk, in contrast, no OS or PFS advantage with autologous 
transplant followed by allogeneic transplant. 
In a prospective trial of newly diagnosed MM patients, based on the availability of an HLA-
identical sibling, were selected for treatment with autologous SCT followed by reduced-intensity 
conditioning allogeneic SCT or autologous SCT140. Induction chemotherapy consisted of the 
chemotherapy that was standard at that time, VAD or VAD-like regimen. After 60 months, in the 
group treated with autologous SCT followed by reduced-intensity conditioning allogeneic SCT 
the incidence of relapse/progression was 49% versus 78% in the autologous SCT group. At 60 
months, the OS and CR rates were 65% and 51%, respectively, for patients treated with 
autologous SCT followed by reduced-intensity conditioning allogeneic SCT compared with 58% 
and 41%, respectively, for those treated with autologous SCT. Based on these results, patients 
who have an HLA-identical sibling as part of their frontline treatment may be considered 
candidates for reduced-intensity allogeneic SCT. 
Mini-allogeneic transplants have also been investigated as therapy for relapsed/refractory MM 
thanks to its graft-versus-myeloma effect. Younger age and response to prior SCT are associated 
with better response and OS rates102-143. In a case series report, patients with previously treated 
relapsed disease or PD (n = 54) were treated with an autologous SCT, followed by a mini-
allogeneic transplant141. 
At a median of 552 days after the mini-allogeneic transplant, OS rate was 78%, with a 57% CR 
rate and an ORR of 83%. This trial concluded that this approach reduced the toxicities of a 
myeloablative allogeneic SCT, while preserving antitumor activity. 
The largest case series was reported by the EBMT142, heterogeneous population of 229 patients, 
where the 3-year OS and PFS were 41% and 21%, respectively. Chemoresistant disease was 
associated to adverse OS, while more than 1 prior transplant, was associated to improved OS 
with graft-versus-host disease (GVHD), thus confirming the importance of a GvT effect144. This 
trial concluded that mini-allogeneic transplantation is an option in relapsed/refractory patients, 
but that heavily pretreated and patients with PD are unlikely to benefit. 
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Donor lymphocyte infusions can be received to stimulate a beneficial GvT effect for patients 
whose disease either did not respond to relapses after allogeneic stem cell or other myeloma 
therapies145-152. 
 
3.2.4 Follow-Up After SCT 
 
Follow-up is the same of other myeloma treatments, in addition, MRD assessment is increasingly 
being incorporated into post-treatment assessments, and it has been identified as an important 
prognostic factor. A prospective trial of newly diagnosed MM patients evaluated MRD in bone 
marrow samples and showed that MRD negativity after autologous SCT translated to 
significantly improved PFS and OS rates, at a median follow-up of 57 months153 and, also in 
another study, MRD negativity post-autologous SCT was predictive of favorable PFS and OS154. 
In the allogeneic SCT setting, similar results have also been reported: the presence of MRD post 
allogeneic SCT has been associated with a significantly adverse PFS and OS144. 
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4. Maintenance Therapy 
4.1 Lenalidomide as Maintenance Therapy After Autologous SCT 
 
Two independent randomized phase III trials evaluated the role oflenalidomide as maintenance 
therapy after autologous transplantation94,95. 
In the first, CALGB 100104, patients were randomized to maintenance treatment with 
lenalidomide (n=231) versus placebo (n=229) after autologous SCT95. 37% of the patients 
receiving lenalidomide versus 58% receiving placebo had disease progression or died, at a 
median follow-up of 34 months. The median time to progression was 46 months in the 
lenalidomide group versus 27 months in the placebo group (P<.001). Second primary cancers 
were revealed in 18 patients who received lenalidomide (8%) and in 6 patients who received 
placebo (3%)95. 
IFM2005-02, international, randomized, double-blind phase III trial94 (n=614) showed that 
patients treated with consolidation therapy with lenalidomide after an autologous SCT followed 
by lenalidomide as maintenance therapy had upgraded responses. Patients enrolled in the trial 
were 614:307 were randomly assigned to lenalidomide maintenance therapy and 307 to placebo 
arm. Maintenance therapy was continued until unacceptable toxic effects occurred, the disease 
progressed, orthe patient withdrew consent. After a median follow-up of 30 months, the final 
analysis of the IFM2005-02 trial was performed and 264 patients had disease progression, 104 in 
the lenalidomide arm and 160 in the placebo arm, with a median PFS of 41 months in the 
lenalidomide arm compared with 23 months in the placebo arm (HR, 0.50; P<.001; median 
follow-up period was 30 months). The probability of surviving without progression for 3 years 
after randomization was 59% in lenalidomide arm and 35% in placebo arm, confirming the 
benefit of lenalidomide maintenance therapy. In particular, this benefit was observed not only in 
patients who had a VGPR at randomization (64% vs 49%; P=.006) but also in those who did not 
(51% vs 18%; P<.001). However, an increased incidence of second primary cancers was 
observed in the lenalidomide arm, with 32 second primary cancers in the lenalidomide arm 
versus 12 in the placebo group94. 
In a phase II trial by the IFM group, maintenance with lenalidomide was shown to upgrade 
responses seen after induction therapy with lenalidomide/bortezomib/dexamethasone followed 
by autologous transplant in 27% of patients (8 of 31 patients)78. 
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Palumbo et al112 showed that, although maintenance therapy with lenalidomide is associated with 
more frequent grade 3/4 neutropenia and infections, it significantly reduced risk of disease 
progression or death (HR, 0.47), compared with no maintenance112. 
HOVON 76 trial indicated that lenalidomide maintenance may not be a feasible option after 
mini-allogeneic SCT155. However, another recently reported trial has shown in patients with 
high-risk MM the feasibility of maintenance therapy with low-dose lenalidomide after allogeneic 
SCT156. 
 
4.2 Lenalidomide as Maintenance Therapy After Non-Transplant Active Primary 
Treatment 
 
MM-015 the phase III trial showed that lenalidomide maintenance after primary therapy with 
MPR significantly reduced the risk of disease progression, increasing PFS157. In this trial, newly 
diagnosed MM patients (n=459), aged ≥65 years, were randomized to receive MP followed by 
placebo, MPR, or MPR followed by lenalidomide until progression. Lenalidomide maintenance 
significantly prolonged PFS and the PFS of patients treated with MPR followed by maintenance 
lenalidomide, compared with the other 2 arms, was significantly prolonged (n=152; median, 31 
months): MPR (n =153; median, 14 months; HR, 0.49; P<.001) or MP (n=154; median, 13 
months; HR, 0.40; P<.001). Lenalidomide maintenance, compared with placebo, improved PFS 
by 66% regardless of age157. In the FIRST trial, use of lenalidomide indefinitely until 
progression was associated with a superior PFS, compared with a fixed duration of 18 months. 
Considering the results of the phase III trials94,95,157, lenalidomide is one of the preferred 
maintenance regimens, having a better efficacy and lacking the neurologic toxicity seen with 
thalidomide. However, the only problem seems to be an increased risk for secondary cancers, 
especially post-transplantation94-96 or after treatment with a melphalan-containing regimen97. 
However, in FIRST trial, in continuous treatment lenalidomide/dexamethasone arm, the absence 
of the alkylating agent melphalan seems to be more effective not only in terms of improving PFS 
but also of lowering incidence of second malignancies93. 
An important meta-analysis of four randomized controlled trials, comparing patients treated with 
lenalidomide maintenance versus those treated without maintenance or with placebo in both the 
transplant and non-transplant settings158, showed that patients treated with lenalidomide 
maintenance had significantly improved PFS (HR, 0.49; P<.001) and a trend toward OS (HR, 
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0.77; P=.071) versus no maintenance or placebo158. Moreover, with the use of lenalidomide there 
was more grade 3/4 neutropenia and a two-fold increased risk of secondary malignancies. 
 
4.3 Bortezomib as Maintenance Therapy After Autologous SCT 
 
HOVON study showed that maintenance with single-agent bortezomib after autologous SCT is 
is associated with improvement of ORRand well tolerated76. In this trial, patients were randomly 
assigned to one of the two arms, consisting of either primary treatment with VAD followed by 
autologous SCT and maintenance with thalidomide, or with PAD followed by autologous SCT 
and bortezomib as maintenance therapy, for 2 years, with high nCR/CR rates after frontline 
treatment with the bortezomib-based regimen. So, bortezomib as maintenance treatmentwas 
associated with additional improvement of response rates and was well tolerated76. A multicenter 
phase III trial in newly diagnosed MM patients showed that improved PFS due to consolidation 
with bortezomib after autologous SCT only in patients not achieving at least a VGPR after 
autologous SCT159: no difference in PFS was seen in patients with a VGPR or better after 
autologous SCT. 
 
4.4 Bortezomib as Maintenance Therapy After Non-Transplant Active Primary 
Treatment 
 
The preliminary results of the UPFRONT randomized phase III trial also show that maintenance 
with single-agent bortezomib is well-tolerated when administered after treatment with 
bortezomib-based primary therapy160. Newly diagnosed MM patients, ineligible for high-dose 
therapy and SCT, enrolled in the UPFRONT trial, were randomized (1:1:1) and treated with one 
of the following bortezomib-based primary regimens, followed by maintenance treatment with 
bortezomib: bortezomib and dexamethasone; bortezomib in combination with thalidomide and 
dexamethasone; or bortezomib with melphalan and prednisone. The response rates, including CR 
and VGPR or better, improved after bortezomib maintenance in all arms, without concomitant 
increase in the incidence of PN160. 
So, considering these results, bortezomib can play a role in mantenance treatment of MM. 
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5. Therapy for relapsed/refractory and progressive Myeloma 
 
Nowadays, several therapies are nowadays as options for previously treated Multiple Myeloma, 
in different clinical situations, such as patients in relapse after allogenic or autologous SCT or 
with primary PD after initial autologous or allogenic SCT and patients who are ineligible for 
SCT with progressive or relapsing disease after primary therapy. 
In particular, if the relapse occurse in less than six months after the end of the therapy, patients 
could be retreated with the same regimen. 
The first possibility is the addition of dexamethasone to bortezomib in rrMM, who had 
progressive disease during bortezomib monotherapy: this can give an improvement of response 
in 18-34% of patients161-163. 
 
5.1 Lenalidomide/Dexamethasone 
 
Lenalidomide has been approved by FDA as treatment for MM who had received at least one 
prior treatment, thanks to two important studies of a total of 692 patients randomized in two 
arms: dexamethasone with or without lenalidomide. The primary endpoint was the time to 
progression (TTP), in both the studies. The median TTP was longer in lenalidomide arm versus 
dexamethasone group, as confirmed in a pre-planned interim analysis164,165. The updated data 
from MM-009, the North American phase III trial, in 353 previously treated MM patients 
showed increased OS and median TTP in lenalidomide plus dexamethasone versus 
dexamethasone plus placebo165, as confirmed also by another international trial, MM-010164: in 
both the trials the patients had been heavily pretreated before enrollment, and many had more 
than three prior lines of therapies, and more than half of patients had also undergone SCT164,165. 
Considering safety, most adverse events and grade 3/4 adverse events were more frequent in 
lenalidomide plus dexamethasone arm, with great prevalence of thrombocytopenia (61.5%) and 
neutropenia (58.8%).  
However, lenalidomide/dexamethasone is an important opportunity in relapsed/refractory MM 
patients165, while lenalidomide monotherapy is a possibility for steroid-intolerant patients. 
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5.2 Carfilzomib/Lenalidomide/Dexamethasone 
 
A randomized, multicenter trial of phase III, ASPIRE, enrolling 792 rrMM patients, compared 
the combination of lenalidomide and dexamethasone with or without carfilzomib in MM patients 
who had received one to three prior lines of treatment. The primary endpoint was PFS, 
significantly improved in carfilzomib arm, by 8.7 months (26.3 months in carfilzomib arm 
versus 17.6 months in len-dexa arm; HR for progression or death, 0.69; 95% CI, 0.57-0.83; 
P=.0001). Considering safety, the incidence of PN was nearly identical in both arms (17.1% 
carfilzomib arm versus 17% len-dexa arm), and non-hematologic adverse-events of at least grade 
3 which were higher in carfilzomib arm included dyspnea, 2.8% vs 1.8%, cardiac failure, 3.8% 
vs 1.8%, and hypertension, 4.3% vs 1.8%. 
In particular, in carfilzomib arm there were fewer discontinuations due to side effects, 15.3% vs 
17.7%, and, in this arm, it was reported superior health-related quality of life166. 
So, nowadays, carfilzomib/lenalidomide/dexamethasone (KRD) is considered one of the best 
options in rrMM, and it has been recently approved in Italy for this setting of patients. 
 
5.3 Carfilzomib/Dexamethasone 
 
An important multicenter, randomized, phase III trial, ENDEVOR, compared 
carfilzomib/dexamethasone (KD) to bortezomib/dexamethasone (VD) in rrMM, treated with 
multiple prior lines of therapy. It was shown a two-fold improvement in median PFS in KD arm 
(18.7 months vs 9.4 months; HR=0.53; P < .0001)167. ORR was 77% in KD arm versus 63% in 
VD group (with rates of CR or better which were 13% versus 6% and VGPR 42% versus 22%, 
respectively). 
Median duration of response was 21.3 months in KD arm versus 10.4 months in VD arm. 
Adverse events of grade 3 or higher were hypertension (6% versus 3%), dyspnea (5% versus 
2%). PN of grade 2 or higher was 6% in KD arm versus 32% in VD arm167. 
Considering these data, KD can be considering a very good option for rrMM. However, it is not 
yet available in Italy. 
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5.4 Pomalidomide/Dexamethasone 
 
Pomalidomide is a new generation IMID, analogue of thalidomide like lenalidomide, and it has 
been demonstrated its potent anti-myeloma and immunomodulatory activities (Figure 6, Figure 
7)168.  
 
 
 
 
Figure 6: Pomalidomide structure 
 
 
Figure 7: Chemical stuctures of IMIDs: Thalidomide, Lenalidomide and Pomalidomide 
 
A ranzomized multicenter phase I trial compared pomalidomide (standard schedule: 4mg orally 
on days 1-21 of each 28-day cycle), with or without dexamethasone (40mg/week), showing 
efficacy and manageable toxicity in rrMM patients, including also those refractoty to both 
lenalidomide and bortezomib169. Then, a randomized open-label phase II trial compared 
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pomalidomide and low-dose dexamethasone versus single-agent pomalidomide in rrMM patients 
who had previously received a trial of lenalidomide and bortezomib170. This trial evaluated 221 
patients, who, after a median follow-up of 14.2 months, showed a median PFS of 4.2 months in 
pomalidomide plus low-dose dexamethasone arm, compared with 2.7 months in patients treated 
with pomalidomide alone (HR, 0.68; P=0.003)171 and median OS was 16.5 months in pom-dexa 
arm compared to 13.6 months with pomalidomide alone171. Considering safety, grade 3-4 
neutropenia occurred in 41% in pomalidomide plus low-dose dexamethasone versus 48% in 
pomalidomide monotherapy arm. No grade 3 to 4 PN was reported. 
Then, MM-003, a phase III, multicenter, randomized, open-label trial, was conducted in Europe, 
comparing the efficacy and safety of pomalidomide and low-dose dexamethasone (n=302) versus 
high-dose dexamethasone (n=153) in rrMM who were refractory to both bortezomib and 
lenalidomide172. Primary endpoint of the study was PFS, which, after a median follow-up of 10 
months, was significantly longer in pomalidomide and low-dose dexamethasone arm compared 
with high-dose dexamethasone (4.0 vs 19 months; HR, 0.45; P<0.0001)173, and also median OS 
was significantly longer in pomalidomide and low-dose dexamethasone (12.7 months vs 8.1 
months; HR=0.74; P=0.0285)173. Considering safety, the most common grade 3 and 4 
hematologic adverse events found to be higher in pom-dexa arm were neutropenia and 
pneumonia173. Other phase III trials of pomalidomide plus low-dose dexamethasone in 
combination with other agents (eg. bortezomib NCT01734928) are currently ongoing. Moreover, 
a European multicenter, single arm, open-label phase IIIb trial, which evaluated the safety and 
efficacy of pomalidamide and low-dose dexamethasone in a large international patient 
population (N=604)174, showed a median PFS of 4.2 months and a OS of 11.9 month. PFS, OR, 
and ORR were similar whether the patients had previously received lenalidomide or 
bortezomib174: these results are consistent with those observed in the pivotal MM-003 trial. 
Then, several complementary phase II trials have been published evaluating pomalidomide and 
dexamethasone in rrMM patients, refractory to lenalidomide and/or bortezomib. A phase II trial 
compared two different dose schedules of pom-dexa in 84 rrMM patients. Pomalidomide was 
given orally at standard dose on days 1 to 21 or continuously over a 28-day cycle, and 
dexamethasone 40mg was given orally once weekly175. ORR was 35% and 34% for patients in 
the 21-day and 28-day arms, respectively. Median follow-up was 23 months, and median 
duration of response, PFS, and OS were 7.3, 4.6, and 14.9 months across both groups, 
respectively. Adverse events were similar in both groups, primarly due to myelosuppression175. 
Another multicenter phase II trial compared two dose-schedules of pomalidomide (2 versus 4 
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mg/day) with dexamethasone 40 mg weekly in heavily pre-treated rrMM patients (n=35)176. 
ORR was 49% in the 2-mg arm versus 43% in the 4-mg, respectively, and myelosuppression was 
the most common adverse event176. 
So, pomalidomide was approved by FDA for MM patients who have previously received at least 
two therapies, including lenalidomide and bortezomib, and have shown disease progression on or 
within 60 days of completion of the last therapy. The recommended schedule and dose of 
pomalidomide is 4 mg orally on days 1 to 21 of 28-day cycles, repeated until disease progression 
of unacceptable adverse events, monitoring patients for hematologic toxicities, especially 
neutropenia. 
So, pomalidomide plus dexamethasone is an option in patients who have received at least two 
prior therapies, including an immunomodulatory agent and bortezomib, and have demonstrated 
disease progression on or within 60 days of completion of the last therapy and, for steroid-
intolerant individuals, pomalidomide monotherapy can be considered. 
 
5.5 Elotuzumab/Lenalidomide/Dexamethasone 
 
Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation 
molecule-F7 (SLAMF7). SLAMF7, also called CS1 (cell-surface glycoprotein CD2 subset 1) or 
CD319 or CRACC, is a glycoprotein expressed on myeloma and natural killer (NK) cells but not 
on normal tissues (Figure 8)177.  
 
 
 
Figure 8: Elotuzumab - Mechanism of action 
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Elotuzumab in combination with lenalidomide and dexamethasone was approved by the FDA for 
the treatment of rrMM patients, who have received one to three prior therapies.  
This approvation was due to the encouraging results of the multicenter phase III trial, 
ELOQUENT-2, which randomized 646 patients (1:1) to receive either elotuzumab in 
combination with lenalidomide and dexamethasone (ERD) or lenalidomide and dexamethasone 
alone178.  
Considering PFS rates at the end of 1 and 2 years, they were higher for those receiving ERD 
(68% at 1 year and 41% at 2 year), and PFS was 19.4 months in ERD arm versus 14.9 months in 
those receiving lenalidomide and dexamethasone alone (HR for progression or death in the 
elotuzuamab group. 0.70; 95% CI, 0.57-0.85; p<0.001), indicating a relative reduction of 30% in 
the risk of disease progression or death178. In both arms of the trial, common grade 3 or 4 adverse 
events were lymphocytopenia, neutropenia, fatigue, and pneumonia.  
Infusion reactions were not common: they occurred in 33 patients (10%) in the ERD arm, and 
were grade 1 or 2 in 19 patients178.  
The subset analyses of extended 3-year follow-up confirmed these results, with median duration 
of response reported with ERD which was 20.3 months versus 16.6 months of lenalidomide-
dexamethasone arm, showing that PFS benefit with the Elo-based triplet was durable over 
time179.  
FDA approved elotuzumab in combination with lenalidomide and dexamethasone in previously 
treated MM, and, thanks to a novel mechanism of action added to immunomodulation, this is one 
of the best options which is available in rrMM. 
 
5.6 Ixazomib/Lenalidomide/Dexamethasone 
 
As previously discussed, ixazomib is an oral, new-generation, proteosome inhibitor. A double-
blind, placebo-controlled, randomized, phase III trial, TOURMALINE MM1, randomized 722 
patients with rrMM, comparing a combination of ixazomib, lenalidomide and dexamethasone 
(IRD) versus lenalidomide and dexamethasone alone (control group). TOURMALINE MM1 was 
designed thanks to the promising results of a phase I/II trial, previously discussed180. 
This trial has shown a significant improvement in PFS with IRD: after a median follow-up of 
almost 15 months, a 35% improvement in PFS was seen in IRD, compared with the control 
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group (HR, 0.742; P=0.012). Median PFS was 20.6 months in IRD versus 14.7 months in Len-
Dexa. Moreover, in IRD, the ORR (78.3% vs 71.5%., P=0.035) and CR (11.7% vs 6.6%, 
P=0.019) were also significantly improved. In particular, high-risk cytogenetics patients enrolled 
in the trial had a similar HR for PFS as the entire study population (HR, 0.596 and 0.543, 
respectively). Considering safety, grade ≥3 adverse events were 68% in IRD versus 61% in 
control group, and these included neutropenia (19% with ixazomib/lenalidomide/dexamethasone 
vs 16% with lenalidomide/dexamethasone), anemia (9% vs 13%), thrombocytopenia (13% vs 
5%), and pneumonia (6% vs 8%). Serious adverse events were reported in 40% in IRD and 44% 
in Len-Dexa180.  
Based on these results, ixazomib/lenalidomide/dexamethasone was approved by FDA for rrMM, 
and can be considered a very good option in this setting of patients, in particular for unfit ones, 
thanks to the oral formulation. It is available in Italy thanks to compassionate use program. 
 
5.7 Daratumumab single agent 
 
Daratumumab is a innovative human IgG kappa monoclonal antibody that targets the CD38 
surface protein on myeloma cells (Figure 9)181, recently approved by FDA, based on the 
surprising results of a phase I/II trial, for the treatment of rrMM patients, who have received at 
least three prior lines of therapy including a PI and a immunomodulatory agent, or who are 
double refractory to PI and IMIDs. 
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Figure 9: Daratumumab – Mechanism of action 
 
In the phase I/II trial, patients who had previously received more than 3 lines of therapy 
including an IMID and a PI or were double refractory to a PI and IMID were randomized to two 
different doses of daratumumab (8mg/kg versus 16 mg/kg). ORR was 29.2% (with 3sCR, 10 
VGPR, and 18PR). Median duration of response was 7.4 months and median time to progression 
was 3.7 months. The estimated 1-year OS rate was 65%182. Reported adverse events were fatigue 
(39.6%), anemia (33.0%), nausea (29.2%), and thrombocytopenia (25.5%). Grade 1/2 infusion-
related reactions were quite common, seen in 42.5% of patients, mainly during first infusion, but, 
however, no patients discontinued the study due to infusion-related reactions182. 
So, daratumumab single agent can be considered as an option for rrMM patients who have 
received at least three prior lines of therapy including a PI and an IMID or who are double 
refractory to a proteasome inhibitor and immunomodulatory agent. 
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5.8 Daratumumab/Bortezomib/Dexamethasone (CASTOR) 
 
CASTOR is a randomized, multicenter, phase III trial evaluating the combination of 
daratumumab, bortezomib and dexamethasone (DVD) in rrMM183. This regimen markedly 
improved outcomes for rrMM patients. Patients (n=498) were randomized to receive DVD 
versus VD. The ORR was 82.9% in DVD arm, compared to 63.2% in the control arm (P<0.001). 
Moreover, the rates of VGPR and CR were double in DVD arm compared to the control arm 
(59.2% vs 29.1%, P<0.001 and 19.2% vs 9.0%, P=0.001. respectively), and the 12-month 
estimated rate of PFS was significantly higher in the DVD arm compared to the control (60.7% 
vs 26.9%). The most common grade 3/4 adverse events reported in daratumumab and control 
groups were thrombocytopenia (45.3% and 32.9%, respectively), anemia (14.4% and 16.0%, 
respectively), and neutropenia (12.8% and 4.2% respectively). Grade 1 or 2 infusion-related 
reactions associated with daratumumab were reported in 45.3% of the patients in the DVD and 
grade 3 in only 8.6% of the patients: these reaction rates are consistent with findings from 
previous trials of daratumumab181,182.  
Daratumumab/bortezomib/dexamethasone was approved by FDA for rrMM and can be 
considered one of the best options in this setting of patients.  
 
5.9 Daratumumab/Lenalidomide/Dexamethasone (POLLUX) 
 
POLLUX is a randomized, multicenter, phase III trial evaluating the combination of 
daratumumab, lenalidomide and dexamethasone (DRD) in rrMM184. This regimen markedly 
improved outcomes for rrMM patients. Patients (n=569) were randomized to receive DRD 
versus RD. 
At a median follow-up of 13.5 months, 12 months-PFS was 83.2% in DRD arm versus 60.1% in 
the control group, and it was shown also a significantly higher ORR, 92.9% in DRD versus 
76.4% in RD, with a rate of CR or better of 43.1% versus 19.2% (p<0.001). 
The most common grade 3/4 adverse events reported in daratumumab and control groups were 
neutropenia (51.9% and 37% respectively), thrombocytopenia (12.7% and 13.5%, respectively), 
anemia (12.4% and 19.6%, respectively). Grade 1 or 2 infusion-related reactions associated with 
daratumumab were reported in 47.7% of the patients in the DRD: these reaction rates are 
consistent with findings from previous trials of daratumumab181,182.  
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Daratumumab/lenalidomide/dexamethasone was approved by FDA for rrMM and can be 
considered, considering these data, the best option in this setting of patients.  
 
5.10 Bortezomib/Liposomal Doxorubicin 
 
Bortezomib combined with liposomal doxorubicin was approved by FDA as option for rrMM 
who have not previously received bortezomib and have received at least 1 prior therapy. The 
FDA approval was based on a priority review of data from an international phase III study 
(n=646), showing that use of bortezomib plus liposomal doxorubicin significantly extended the 
median time to disease progression compared with bortezomib alone (9.3 vs 6.5 months)185. In 
particular, median duration of response was increased from 7.0 months to 10.2 months. So, 
bortezomib plus liposomal doxorubicin can be considered another effective option in rrMM. 
 
5.11 Bendamustine single agent 
 
Bendamustine is an alkylating agent, with a demonstrated activity in many hematological 
malignancies (Figure 10). 
 
 
Figure 10: Bendamustine structure 
 
Knop et al evaluated 31 patients, who had experienced relapse after autologous transplation, and 
received increasing doses of bendamustine186. ORR was 55%, with a median PFS of 26 weeks 
for all patients, and 36 weeks for patients treated with higher doses (90-100 mg/m2). Considering 
safety, toxicity was mild and mainly hematologic. Then, a retrospective analysis of 39 rrMM 
patients has reported that bendamustine is effective and tolerable in this setting of advanced MM, 
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with an ORR of 36%187. Bendamustine single agent can be considered one of the options in 
rrMM. 
 
5.12 Bendamustine/Lenalidomide/Dexamethasone 
 
The combination of bendamustine, lenalidomide, and dexamethasone (BRD) was evaluated in a 
multicenter phase I/II trial, as treatment for rrMM patients (n=29)188. Considering results, PR 
rate was 52% (n=13) of patients, VGPR 24% (n=6). The median PFS was 6.1 months (95% CI, 
3.7-9.4 months), and the one-year PFS rate was 20% (95% CI, 6%-41%)189.  
BRD can be considered one of the approved options for rrMM, not refractory to lenalidomide. 
 
5.13 Bendamustine/Bortezomib/Dexamethasone 
 
Bendamustine/bortezomib/dexamethasone (BVD) was evaluated in a phase II trial. BVD was 
administered over six 28-day cycles and then every 56 days for six more cycles in patients 
(n=75; median age 68 years) with rrMM treated with multiple prior therapies and not refractory 
to bortezomib. Considering results, ORR was 71.5% (16% CR, 18.5% VGPR, 37% PR). At 12-
month follow-up, median time to progression was 16.5 months and 1-year OS was 78%189.  
Based on these results, BVD can be considered one of the approved options for rrMM, not 
refractory to bortezomib. 
 
5.14 Bortezomib/Lenalidomide/Dexamethasone 
 
It has been demonstrated in preclinical studies that lenalidomide sensitizes myeloma cells to 
bortezomib and dexamethasone. In particular, phase I and phase II trials have demonstrated that 
bortezomib/lenalidomide/dexamethasone (VRD) is a well-tolerated and active regimen in rrMM, 
with durable responses in heavily pretreated patients, also those previously treated with 
bortezomib, lenalidomide, thalidomide and SCT189,190. Updated data after over two years of 
follow-up show a median PFS of 9.5 months with a median OS of 26 months, together with a 12- 
and 24-months OS rates of 86% and 55%, respectively193. 
Bortezomib/Lenalidomide/Dexamethasone, is a very good option for rrMM. However, it is not 
yet approved in Italy. 
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5.15 Bortezomib/Cyclophosphamide/Dexamethasone 
 
Another option for rrMM is the addition of an alkylating agent, such as cyclophosphamide, and a 
novel agent, such as bortezomib or lenalidomide, to dexamethasone. 
Bortezomib/cyclophosphamide/dexamethasone (VCD) is an effective regimen, with an 
acceptable toxicity profile, in rrMM191. 
 
5.16 Pomalidomide/Bortezomib/Dexamethasone 
 
Pomalidomide/bortezomib/dexamethasone has been evaluated in rrMM patients in early phase 
I/II studies192,193. Considering the particularly encouraging ORRs observed in these trials, this 
triplet is being currently evaluated in an ongoing phase III trial194.  
 
5.17 Pomalidomide/Carfilzomib/Dexamethasone 
 
Encouraging results of a phase I trial195, were the basis for a phase II trial aiming to evaluate the 
safety and efficacy of pomalidomide/carfilzomib/dexamethasone in rrMM patients refractory to 
lenalidomide and proteosome inhibitor-naive or sensitive. Median follow-up was of 7.2 cycles 
(range= 0.6-27.1 cycles), after which PR reported was 84%, MR 91%, VGPR 26%, and CR/nCR 
was 12%196. Moreover, after a median follow-upof 18 months (r. 1-39 months), median PFS for 
all 55 patients was 12.9 months and the estimated 18-month OS was 86.5%196.  
So, considering the promising results, pomalidomide/carfilzomib/dexamethasone could be a 
potential option in rrMM patients who have previously received at least two therapies, including 
an IMID and bortezomib, and who have demonstrated disease progression on or within 60 days 
of completion of the last therapy. 
 
5.18 Lenalidomide/Cyclophosphamide/Dexamethasone 
 
The efficacy of lenalidomide in combination with cyclophosphamide and dexamethasone was 
assessed thanks to a retrospective analysis which showed that this regimen is effective in heavily 
pre-treated patients with manageable toxicity profile197. 
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5.19 Ixazomib/Dexamethasone 
 
Ixazomib as single-agent, in combination with dexamethasone, has been evaluated in two phase I 
trials for rrMM, which estabilished the maximun tolerated dose of ixazomib to be 2.0 mg/m2 on a 
twice-weekly schedule and 2.97 mg/m2 on a weekly schedule198,199. The enrolled patients had 
multiple prior lines of therapy, with a median of 4 prior lines of therapy in both studies. In the 
trial with the weekly schedule198, the rate of PR or better (≥PR) was 27%. In the twice-weekly 
schedule trial, ≥PR rate was 15%199. Considering safety, adverse events, grade ≥3, were reported 
in 78% on the twice weekly schedule198, and they were considered drug-related in 62%, and 65% 
on the weekly schedule199. These were particularly related to hematological toxicity, and 
included thrombocytopenia (37%), neutropenia (17%), and skin and subcutaneous tissue 
disorders (8%) on the twice-weekly schedule, and thrombocytopenia (33%), neutropenia (18%), 
and diarrhea (17%) on the weekly schedule. PN was reported in 17%, drug-related in 12%, with 
no grade 3 events, on the twice-weekly schedule199. On the weekly schedule drug-related 
peripheral neuropathy was reported in 20% of patients, with 2% grade 3198. 
Then, phase II trials were designed to evaluate the role of ixazomib with or without 
dexamethasone in rrMM patients, who have limited prior exposure to bortezomib200,201. In one 
trial, 33 patients with rrMM received weekly ixazomib 5.5 mg and had dexamethasone added for 
suboptimal response or disease progression (67% of patients). After the addition of 
dexamethasone, 6 additional patients achieved a PR200. Patients were responders if they achieved 
at least PR, so, reported ORR (≥PR), with or without the addition of dexamethasone, was 
34%200. The most common adverse events observed included thrombocytopenia, fatigue, nausea, 
and diarrhea, and grade ≥3 were reported in 78%200.  
Another phase II trial evaluated the efficacy of two doses of weekly ixazomib (arm A, 4 mg and 
arm B, 5.5 mg) plus weekly dexamethasone (40 mg), in rrMM patients, who had not been 
previously treated with a proteasome inhibitor, including bortezomib, or had received less than 6 
cycles of therapy with bortezomib and had at least PR and no progression at the time of 
bortezomib-discontinuation201. The ORRs were 31% in arm A (95% CI: 17-49) and 51% (95% 
CI: 34-69) in arm B, and, in particular, the response rates were 38% for arm A and 52% for arm 
B among the patients with no prior bortezomib exposure. The most common toxicities were 
fatigue, thrombocytopenia, diarrhea, and nausea (with more grade 3 toxicities among arm B). 
PN, possibly related to ixazomib, was seen in arm A in 55%, only grade 1 or 2, and in arm B in 
43% (2 patients with grade 3)201.  
53 
 
So, combination ixazomib/dexamethasone is another treatment opinion for rrMM, who have 
received at least one prior therapy, available in Italy in compassionate-use program. 
 
5.20 Elotuzumab/Bortezomib/Dexamethasone 
 
Elotuzumab is a humanized monoclonal antibody specific for SLAMF7, previously described. 
Numerous randomized trials have shown that triplets combinations have been shown to be 
consistently more effective than 2-drug combinations for rrMM. An interesting phase II trial 
evaluated the effect of addition of elotuzumab to bortezomib and dexamethasone in rrMM 
patients202.  
At the moment, interim analysis results have demonstrated a 28% reduction in risk of disease 
progression or death for triple-drug arm compared to bortezomib/dexamethasone (HR, 0.72; 70% 
CI, 0.59-0.88). In the elotuzumab-conteining arm, median PFS was significantly higher, 9.7 
months vs 6.9 months. After 2 year of follow-up, the addition of elotuzumab continued to show 
an efficacy benefit, compared to bortezomib/dexamethasone alone, with a 24% relative risk 
reduction in PFS (HR, 0.76; 70% CI, 0.63-0.91)202.  
Elotuzumab/bortezomib/dexamethasone can be considered as treatment option for patients with 
rrMM, who have received at least one prior therapy. 
 
5.21 Panobinostat/Carfilzomib 
 
Panobinostat is a pan-deacetylase inhibitor, a new mechanism of action in MM, that 
epigenetically modulates class I and II HDAC enzymes (Figure 11).  
 
 
 
Figure 11: Chemical structure of Panobinostat 
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A multicenter, phase I/II trial evaluated the efficacy and safety of the combination of 
panobinostat and carfilzomib in rrMM, who had relapsed after at least one prior treatment203,204.  
The phase I aimed to determine the maximum tolerable dose of panobinostat plus carfilzomib, 
while the primary endpoint of the phase II was ORR. 
In the phase I trial, no dose-limiting toxicities were observed at any of the planned dose levels. In 
phase II, of the 42 evaluable patients, ORR was 67% and the clinical benefit rate was 79%203. 
Moreover, ORR was 67% for patients who are refractory to prior PI tratment and 75% for 
patients refractory to prior immnune-modulating drug treatment. Median PFS was 7.7 months, at 
a median follow-up of 17 months203,204. Grade 3/4 treatment-related adverse events included 38% 
thrombocytopenia, 21% neutropenia, 11% fatigue, 9% anemia, 9% hypertension, and 7% 
diarrhea. 
The MDT of carfilzomib plus panobinostat was not reached with the 4 dosing schedules in the 
first phase I study, and so two additional dosing schedules were evaluated. The maximum 
planned dose from the first trial was panobinostat 30 mg plus carfilzomib 20/45 mg/mg2. The 
dose of carfilzomib was escalated to 20/56 mg/mg2 in this study205. Considering safety, the most 
common adverse events grade ≥3 were thrombocytopenia (31%), fatigue (4%), and diarrhea 
(4%). Considering efficacy, ORR was 82%, with 34% ≥VGPR and 48% PR and the clinical 
benefit rate was 91%. 
Panobinostat in combination with carfilzomib could be considered another interesting option in 
rrMM. 
 
5.22 Panobinostat/Bortezomib/Dexamethasone 
 
Panobinostat in combination with bortezomib and dexamethasone was recently approved by 
FDA for rrMM patients who have previously had at least two prior therapies with regimens 
containing an immunomodulatory agent and bortezomib. 
This approval was based on the results of PANORAMA-1, a randomized placebo-controlled 
phase III study. This trial randomized 768 rrMM patients, who had received prior treatment with 
an immunomodulatory agent and bortezomib, to receive bortezomib and dexamethasone along 
with either panobinostat or placebo. Panobinostat-containing regimen showed an improved 
median PFS (11.99 months [95% CI; 10.33-12.94 months] vs 8.08 months [95% CI; 7.56-9.23 
55 
 
months]; HR, 0.63;95% CI, 0.52-0.76; P<0.0001) along an increased depth of repsonse206-207, 
while the final OS data from this study are not yet available. 
The regimen containing panobinostat is associated with significant toxicity. Serious adverse 
events were reported in 228 (60%) of 381 patients in the panobinostat group and 157 (42%) of 
377 patients in the placebo group. Common grade 3-4 laboratory abnormalities and adverse 
events were more in the panobinostat group versus the control group including 
thrombocytopenia (67% vs 31%), lymphopenia (53% vs 40%), diarrhea (26% vs 8%), fatigue 
(4ç% vs 2%), and peripheral neuropathy (18% vs 5%).  
A phase II, single-arm, multicenter trial, PANORAMA-2, evaluated the combination of 
panobinostat with bortezomib and dexamethasone in patients who had rrMM, refractory to 
bortezomib (N=55)207. ORR was 34.5% with the panobinostat-containing regimen, and median 
PFS was 5.4 months, while OS had not been reached at a median follow-up of 8.3 months207. 
Considering safety, common grade 3/4 adverse events included thrombocytopenia (63.6%), 
fatigue (20.2%), and diarrhea (20.0%).  
Thanks to the results of these trials, panobinostat plus bortezomib and dexamethasone can be 
considered an option in rrMM patients who have received at least two prior therapies, including 
an IMID and bortezomib. However, it is not yet approved in Italy. 
 
5.23 Pomalidomide/Cyclophosphamide/Dexamethasone 
 
The combination of pomalidomide/cyclophosphamide/dexamethasone was compared to 
pomalidomide/dexamethasone in a phase II trial rrMM patients (n=70), who had received more 
than 2 prior therapies208. 
The triplet significantly improved the ORR, with ≥PR in 64.7% versus 39.9% in pom-dexa arm 
(P=0.0355), while median PFS was 9.5 months versus 4.4 months. Considering safety, there 
were no significant differences in AE reports between the two arms: grade 3 and 4 anemia, 
neutropenia, and thrombocytopenia, respectively, were reported in 11%, 31% and 6% of patients 
treated with pom-dexa and 24%, 52%, and 15% of patients treated with 
pomalidomide/cyclophosphamide/dexamethasone209. A single center retrospective study209 of 
rrMM patients (n = 20) who received pomalidomide/cyclophosphamide/dexamethasone until 
SCT or disease progression, reported similar results, with ORR of 63%, and with 42% of patients 
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responding after 1 cycle with a median time to response of 3 cycles. Morevoer, 1-year median 
PFS was 80.7% and 65% of patients were relapse-free210. 
Pomalidomide/cyclophosphamide/dexamethasone is another treatment option rrMM patients 
who have received at least one prior therapy. 
 
5.24 High-dose Cyclophosphamide 
 
The ECOG group (Eastern Cooperative Oncology Group) evaluated high-dose 
cyclophosphamide treatment in poor-risk myeloma patients, who had disease refractory to prior 
chemotherapy211. ORR was 43%, with 29% response rate in patients who are refractory to prior 
therapy with cyclophosphamide. Also high-dose cyclophosphamide can be considered as option 
in rrMM. 
 
5.25  Pegylated liposomial doxorubicin/cyclophosphamide/dexamethasone (CED 
regimen) 
 
Since 2009, in our Institution, some patients affected by Multiple Myeloma, relapsed and 
refractory to most of the available therapeutic options (2-7), have been treated with courses of 
pegylated liposomial doxorubicin (35 mg/sqm, day 1), cyclophosphamide (800 mg/sqm day 1) 
and dexamethasone (20 mg days 1-4), with pegfilgrastimat day +4, every 28 days (CED 
regimen), until progression of disease.  
So far, 31 patients (16 women, 12 men), with median age 63.4 years (range: 43-84) affected by 
relapsed and progressive multiple myeloma, whose median number of previous treatments was 6 
(range 2-11) have been treated with CED schedule (mediannumber of courses: 4.3, range: 2-17). 
Available results refer to 31 patients completing at least two courses of CED, while 4 patients 
who received only 1 cycle were excluded from analysis. Tolerability profile of CED was 
satisfactory: hematological toxicity was present in all patients, but grade 3 transfusion-dependent 
anemia or neutropenia was verified in 37% and 46% of cases, without necessity of 
hospitalization. No severe extrahematologic toxicity was observed: grade 1 gastrointestinal side 
effect (nausea) in the majority of patients, and two grade 3 extra-hematological events: acute 
renal failure in a patient and bradycardia in another patient, both of them not requiring 
hospitalization. According to IMWG response criteria, after a median follow-up of 6 months of 
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treatment (r.2-17+), ORR was 51% (2 CR, 2 VGPR, 8 PR, 4 MR) with 10 disease progressions 
and 5 patients in stable disease. Median OS from start of CED was 5.9 months (range 2-17). 
These effects appear impressive, in patients so far lacking available therapeutic options. 
Together to Romano’s results212,213, our observations underline the efficacy of pegylated 
liposomial doxorubicin, that seems to give a contribute in a particularly severe setting of 
patients, without significant side effects. 
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6. Supportive care in MM 
 
Recently, important advances have been made in supportive care of patients with MM. This 
involves careful patient education about the possibility of side effects of each drug, the 
informations about drug combinations being used, and the supportive care measures required. In 
fact, supportive care in MM, can be categorized into those measures that address specific drugs 
and those required for all patients. 
 
6.1 Bone disease and bisphosphonates 
 
Bone disease of myeloma develops in 85% of patients, in the form of osteolytic lesions and/or 
diffuse osteopenia, and the related complications can be considered as the major cause of 
limitations in performance status and in quality of life in patients with MM. A double-blind, 
large, randomized trial has shown, in patients with Durie-Salmon stage III MM and at least one 
lytic lesion, that monthly use of intravenous bisphosphonate pamidronate can decrease pain and 
bone-related complications, improving performance status and preserving quality of life214,215. 
Equivalent benefits were demonstrated with zoledronic acid216. Zervas et al217 showed with 
zoledronic acid compared with pamidronate a 9.5-fold greater risk for the development of 
osteonecrosis of the jaw and so, they should have a dental examination before the start of 
bisphosphonate therapy and be monitored for osteo-necrosis of the jaw. Moreover, it’s 
mandatory to monitor accurately renal function patients who are on bisphosphonates treatment. 
A multicenter, international trial, MRC Myeloma IX, compared effects of zoledronic acid versus 
clodronate, a bisphosphonate not currently FDA-approved, in MM patients initiating 
chemotherapy regardless of bone disease. The enrolled patients were randomized to receive 
zoledronic acid (n=981) or clodronic acid (n=979). Zoledronic acid was previously reported to 
reduce mortality and significantly improve PFS218. Considering safety, patients on both arms had 
similar occurrence of acute renal failure and treatment-related serious adverse events, even if 
zoledronic acid was associated with significantly higher rates of confirmed osteonecrosis of the 
jaw218-220.  
Recently, the study reanalyzed and reported survival outcomes, and after an extended follow-up 
of a median of 5.9 years, in addition to PFS, also the OS was significantly improved (52 vs 46 
months; HR, 0.86; P=.01) in zolendronic acid arm, compared with clodronic acid221. However, 
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also the long-term rates of osteonecrosis of the jaw were higher with zoledronic acid (3.7% vs 
0.5%; P=.0001)221. 
A recent interesting meta-analysis of 20 randomized controlled trials of comparing 
bisphosphonates with either placebo or a different bisphosphonate as a comparator concluded 
that adding bisphosphonates to MM treatment reduces vertebral fractures and probably reduces 
pain. However, whether zoledronate is superior to pamidronate and other bisphosphonates 
remains to be determined222. Bisphosphonates should be recommended for all patients receiving 
myeloma therapy for symptomatic disease regardless of documented bone disease, while, in 
patients with smoldering or stage I MM, they could be considered but preferably in a clinical 
trial. For monitoring these patients, a skeletal survey annually or as clinically indicated is 
recommended, while bone densitometry or other metabolic studies should be reserved for 
clinical trials. 
 
6.2 Radiotherapy 
 
Even in the era of novel agents, radiotherapy has an important role in MM, in particular for 
palliative treatment. In particular, low-dose radiation therapy (10–30 Gy) is used for the 
palliative treatment of uncontrolled pain, impending pathologic fracture, or impending spinal 
cord compression223. To limit the effect of irradiation on stem cell harvest or its effect on 
potential future treatments, limited involved fields should be used, and, moreover, the radiation 
doses administered should not preclude stem cells collection in potential candidates for high-
dose therapy and SCT. However, orthopedic consultation should be obtained for impending bone 
compression of the spinal cord, or vertebral column instability or actual fractures in weight-
bearing bones, and, in particular, either vertebroplasty or kyphoplasty should be considered for 
symptomatic vertebral compression fractures. 
 
6.3 Hypercalcemia 
 
In MM, excess bone resorption from MM bone disease can lead to excessive release of calcium 
into the blood, and this could contribute to hypercalcemia. Its symptoms include gastrointestinal 
disturbances and polyuria, with progressive dehydration and decreases in glomerular filtration 
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rate. Hypercalcemia treatment can be performed with hydration and furosemide, steroids, 
bisphosphonates (better zolendronic acid), and/or calcitonin219,224,225.  
 
6.4 Plasmapheresis, ESAs, Infections and Thrombosis 
 
In MM, plasmapheresis should be used as adjunctive therapy for symptomatic hyperviscosity, 
and also for adjunctive treatment of renal dysfunction226. 
Erythropoietin therapy should be considered for MM anemic patients, especially for those with 
renal failure, and in these patients to measure endogenous erythropoietin levels may help in 
treatment planning225,226. 
Many strategies are helpful to prevent infection in MM, and, in particular, intravenous immuno- 
globulin (IVIg) therapy should be considered for recurrent, life-threatening infections; 
pneumococcal and influenza vaccine could also be considered; and Pneumocystis carinii 
pneumonia (PCP), herpes, and antifungal prophylaxis is recommended if a high-dose regimen is 
used. In particular, as previously described, bortezomib treatment has been associated with an 
incidence of herpes zoster, and in these patients herpes prophylaxis is recommended48,49. 
Thrombosis is relatively common when IMIDs (thalidomide or lenalidomide) are used with 
steroids, and it can be particularly frequent when treating newly diagnosed patients. As 
previously described, when IMiDs are used in combination therapy during induction, the use of 
prophylactic anticoagulation agents should be recommended64,229,230. 
Moreover, hydration should be maintained while non-steroidal anti-inflammatory drugs 
(NSAIDs) should be avoided to decrease the chances of renal dysfunction.   
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7. Aim of the study 
 
Despite the context of several promising therapeutic advances, there are still few effective and 
durable treatment options for rrMM, even if the last decade has been signed by a reawaking of 
bendamustine, a molecule already largely adopted in hematological malignancies, as effective 
agent for Hodgkin lymphoma, non-Hodgkin lymphoma and chronic lymphatic leukemia 
treatment231,232. Bendamustine is a chemotherapeutic agent with unique properties of alkylating 
agent that differs from the other major compounds of this category, such as cyclophosphamide, 
melphalan and chlorambucil233. Several mechanisms of action are supposed to be the key of 
efficacy of bendamustine in inducing an extensive and long-lasting DNA damage: stress 
response to DNA damage and apoptosis via p53-pathway, inhibition of mitotic checkpoints, and 
induction of mitotic catastrophe233,234. Moreover, due to its chemical structure, besides its 
peculiar alkylating agent activity, it is supposed that bendamustine has also antimetabolite 
properties, resulting in a bi-functional chemotherapy agent, with a unique mechanism of actions 
among alkylating agents234. It is not yet clear whether bendamustine can overcome the resistance 
to melphalan or have a synergic mechanism of action with this molecule, but its multiple actions 
explain its lack of cross-resistance with other DNA-damaging agents previously adopted in the 
same patient235,236. Bendamustine was evaluated in patients with MM as single agent or 
combined with IMIDs (thalidomide and lenalidomide) or bortezomib, giving promising results as 
upfront therapy and, especially, in pre-treated patients, also with renal impairment237. According 
to a study conducted by Pönisch et al. in 2010, combination of bendamustine-prednisone was 
approved in Europe as first-line treatment for patient older than 65 years not ASCT eligible and 
with a diagnosis of peripheral neuropathy impeding the use of bortezomib or thalidomide-based 
regimens238. However, given the well know evidence of effectiveness of various bortezomib-
based regimens as salvage treatment for rrMM164,239,240 and according to pre-clinical studies241, 
bendamustine combined with bortezomib and dexamethasone (BVD) could be a feasible 
therapeutic option, also for heavily pre-treated patients242. Starting from preliminary data about 
efficacy and safety on BVD regimen for rrMM elderly patients reported in an abstract by 
Hrusovsky I et al in 2007 with an overall response rate (ORR) of 72.5%243, several other trials 
have demonstrated or are still underway to demonstrate the effectiveness of this regimen in 
rrMM setting. Pönisch et al. adopted bendamustine/prednisone/bortezomib (BPV) regimen in 
patients with rrMM, obtaining an ORR of 69% with no severe toxicity244. A phase II italian 
study by Offidani et al. showed an ORR of 61.5% with BVD in rrMM patients who underwent to 
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more than two prior line of treatment189. Another phase II study by Ludwig et al. gave as results 
an ORR of 60.8 %, but in patients with a median of two prior therapy lines before BVD245. The 
aim of this observational retrospective study is to evaluate efficacy and safety of BVD regimen 
in patients with rrMM in a real-life setting and to compare it with the results of the major studies. 
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8. Methods 
 
From October 2014 to December 2016, 56 patients, affected by rrMM, and referred as 
outpatients to our institutions (Hematology, University Hospital Policlinico Federico II and 
Hematology, AORN Cardarelli Hospital, Naples, Italy), previously treated with several lines of 
therapy, were assigned to receive BVD as salvage treatment. All patients had become refractory 
to previous therapies and had received at least two previous lines of treatment (median n. 6, 
range 2-11). All patients had been treated with bortezomib-based regimen, such as bortezomib-
dexamethasone (VD), bortezomib-thalidomide-dexamethasone (VTD), bortezomib-melphalan-
prednisone (VMP) and with lenalidomide-based regimens, such as lenalidomide-dexamethasone 
(RD) or bortezomib-lenalidomide-dexamethasone (VRD). Particularly, it has to be underlined 
that 100% of patients had developed resistance to a bortezomib-containing regimen, i.e. VD, 
VTD, VMP and VRD. Thirthy-eight young patients had received ASCT (68%); particularly, 28 
(50%) had received one ASCT and 10 (18%) double ASCT. Also patients who underwent to two 
prior ASCT, at relapse, were treated with at least one bortezomib-based regimen. Finally, of 
notice, some patients had also received and subsequently became refractory to a novel agent-
containing regimen: in details, two patients (3.5%) had been treated with pomalidomide-
dexamethasone and three patients (5.3%) with carfilzomib-lenalidomide-dexamethasone. 
Characteristics of the patients are summarized in Table 3. 
Table 3: Baseline characteristics of patients 
Characteristic No. 
Number of patients 56 
  Sex   
  Male/Female 31/25 
  Median age, years (range)  
At diagnosis 
At start of BVD 
57 (45-73) 
61.8(37-83) 
Median previous regimens (range) 6 (2-11) 
FISH analysis  12/56 
Negative  10/56 
del13q 
t(11;14)  
1/56 
1/56 
Previous therapies, no of patients/(%)  
Bortezomib 
First and second generation IMIDs (thalidomide and lenalidomide) 
Carfilzomib 
Pomalidomide 
Autologus SCT 
    First  
    Second  
 
56(100%) 
56(100%) 
3(5.3%) 
2(3.5%) 
38 (68%) 
28 (50%) 
10 (18%) 
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Elderly patients and young patients no more ASCT-eligible were treated at the clinical or 
biochemical relapse according to IMWG criteria: onset of new or worsening of pre-existent 
CRAB symptoms, appearing of a new bone or soft-tissue lesion (plasmocytoma), doubling of 
monoclonal component. BVD treatment schedule adopted was: bendamustine (B) 90 mg/sqm i.v. 
days 1, 2; Bortezomib (Vel) 1/1.3 mg/sqm s.c. days 1, 4, 8, 11; Dexamethasone (Dexa) 20 mg, 
p.o., days 1, 2, 4, 5, 8, 9, 11, 12. Cycles were planned to be repeated every 28 days, until 
progression of disease or unacceptable toxicity, but were actually administered with median of 
32 days (range 28-39) due to possible delaying adverse events. Associated supportive care to 
prevent anemia and neutropenia was administered. In particular, G-CSF analogue pegfilgrastim 6 
mg s.c. was given in day + 4 of treatment and epoietin alfa 40.000 I.U. s.c. was indicated if 
required (Hemoglobin < 10 g/dl). Prophylactic antimicrobial therapy was prescribed: 
levofloxacin 500 mg/d, p.o., days 9-21 and fluconazole 100 mg/d days 9-21. Antiemetic drugs 
and allopurinol if required were given. All patients were evaluated for response to therapy 
according to uniform IWMG response criteria10. Primary endpoint was to evaluate ORR (≥MR) 
and ORR2 (≥SD) in our population of rrMM patients treated with BVD regimen. With adoption 
of ORR2 as one of primary endpoints, we can better define the treatment response in a cohort of 
patients whose outcome is significantly poor due to a heavily pre-treated advanced disease. 
Secondary endpoints were progression-free survival (PFS), overall survival (OS), time to 
response (TTR) and safety in the same population. Regarding safety data, despite there are no 
biological parameters that can be used to evaluate the peculiar damage of a given drug on the 
bone marrow, we aimed to distinguish the hematological adverse events (AEs) in two separate 
toxicity profiles for each patient: pre-BVD toxicity profile (Safety 1) and post-BVD toxicity 
profile (Safety 2). Moreover, all these parameters were evaluated in a retrospective real-life 
context of our two institutions, focusing also on aspects as: feasibility of a BVD re-challenging 
in patients heavily pre-treated, G-CSF supportive care effectiveness and differences between 
drug-induced toxicity and pre-existing toxicity on bone marrow. Response evaluation was 
routinely performed every month with physical examination, complete blood count, biochemical 
serum and urine analysis and, when necessary, bone marrow examination, PET/CT or MRI. Due 
to the observational/retrospective nature of the study and anonymous data collection, informed 
consent was not necessary. 
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9. Results 
 
Median follow-up of patients was 14 months (range 2-36+). Analysis on all rrMM patients 
treated with BVD as salvage line showed the outstanding values of 67.8 % and 89.2%, for ORR 
and ORR2 respectively, after a median of 6 cycles of BVD. In particular, according to IMWG 
criteria, one patient (1.8%) achieved a sCR, 3 patients (5.3%) achieved a CR, 7 patients (12.5%) 
achieved a VGPR, 18 patients (32.1%) achieved a PR, 9 patients (16%) achieved a MR, 12 
patients (21.4%) achieved a SD, and 8 patients (14.3%) were in PD (Table 4). 
 
Table 4: Response rates according to IMWG criteria. sCR: stringent complete response, 
CR: complete response, VGPR: very good partial response, PR: partial response, MR: 
minimal response, SD: stable disease, PD: progressive disease, ORR: overall response rate 
(≥MR), ORR2: overall response rate 2 (≥SD), OS: overall survival, PFS: progression-free 
survival and TTR: time to response.Response rates are expressed as percentage with n. of 
patients in brackets; OS, PFS and TTR are expressed in median number of months with 
range in brackets.  
 
 
Response evaluation   
ORR 67.8% 
ORR2 
sCR 
CR 
VGPR 
PR 
MR 
SD 
PD 
89.2% 
1.8% (1/56) 
5.3% (3/56) 
12.5% (7/56) 
        32.1% (18/56) 
16% (9/56) 
21.4% (12/56) 
14.3% (8/56) 
OS from diagnosis              62.7(6-151) 
OS from start BVD 9.8(2-36) 
  PFS 8.5(7-25) 
  TTR 1.2(1-3) 
 
 
Interesting additional results in terms of ORR (obtaining at least a PR) were also achieved in 
particular settings of patients. Concerning efficacy of BVD in patients refractory to previous 
bortezomib-based lines of therapy, in 21 patients (37.4%) refractoriness to bortezomib was 
overtaken by synergistic action of bendamustine with this proteasome inhibitor, obtaining at least 
a PR. BVD regimen was also active in a small, but important group of patients who previously 
had received a novel agent-based therapy: in particular, 2/56 patients (3.5%) previously treated 
with pomalidomide-dexamethasone achieved at least a PR and 3/56 patients (5.3%) previously 
treated with carfilzomib-dexamethasone regimen obtained a PR. Bendamustine was also 
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effective as “bridge to transplant” both for second ASCT or alloSCT, in 11 patients (19%) and  
2 patients (3.5%), respectively. Finally, this treatment was also effective, after previous efficacy, 
as re-treatment effective strategy post-ASCT in 1 patient (1.8%)242. Regarding secondary 
endpoints, an OS of 62.7 months from diagnosis (Figure 12) and of 9.8 from BVD start were 
achieved (Figure 13), and a median PFS of 8.5 months (Figure 14) with a TTR of 1.2 months 
were observed (Figure 15).  
 
 
 
Figure 12: OS from diagnosis 
 
 
Figure 13: OS from start therapy with BVD 
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Figure 14: Progression Free Survival (PFS) 
 
 
 
Figure 15: Time to Response (TTR) 
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9.1 Safety 
 
Safety 1 profile showed no grade 4 hematologic AEs, 46% of grade 2-3 anemia, 14 of grade 3 
neutropenia and 43% of thrombocytopenia. In the Safety 2 profile, it was not encountered any 
grade 4 hematological AE, grade 3 anemia in 41 % and grade 2 in 52% of patients (ESA largely 
required). Grade 2-3 neutropenia and thrombocytopenia in 37% and 34% were present, 
respectively. No severe extra-hematological AEs requiring hospitalization were noted. Safety 1 
and Safety 2 profiles are summarized in Table 5 and 6. 
 
Table 5: Safety 1 profile 
 
Safety 1 profile - Adverse events %/No. 
Anemia  
Grade 4 (transfusion-dependent) 0 
Grade 3 (transfusion-dependent) 8 (14%) 
Grade 2 (ESAs-dependent) 18 (32%) 
Grade 1/No Anemia 30 (53%) 
Neutropenia  
   Grade 4 0 
   Grade 3 8 (14%) 
   Thrombocytopenia  
Grade 4 0 
Grade 2 and 3 24 (43%) 
   Grade 1/No Thrombocytopenia 32 (57%) 
Peripheral Neuropathy  
Any grade 18 (32%) 
   ≥ grade 3 3 (5%) 
 
Table 6: Safety 2 profile 
 
Safety 2 profile - Adverse events %/No. 
Anemia  
Grade 4 (transfusion-dependent) 0 
Grade 3 (transfusion-dependent) 23 (41%) 
Grade 2 (ESAs-dependent) 29 (52%) 
Grade 1/No Anemia 4 (7%) 
Neutropenia  
   Grade 4 0 
   Grade 2-3 21 (37%) 
   Grade 1 11 (19%) 
   Thrombocytopenia  
Grade 4 0 
Grade 2 and 3 19 (56%) 
   Grade 1/No Thrombocytopenia 37 (66%) 
Peripheral Neuropathy  
   Any grade 23 (41%) 
   ≥ grade 3 5 (9%) 
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10. Discussion 
 
Our aim is to compare our real-life retrospective data with other previously conducted trials. In 
an early dose-escalation study of 2007 by Fenk et al.247, 7 rrMM patients treated with triplet 
combination of BVD (B 50-100 mg/m2 d 1, 8 + Vel 1.3 mg/m2 d 1, 4, 8, 11 + Dexa 40 mg d 1, 4, 
8, 11 every 28 d), had an ORR of 86%. A phase I/II trial by Berenson et al.248, involving 40 
patients, aimed to evaluate maximum tolerated dose (MTD), efficacy and toxicity of 
bendamustine-bortezomib without dexametasone, with the following schedule: B 90 mg/m2 d 1,4 
+ Vel 1.0 mg/m2 d 1, 4, 8, 11 every 28 days). Maximum Tolerated Dose was established at 90 
mg/m2, and an ORR of 48% with a median OS of 13.3 months clearly demonstrated the 
synergistic action of dexamethasone with bendamustine, because its exclusion from the 
treatment schedule can notably affect the effectiveness of therapy. Pönisch et al.244, in a 
retrospective analysis of 78 patients treated with BPV (B 60 up to 120 mg/m2 d 1, 2 + PDN 100 
mg d 1, 2, 4, 8, 11 + Vel 1.3 mg/m2 d 1, 4, 8, 11 every 28 days), distinguishes between cases 
without and with severe hematological toxicities, due to previous treatment, reporting no 
differences in ORR (69%) but, statistical differences in median PFS (50 and 5 months, 
respectively) and in median PFS (11 and 3 months, respectively). Complete and accurate data on 
efficacy and safety of BVD in rrMM were reported in a phase 2 trial by Offidani et al.189, whose 
schedule treatment was: B 70mg/m2 d 1, 8 + Vel 1.3 mg/m2 d 1, 4, 8, 11 + Dexa 20 mg d 1, 2, 4, 
5, 8, 9, 11, 12 every 28 days for 2 cycles, subsequently B 70 mg/m2 d 1, 8 + Vel 1.3 mg/m2 d 1, 
8, 15, 22 + Dexa 20 mg days 1, 8, 15, 22 every 28 days. For 75 rrMM patients the ORR reported 
was 75%, whereas PFS and OS were 12.5 months and 24 months, respectively. Univariate 
analysis showed that previous lines of treatment containing both lenalidomide and bortezomib 
affected negatively ORR and time to progression. Phase 2 trial involving 79 patients carried out 
by Ludwig et al.245 reported valid data of BVD activity and safety in rrMM patients. The 
algorithm of treatment consisted in B 70 mg/m2 d 1, 4 + Vel 1.3 mg/m2 d 1, 4, 8, 11 + Dexa 20 
mg d 1, 4, 8, 11 every 28 days for maximum 8 cycles. The ORR measured was 60.9%, median 
OS was 25.6 months and median PFS was 9.7 months. Pre-treatment with bortezomib, 
lenalidomide or bortezomib-lenalidomide did not affect significantly ORR and, furthermore, a 
PR or better response was reported for 5 of 8 patients previously exposed to 2 or 3 bortezomib 
lines. In a French multicenter trial, Rodon et al.249 reported an ORR of 69.8%, an OS of 23 
months and a PFS of 10.8 months in 73 patients, with median age slightly higher than in other 
trials (76 years), adopting the sequent schedule: B 70 mg/m2 d 1, 8 + Vel 1.3 mg/m2 d 1, 8, 15, 
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22 + Dexa 20 mg d 1, 8, 15, 22 every 28 days; responder patients received also a maintenance of 
6 cycles given 1 month out of 2. Finally, regarding BVD regimen efficacy given to previously 
untreated patients, Mateos et al.250 adopted this schedule for 60 MM patients (42 of them 
candidate to ASCT) as front-line treatment: B 90 mg/m2 d 1, 4 + Vel 1.3 mg/m2 1, 4, 8, 11, 22, 
25, 29, 32 + prednisone 60 mg/m2 d 1-4 for the first cycle, then B 90 mg/m2 d 1, 8 + Vel 1.3 
mg/m2 d 1, 8, 15, 22 + prednisone 60 mg/m2 d 1-4. ORR in all population was 84%, whereas the 
2-years OS and 2-years PFS were 86% and 62% respectively. Data obtained by our cohort 
showed a remarkable ORR of 67.8% for all patients enrolled in the BVD salvage protocol. This 
is an impressive result and comparable with ORR obtained by Ludwig et al. and Offidani et 
al.189,245. However, in the aforementioned trials, the median number of prior therapy lines was 2 
(range 1-6) and 1 (range 1-4) respectively, while in patients enrolled by our institution the 
median number of preceding lines was 6 (median 2-11). Moreover, our study was focused on a 
cohort of patients that were all previously exposed and became refractory to bortezomib, 
whereas the percentage of this type of patients were 63.3% in Ludwig trial and 46.5% in 
Offidani population. Higher number of prior lines of therapy and higher proportion of 
bortezomib-refractory patients in our real-life setting make the obtained ORR value of 67.8% an 
excellent response rate for a salvage therapy. These results are also strengthened by the 
observation that, in our cohort, 2 patients (3.5%) previously treated with and became refractory 
to pomalidomide-dexamethasone and 3 patients (5.3%) to carfilzomib-lenalidomide-
dexamethasone responded to BVD when, showing an impressive capability of bendamustine, 
when associated to bortezomib, to overcome several therapy resistances. Furthermore, if we 
consider as “responders” also patients who achieve a SD (ORR2), the result of 89.2% in our 
population, is a valid parameter to assess responses rates in this particular setting of frail and 
poor responder patients.  Regarding safety profile of bendamustine, in our study we should 
highlight the cumulative toxicity effect of prior lines on bone marrow, that unavoidably impaired 
marrow function, creating a “background” of hematological toxicity in the patient. As nowadays 
there is a survival improvement of patients affected with MM thanks to novel agents’ 
introduction and improvement of supportive care4, it is increasingly common that clinician 
specialists may face long-survivor patients with pre-existing poor and frail bone marrow function 
due to toxicity of prior therapy lines applied. Therefore, to assess the safety profile of a salvage 
line of therapy in a heavily pre-treated cohort of patients, such as rrMM patients, whose possible 
hematological AEs incidence and severity are clearly affected by previously damaged bone 
marrow function, we distinguished two safety profiles both by chronological and biological 
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criteria. Safety 1, in fact, is the cumulative result of all previously chemotherapy lines who 
patient underwent, and it is disease-related, host-related, and treatment-related251 and it was 
supposed to be the baseline bone marrow function prior to BVD. On the other side, Safety 2 
profile is related to the mere effect of bendamustine or, possibly, of bortezomib and 
dexamethasone when combined with bendamustine, on the bone marrow at the moment of 
starting BVD regimen. All our data on hematological toxicity showed, despite high dose of 
bendamustine used in our schedule (90 mg/m2) and the median number of 6 prior lines of 
therapy, the level of bone marrow function impairment was highly manageable, for both anemia 
and neutropenia. Adoption of Epoietin alfa, usually in a weekly dose of 40.000 I.U., until 
hemoglobin values of 10 g/dl were obtained, was sufficient to avoid blood transfusion in more 
than 50% of patients. Regarding febrile neutropenia management, the risk was effectively 
reduced with adequate use of a long-acting GCSF (pegfilgrastim 6 mg) given by subcutaneous 
route, as suggested by EORTC international guidelines252. Moreover, according to our previous 
published experience, is clearly demonstrated that pegfilgrastim is more effective for reducing 
febrile neutropenia episodes than filgrastim, in patient undergoing BVD253. In fact, the cohort of 
patients whose neutropenia was managed with pegfilgrastim had fewer febrile neutropenia-
related chemotherapy delay than those with filgrastim (8.3% and 17.3% respectively) and also 
fewer days of hospitalization due to febrile neutropenia complications (median of 0 and 15 days, 
respectively). These data account for the favorable hematological safety profile, with low rates of 
chemotherapy-related infectious episodes, despite we adopted a treatment schedule with high 
dose of bendamustine in a frail population of patients. Moreover, pegfilgrastim has the advantage 
of mono-administration, with fewer GCSF-related side effects as bone pain, easily manageable 
by paracetamol. Regarding extra-hematological toxicity profile of BVD, grade 1 gastro-intestinal 
impairment (nausea, vomiting, diarrhea, etc) reported in 55% of patients, easily manageable with 
common anti-emetic prophylaxis and treatment. Regarding peripheral neuropathy (PN) rate, 
probably the most clinically relevant extra-hematological AE, is clearly affected by the re-
treatment with a bortezomib-based regimen (BVD, in this case) in patients previously exposed to 
bortezomib. Thus, it can be expected a certain grade of PN in these patients, but as data revealed, 
also this AE was acceptable in terms or rates and grade of severity. Particularly, at baseline, 32% 
(n=18) any grade PN was noted, 6% (n=3) of ≥ grade 3 cases. After a median of 6 cycles, overall 
PN rate was 41% (n=23), with 9% (n=5) of ≥ grade 3. Neither at baseline nor after BVD 
treatment grade 4 of PN were detected. Therefore, the overall safety profile results very 
acceptable, also in frail patients with a poor outcome, as rrMM patients.  
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In the rrMM setting, an old and well known drug as bendamustine, combined in the BVD 
regimen employed in patients also heavily pre-treated with and resistant to bortezomib, can be an 
effective and safe treatment option, despite the increasing availability of new generation 
therapeutic molecules. Data emerging from this real-life retrospective evaluation have been 
demonstrated to be highly comparable to major clinical trials adopting this combination in the 
same setting, in terms of ORR, OS, PFS and safety profile in rrMM patients. Moreover, the 
observation that in our cohort of patients with high median number of previous therapy lines and 
all refractory to bortezomib, shows that bendamustine combined with bortezomib breakthroughs 
the acquired pharmacological resistance. Furthermore, bendamustine appears as a molecule 
capable to induce response also in a patient with a background of severe pre-existing bone 
marrow impairment due to previous therapies. In conclusion, a so-called “old” chemotherapeutic 
molecule, already adopted for long time in other clinical settings, can be a feasible, effective and 
safe treatment option for rrMM patients with no other therapeutic options. 
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ACUTE AND CHRONIC PH+ LEUKEMIAS: DIFFERENTIAL LEUKEMOGENESIS PATHWAYS
TRANSLATE INTO DIFFERENT CLINICAL NEEDS
Pane F., Quintarelli F., Esposito N., Izzo B., De Angelis B., Peluso A.,
Muccioli Casadei G., Cosenza M.,Cerchione C., Camera A., 
Luciano L.
AF di Ematologia, University of Naples Federico II and CEINGE Biotecnologie
Avanzate, Naples, Italy
Philadelphia (Ph) chromosome - a balanced, reciprocal translocation
involving the long arms of chromosomes 9 and 22 is the hallmark of two
types of leukemias. Virtually 100% chronic myeloid leukemia (CML)
patients are characterized by the presence of Ph chromosome or, in
patients with complex or masked translocations and consequently lack
the classical Ph chromosome, by the BCR/ABL gene. The Ph chromoso-
mal aberration is not restricted to the CML, but a sizeable subset of
acute lymphoid leukemia (ALL) patients may have this abnormality.
Hence, despite the presence of a consistent genetic abnormality Ph
leukemias display considerable clinical and hematological heterogeneity,
the basis of which is only partially understood. 
For various reasons, CML is, between the two types of Ph leukemias,
probably one of the most comprehensively studied human malignancies.
CML was the first human cancer to be associated with a consistent chro-
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mosomal abnormality - the Ph chromosome. CML is characterized by
distinct clinical phases: most patients present in chronic phase (CP), a
phase in which mature granulocytes are still produced, but patients have
an increased number of myeloid progenitor cells in the peripheral blood.
As the disease progresses, patients enter an accelerated phase (AP) fol-
lowed by blast crisis (BC), in which hematopoietic differentiation has
become arrested and immature blasts accumulate in the bone marrow
(BM) and spill into the circulation. The CP is relatively long-lasting, so
researchers have the opportunity to study malignant cells with an ‘indo-
lent’ behavior and to identify the changes associated with transforma-
tion to the ‘aggressive’ phenotype of blast crisis. Furthermore, CML is
unusual in that a single genetic lesion occurring in a hematopoietic stem
cell generates a fusion oncogene, BCR-ABL, which encodes a protein
tyrosine kinase that is necessary and sufficient for cell transformation.
The cytoplasmic location of the BCR-ABL oncoprotein allows access to
many cellular substrates that are unavailable to the predominantly
nuclear ABL protein, determining their phosphorylation and therefore
the activation of proliferation and survival pathways. Finally, CML was
the first hematological malignancy for which a program of rational drug
design yielded an effective targeted molecular therapy (imatinib mesy-
late), that is now considered the precursor of a new family of anticancer
drugs, the tyrosine-kinase inhibitors (TKIs). 
The introduction of TKIs for the treatment of chronic myeloid
leukaemia has had a profound and beneficial effect on this disease,
which previously had a median survival of 5–7 years. Imatinib moved
rapidly from phase I and II trials to a phase III randomised controlled tri-
al (International Randomised Study of Interferon versus ST1571 [IRIS])
in which it was compared with interferon alfa plus cytosine arabinoside
(IFN-ara-C). Complete haematological responses and complete cytoge-
netic remissions were 95% and 94%, respectively, for imatinib, com-
pared with 55% and 8.5% for IFN-ara-C. Progression-free survival at 18
months was 96.7% for imatinib compared with 91.5% for IFN-ara-C.
These early findings led to accelerated regulatory approval of imatinib
for all phases of CML and the drug became first-line treatment for most
patients. At 60 months, the estimated rate of event-free survival was
83% in imatinib recipients, and 93% had not progressed to
accelerated/blast-phase CML. The efficacy of imatinib has been con-
firmed in a recent intention-to-treat analysis of 204 consecutive patients
with newly diagnosed CML-CP who received standard-dose imatinib
for a median of 38 months, most of them outside of the IRIS trial set-
ting. Follow-up was available for all patients, giving a cumulative CCyR
rate of 77% and a projected five-year event-free survival rate of 81% (de
Lavallade et al, J Clin Oncol 2008) .
Imatinib also induces responses in a significant percentage of patients
with AP or BP CML, although these tend to be transient. In phase II stud-
ies in patients with AP (600 mg/day) or BP (majority of patients [86%]
received 600 mg/day), sustained CHR rates were 37% and 15%, MCyR
rates were 28% and 16%, and CCyR rates were 19% and 7%, respec-
tively. These clinical results support the notion that BCR-ABL must be
important for the continued maintenance of the neoplastic phenotype,
even in the advanced phase, and that a selection pressure favors the
continued activity of the oncoprotein. In fact, increased BCR-ABL
expression is likely to contribute to the phenotype of advanced phase
disease, as studies using cell line models of CP and BC CML indicate that
the oncoprotein exerts dose-dependent effects on growth factor depend-
ence, clonogenicity, migration and the rate at which cells develop resist-
ance to imatinib. Other factors, however, that could affect differentia-
tion arrest and the inappropriate reactivation of self-renewal capacity are
important in disease evolution in CML. CML is a good example of a can-
cer in which the transition from mature, terminally differentiated cells
to immature, undifferentiated cells can be observed in the malignant
clone. This differentiation arrest implies pathological interference with
differentiation ‘programmes’ involving the targeted activation of tissue-
specific genes by transcription factors. Such interference may be activat-
ed by oncogene products, as has been demonstrated for the suppression
of the transcription factor CEBP alfa by BCR-ABL, or by mutations or
gene translocations that result in the formation of dominant-negative
transcription factors, such as AML1–EVI1 or NUP98–HOXA9 fusion
genes, which have been described in a few isolated cases of myeloid BC.
Another aspect of the maturation arrest in BC is the question of whether
the transformed subclone originates from a cell that is at a distinct dif-
ferentiation stage from that which gives rise to CP. Thus, disease pro-
gression in CML may originate in more committed precursors than had
been previously supposed, as myeloid BC has been reported to involve
the granulocyte-macrophage progenitor (GMP) ‘pool’ rather than the
haematopoietic stem cell pool. The self-renewal of GMPs requires the
activation of the _-catenin pathway.
One of the most remarkable and intriguing results of the treatment of
CML in chronic phase  with imatinib is the low rate of progression to
advanced phase or BC (2% at 5 years follow-up) in patients who achieve
and maintain a complete cytogenetic response within the first 12–18
months after starting the drug treatment. The biological basis of this
phenomenon is unknown, but is a matter of great interest and specula-
tion. Genomic instability may be based on alterations of the mecha-
nisms involved in genome surveying for DNA damages and of those
responsible for repairing these lesions; it is likely that similar failures of
genome surveillance and DNA repair may contribute to the genomic
instability of all human cancers. It has been proposed that BCR-ABL
induces mutations in genes responsible for maintaining genomic integri-
ty, and that such mutations function as “amplifiers of a genetically unsta-
ble phenotype”. This could explain the occurrence of the non-random
chromosomal abnormalities that characterize CML progression. The
most frequent are trisomy 8 (33%), an additional Ph chromosome (30%),
isochromosome 17 (20%), trisomy 19 (12%), loss of the Y chromosome
(8% of males), trisomy 21 (7%) and monosomy 7 (5%)51. These
changes have been used as markers of disease progression, but may not
necessarily be causal agents of transformation.
As BCR-ABL increases the level of genomic instability, continuous
inhibition of its kinase activity by imatinib should lead to a decreased
risk of mutations in general, including in genes that can trigger the blast
crisis process. Moreover, although imatinib may be unable to kill the
leukemic stem cell, it may drastically reduce its rate of proliferation and
self-renewal, driving it to a deep and prolonged quiescence where the
chances of DNA breaks and mis-repair are lower in the absence of DNA
replication. Another possible mechanism relies on the evidence that the
cell of origin of BC may not be a ‘true’ stem cell, but rather a more com-
mitted granulocyte-macrophage progenitor (GMP), and it has been
shown that imatinib can eliminate a large proportion of these cells,
reducing the population at risk of blastic transformation. An additional
aspect of the 5-year clinical trial follow-up study was the observation
that the rate of disease progression is not only low, but seems to decrease
with time under successful treatment, and the reasons for this are not
entirely clear. As the emergence of a subclone of leukemic cells with
mutations in the kinase domain of BCR-ABL is the main cause of relapse
in patients treated with imatinib, it is reasonable to suppose that the
chances of this happening at any time during treatment depend largely
on the size of the mutant sub-clone at the start of therapy and on its pro-
liferation rate. Therefore, assuming that both the original (non-mutat-
ed) and the mutant BCR-ABL clones have a similar doubling time, it
could be predicted that the highest risk for a mutant clone to become
dominant and lead to relapse and disease progression occurs within the
first years of therapy. A longer follow-up of chronic phase patients treat-
ed up-front with imatinib should confirm whether such a trend for a
continuous decrease in the risk of disease evolution is statistically sig-
nificant.
Close molecular monitoring of the blood of patients treated with ima-
tinib or other TKIs demonstrated that a 3- to 4-log reduction in BCR-ABL
expression strongly correlated with the ability to achieve long-term
remissions. However, most of the patients have low-level persistent
BCR-ABL transcripts and relapse on discontinuation of the drug, thus
indicating that treatment spares a Ph cell sub-fraction with long term
repopulating capability, that may be able to originate the progression of
disease. Human cells with long-term engraftment potential were
enriched for CD34+ primitive HCS characterized by CD90 expression.
Closer analysis of transplantable and long-term culture initiating Ph+
cell subpopulations of CD34+ cells demonstrated predominance of qui-
escent G0 cells. Phenotypically primitive CD34+CD38- cells from the
long-term culture initiating cells of chronic phase CML patients had a
propensity to differentiate along the myeloid lineage on long-term
engraftment in immunocompromised mice and probably constitute the
leukemia-initiating cells thought to be resistant to chemotherapy and tar-
geted therapy. Some studies indicate that specific molecular factors such
as promyelocytic leukaemia protein (PML) tumour suppressor protein
may have a critical role in haematopoietic stem cell maintenance of
CML patients. More recently, it has been shown that constitutively
active Smoothened, an essential component of the of Hedgehog (Hh) sig-
nalling pathway, augments CML stem cell number. Therefore, Hh path-
way activity is required for maintenance of normal and neoplastic stem
bb | haematologica| 2009; 94(s4)
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cells of the haematopoietic system and raise the possibility that the drug
resistance and disease recurrence after imatinib treatment of CML might
be avoided by targeting this essential stem cell maintenance pathway. As
already mentioned, the more common causes of TKI resistance have
been clonal evolution present in up to a quarter of patients on disease
progression and mutations of the BCR-ABL. The cells harboring previ-
ously mentioned resistance mechanisms are less likely to arise in early
chronic phase of the disease and may have preexisted at a more
advanced diagnostic stage, but more potent TKIs failed to act on the sig-
naling or the behavior of these CML progenitors. Taken together, these
observations suggest that new strategies will be needed to eliminate
CML.
The Ph chromosome encodes defines a subgroup of ALL with a par-
ticularly unfavorable prognosis. The reasons for the aggressive nature of
Ph ALL are still under investigation and have not yet been elucidated. In
a large survey recently completed by the GIMEMA group on a large
cohort of acute Ph leukemias,  75% of ALL patients and 66% of lym-
phoid blast crisis CML patients, but none of the patients with myeloid
blast crisis, showed homozygous or heterozygous deletions in the IKZF1
gene. IKZF1 encodes the Ikaros protein, a ZnF transcription factor,
required for lymphoid lineage differentiation, proliferation, and func-
tion. Ikaros contains two separate regions with Zinc Finger domains.
Isoforms that lack the N-terminal ZnFs are unable to bind transcription-
al targets normally but retain the Carboxy-terminal ZnFs and the abili-
ty to dimerise and act as dominant negative inhibitors of Ikaros function.
Ikaros transgenic and mutant mouse models have clearly demonstrated
the important role of Ikaros in both normal hematopoiesis and tumor
suppression. An elevated frequency of genomic aberrations could be
directly caused by an abnormally high incidence of DNA double-strand
breaks. In normal cells, DNA lesions are detected and repaired by sophis-
ticated physiologic machinery and a system of cell cycle checkpoints,
preventing cells that have sustained DNA damage from proliferating fur-
ther. In Ph cells from ALL patients, however, the already mentioned role
of the BCR-ABL oncoprotein to promote DNA damages may be one of
the factors involved in the onset of these deletions at the IKZF1 gene.
However, sophisticated DNA analysis along the breakpoint cluster
regions suggesting that IKZF1 deletions could arise from aberrant RAG-
mediated recombination. Consistent with this hypothesis, cells from
ALL or lymphoid blast crisis patients, but not those from chronic phase
CML patients, were found to contain high levels of activation-induced
cytidine deaminase (AID). Indeed, ALL cells are derived from B cell pre-
cursors in most cases and typically carry rearranged immunoglobulin
heavy chain (IGH) variable (V) region genes devoid of somatic mutations.
Somatic hypermutation is restricted to mature germinal center B cells and
depends on AID. It was also demonstrated that AID expression in CML
cells promotes overall genetic instability by hypermutation of tumor
suppressor (including IKZF1) and DNA repair genes. Importantly, these
finndings uncover a causative role of AID activity in the acquisition of
BCR-ABL mutations leading to Imatinib resistance, thus providing a
rationale for the rapid development of drug resistance and disease pro-
gression in ALL and lymphoid blast crisis patients.
In conclusion, therapeutic development in CML represents a success
story for modern medicine. Patients diagnosed with CML today are
expected to have a substantially longer survival than patients diagnosed
20 or even 10 years ago. Despite this, disease eradication and further
improvements in prognosis of CML remain high on the agenda. On the
other hand, treatment of the advanced phase of Ph leukemias including
ALL still remain problematic despite the central role of BCR/ABL onco-
protein in the pathogenesis and the possibility to target its activity by
first and second generation TKIs. However, additional factors play
important roles in sustaining viability and growth of the Ph cells in the
advanced phases and causing the observed rapid loss of TKI treatment
response in these patients. Hopefully, the new molecular findings might
open the way to the discovery of new and more effective treatment
strategies also for these patients.
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Myelodysplastic syndromes/myeloproliferative neoplasms
(MDS/MPNs) are rare myeloid malignancies characterized by the pres-
ence of both dysplastic and proliferative features [Table 1]. They have
been recognized as a separate group of diseases for the first time in 2001
by the WHO classification of Tumors of the Hematopoietic and Lym-
phoid Tissues.1 This new category incorporated chronic myelomono-
cytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML),
atypical chronic myeloid leukemia, BCR/ABL1-negative (aCML), togeth-
er with the less well defined unclassifiable forms of MDS/MPNs
(MDS/MPN-U), including refractory anemia with ring sideroblasts and
thrombocytosis (RARS-T) as a provisional entity. 
Because no significant progresses have been made over the last few
years in understanding molecular pathogenesis of MDS/MPNs, the 2008
revision of the WHO classification of myeloid neoplasms contained lit-
tle changes with regard to this disease category.2 In particular, some cas-
es of CMML with eosinophilia were relocated to the  “myeloid/lym-
phoid neoplasms with eosinophilia and platelet-derived growth factor
receptor-‚ (PDGFRB) rearrangement” category, while for RARS-T the
platelet threshold to define thrombocytosis was lowered from 600 to 450
x 109/L and the presence of proliferating large megakaryocytes in the
marrow resembling those in ET or PMF was added as a required diag-
nostic criteria. 
Taken together, MDS/MPNs represent disease entities with high het-
erogeneity of clinical and hematologic features, varying from predomi-
nantly myelodysplastic to predominantly myeloproliferative forms,
which entail different prognosis and demand different medical manage-
ment. As it has been well expounded in a recent review by Orazi and
Germing, the lack of known distinctive genetic features brings about
the diagnosis of specific MDS/MPN subtypes to be ascertained by the
integration of bone marrow and peripheral blood morphology with oth-
er laboratory and clinical findings.3
Among MDS/MPNs, CMML and JMML represent the main disor-
ders, respectively, in elderly and in childhood age.
Chronic myelomonocytic leukemia (CMML)
The WHO classification did not make any significant changes in the
original FAB criteria for the diagnosis of CMML, which are listed in Table
1. In addition, because in this disease entity a higher proportion of blasts
has always been unanimously recognized as being associated to a more
unfavorable prognosis, the WHO separated CMML into 2 prognostic
subcategories, CMML-1 and CMML-2, depending on the number of
blasts in the blood and bone marrow (Table 1).1
Having classified CMML among MDS/MPNs, the WHO virtually
abolished the distinction between a “dysplastic” (MD-CMML) and a
“proliferative” (MP-CMML) variant of the disease, originally proposed
by the FAB group in 1994 on the basis of the arbitrary chosen threshold
of 13x109/L WBC in the blood4. Nonetheless, individual patients neces-
sitate different treatments according to the clinically predominating dys-
plastic or proliferative manifestations; moreover, MP-CMML are most
often related to aberrancies in the RAS/MAPK signalling pathways or, in
a minority of cases, to the presence of the JAK2V617F activating mutation,
whereas MD-CMML are characterized by a higher frequency of cyto-
genetic abnormalities. Therefore, even though different etiology and
pathogenesis have not been demonstrated so far, from a practical point
of view the MD- versus MP- distinction represents a meaningful tool
both for clinical management and for further scientific investigations.
The natural course of CMML is highly heterogeneous, with patient life
expectancy varying from a few months to numerous years. Besides mar-
row blasts, several disease- and patient-related variables have been rec-
ognized as having significant association with survival length in various
retrospective studies, and a few scoring systems have been proposed to
estimate the risk of death in patients with CMML. The MD Anderson
Prognostic Score (MDAPS), which was developed from the analysis of
a large cohort of well-defined patients with CMML, included hemoglo-
bin <12 g/dL, the presence of circulating immature WBCs, absolute blood
haematologica | 2009; 94(s4) | bc
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Dear Editor,
Myelodysplastic syndromes (MDS) are a heterogeneous
group of clonal disorders of haematopoietic stem cell disor-
ders, characterized by ineffective haematopoiesis that results
in peripheral cytopenias and hypercellular bone marrow, with
increased propensity to progression into acute myeloid leu-
kaemia (AML) [1].
In a minority of cases, very few (less than 5 %)
erythroid precursors are found, whereas the other line-
ages maintain their dysplastic characteristics. This entity
is called MDS associated with pure red cell aplasia
(PRCA).
MDS associated with PRCA is a rare condition char-
acterized by severe anaemia, transfusion dependence,
reticulocytopenia, reduction of erythroid precursors and
multilineage dysplasia [2]. In PRCA, erythroid precursors
are nearly absent, while megakaryocytes and granulocyt-
ic precursors are usually present at normal levels [3].
Damage of erythroid progenitors appears to be immune
mediated; in about 10 % of cases, AML may finally
develop. Conventional immunotherapy is ineffective
while alemtuzumab combined with cyclosporine A (CyA)
seems to be a valid choice [4].
Lenalidomide is an immunomodulatory drug (IMiD),
which is well established and approved in the treatment
of 5q-myelodysplastic syndromes (MDS). The mode of
action includes immune modulation, anti-angiogenetic,
anti-inflammatory and anti-proliferative effects. It could
be useful to investigate its role in the treatment of
PRCA/MDS.
In a large series of 360 patients with MDS, 1.6 % of them
were found to have a PRCA [5]. At least 25 cases of MDS
with PRCA have been described until today, and 5 of them
were associated with del (5) (q14q34) [6]. WHO classification
in 2008 has definedMDSwith isolated del (5q) as a syndrome
characterized by bone marrow blast count <5 %, isolated del
(5q) and absence of Auer rods [7]. We report three cases of
severe transfusion-dependent macrocytic anaemia with low
reticulocyte counts (<1 %) in which del (5) (q14q34) was
associated with erythroblastopenia and myelodysplasia
(Table 1).
A 61-year-old Caucasian man, with a diagnosis of
MDS (refractory anaemia, RA) non-responsive to
erythropoiesis-stimulating agents (ESAs) treatment, reg-
ularly transfused with 4 blood packages/month, re-
ceived diagnosis of PRCA and underwent 12 cycles
of alemtuzumab+CyA. During 3 years of treatment,
transient remissions from transfusion dependence were
followed by relapses. During the third year of follow-up, del
(5q) was found in bone marrow, with marked dysplastic
features: lenalidomide was started, but after a few months,
AML emerged with fatal evolution. Evolution towards AML
and acquisition of chromosomal abnormalities could have
been induced by immunosuppressive therapy, and, in this
case, the 5q abnormality might be less responsive to
lenalidomide (Fig. 1).
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A 35-year-old Caucasian woman, with diagnosis of
MDS (RA) non-responder to ESAs treatment, received
diagnosis of MDS/PRCA after 1 year of transfusion
dependence (2 units/month). She underwent three
courses of CyA and alemtuzumab with short transient
periods of transfusion independence: a second bone
marrow investigation, performed after 1 year, showed
del (5q). Lenalidomide therapy was started; transfusion
independence was obtained after 2 months and she
maintains the response until now (Fig. 1).
A 65-year-old Caucasian man, with a diagnosis of
MDS (RA) non-responder to ESAs treatment, and a
transfusion need of 4 blood packages/month, received
diagnosis of PRCA and was treated with a single course
of alemtuzumab and CyA without any result. Cytogenetic
revision of bone marrow highlighted the presence of del
(5q), and treatment with lenalidomide was started
3 months after diagnosis. No haematological improve-
ment was observed and therapy was stopped after nine
courses. The patient is now transfusion-dependent,
21 months after diagnosis (Fig. 1).
Discussion
In MDS, PRCA could be a consequence of extreme
apoptosis of the red cell progenitors leading to their
total destruction. Programmed cell death is maximal in
advanced RA, RARS, and RAEB. This correlates with
the findings that erythroblastopenia is diagnosed mainly
in MDS with less than 10 % of blasts, as in our cases.
Excessive cell death could be due to cytokines like
TNF-α. The EPO action is related to its anti-apoptotic
action and has been reported to be efficient in PRCA
with myelodysplas ia that d id not respond to
corticotherapy [6].
The association of PRCA with lymphoproliferative
disorders and a good response to immunosuppressive
therapy point to the fact that erythroblastopenia can be
mediated by an autoimmune T cell subset. In vitro
inhibition of erythropoiesis in marrow culture systems
from patients with PRCA by T cells was demonstrated
by Abkhowitz et al. [7]. A study has reported a good
e ry t h ro i d r e sponse a f t e r cyc l o spo r i n A and
antithymocyte globulin in hypoplastic myelodysplastic
syndrome [8].
Alemtuzumab has also an important role, in combi-
nation with CyA, in the treatment of bone marrow
failure syndromes [9].
Lenalidomide has a role in the treatment of MDS with del
(5q) [10] and trials in low-risk MDS without del (5q) are
ongoing, but no reports are available about its role in this
setting of patients.T
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In conclusion, here we stress the difficulty of diagnosing
PRCA within myelodysplastic syndromes and focus on the
relationship among MDS with erythroid aplasia and del (5q),
with speculation on the role that lenalidomide could play in
such entities.
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Dear Editor,
Febrile neutropenia (FN) is a serious side effect of chemother-
apy, and even when it does not result in significant morbidity,
mortality and costs, it normally leads to a delay in subsequent
chemotherapy treatments [1]. FN is also associated with sub-
optimal delivery of chemotherapy and reduced relative dose
intensity (RDI), which adversely affects long-term cancer
outcome and survival [2]. FN is a surrogate marker for infec-
tion during chemotherapy and is characterized by an absolute
neutrophil count (ANC) <1000/mm3 and a single temperature
of >38.3 °C (101 °F) or a sustained temperature of ≥38 °C
(100.4 °F) for more than 1 h [1, 3]. Risk of FN is dependent on
both patient-specific factors (e.g. type of cancer, disease stage,
co-morbid conditions and age) and the myelotoxicity of the
chemotherapy regimen [1]. Once an episode of FN occurs, the
risk of FN increases in subsequent chemotherapy cycles [4].
The American Society of Clinical Oncology (ASCO) and
the National Comprehensive Cancer Network (NCCN) rec-
ommend the use of granulocyte colony-stimulating factors (G-
CSFs) as primary prophylaxis (PP) when the overall FN risk is
greater than 20 % following myelosuppressive chemotherapy,
and secondary prophylaxis (SP) following FN or a dose-
limiting neutropenic event [4, 5].
Recombinant granulocyte colony-stimulating factors (G-
CSFs) have been developed to stimulate proliferation and
differentiation of neutrophils in patients receiving chemother-
apy. Pegfilgrastim is a pegylated long-acting recombinant
form of G-CSF which extends the half-life, requiring less
frequent dosing than non-pegylated G-CSF [6]. It is indicated
to decrease the incidence of infection, as manifested by FN, in
patients with non-myeloid malignancies receiving
myelosuppressive chemotherapy associated with a clinically
significant incidence of FN [5]. Pegfilgrastim is cleared via a
neutrophil-mediated system and requires only a single dose
administered subcutaneously once per chemotherapy cycle
[6–8].
Multiple myeloma (MM) in advanced phases of disease
may be managed by regimens combining agents not frequent-
ly employed in early phases of treatment [9] (e.g.
anthracyclines, alkylating agents, etc.), but myelotoxicity is
the main expected side effect [10]. In this context, G-CSFs are
often necessary to warrant an effective chemotherapy,
counteracting the risks of febrile neutropenia: their use is
bound to frequent evaluation of neutrophil counts which
may not be frequently performed by patients in home-care.
Avoiding severe neutropenia by prophylactic pegfilgrastim
seems particularly useful in these cases, where treatment is
performed with palliative intent and prolonging life in the best
possible conditions is the aim.
The objective of this observational study was to
evaluate the efficacy and safety of pegfilgrastim in
patients affected by multiple myeloma in an advanced
phase of disease, in order to determine whether a single
subcutaneous injection of pegfilgrastim is as effective as
daily injections of standard filgrastim, in terms of hae-
matological toxicity, febrile neutropenic episodes, anti-
biotic usage and hospitalization duration.
We have considered 41 patients (22 male and 19 fe-
male) with a median age of 63.8 years (range 39–82)
affected by multiple myeloma, all relapsed and refractory
to a median of six lines of therapy (range 4–8), all
previously exposed to bortezomib, lenalidomide and mel-
phalan and all relapsed after auBMT, which have been
treated with different chemotherapy regimens combining
bortezomib, lenalidomide, bendamustine, melphalan and
doxorubicin.
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Pegfilgrastim in primary prophylaxis of febrile neutropenia
during chemotherapy of relapsed and refractory multiple
myeloma: a real-life experience
Since first course, received in our outpatient unit, pa-
tients performed blood counts twice weekly and received,
from day +8 to day +19 (considering “day +1” the day in
which the chemotherapy protocol starts), prophylactic oral
quinolones and anti-fungal drugs. During neutropenia after
first cycle of chemotherapy, filgrastim (5 μg/kg/day for
3 days) was given if neutrophils count was <1000×
109 cells/L. Median number of filgrastim administrations
was 4.7 (r. 3–6); nadir neutropenia was registered after a
median of 11.3 days (r. 8–14); median of nadir neutrophil
count was 1.16×109 cells/L (range 0.4–1.8×109 cells/L),
with maximum duration of 13 days.
From the second course of chemotherapy, all patients
switched to prophylactic therapy with pegfilgrastim (6 mg),
injected subcutaneously with a single administration on day +
3. Primary end point of this study was the duration of neutro-
penia (neutrophil count <1.5×109 cells/L), comparing
pegfilgrastim and filgrastim. During pegfilgrastim, neutrope-
nia was never longer than 8 days, with a consequent reduction
of neutropenia-related infections. Median nadir neutrophil
count, evaluated for every patients for at least three courses
of therapy (r. 3–6) registered at day +11, was 1.628 (range
0.93–2.25×109 cells/L); four patients (9.7 %) needed, after
pegfilgrastim administration, a supplement of three adminis-
trations of filgrastim. During pegfilgrastim prophylaxis, neu-
tropenia, when present, was shorter than during filgrastim
treatment (median of 4 days, range 3–7). Apart from the
advantage of the mono-administration, pegfilgrastim was well
tolerated in all patients: main side effects in our patients were
mild fever and bone pain (5/41 patients, 12 %). Moreover, no
hospitalization was needed during pegfilgrastim treatment
versus two hospitalizations for FN during filgrastim. During
the observation period, no patient died during filgrastim or
pegfilgrastim supportive treatment.
The reduction of the days of administration and of the days
spent in the hospital make pegfilgrastim an advantageous
option in most cases both in terms of quality of life and of
cost-effectiveness.
In conclusions, in patients affected by MM exposed to
myelosuppressive agents in advanced phases of myeloma
disease, pegfilgrastim seems to reduce the incidence of neu-
tropenia, is better tolerated and may increase the possibility to
maintain the scheduled time of treatment.
Conflicts of interest No conflicts of interest.
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18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction
of Outcome of Patients With Multiple Myeloma
A Comparative Study
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Purpose: The aim of this study was to compare the relative contribution of
18F-FDG PET/CT, 99mTc-MIBI, and MRI in predicting progression-free survival
(PFS) and overall survival (OS) in multiple myeloma (MM) patients.
Patients and Methods: Thirty-three newly diagnosed MM patients had been
evaluated in a previous study by 18F-FDG PET/CT, 99mTc-MIBI, and spine and
pelvis MRI reporting focal lesions and diffuse bone marrow involvement.
Twenty-seven patients were then subjected to a mean follow-up period of
58 months, whereas 6 patients were lost.
Results: 18F-FDG PET/CT, 99mTc-MIBI, and MRI were positive in 26, 24, and
22 patients, respectively, showing diffuse bone marrow involvement in 12, 21,
and 17 patients and a total of 185, 56, and 39 focal lesions, respectively. At
follow-up, 18 patients showed complete or partial remission, whereas 9 patients
developed progressive disease, 7 of which died of myeloma. Univariate and sub-
sequent multivariate analysis showed that 18F-FDG PET/CT focal uptake and
99mTc-MIBI focal and diffuse uptake predicted PFS (P = 0.0006), whereas
18F-FDG PET/CT focal uptake and 99mTc-MIBI focal uptake predicted OS
(P = 0.0010). Although MRI diffuse pattern predicted PFS at univariate analysis
(P = 0.0376), it was not retained in the model at multivariate analysis. Receiver
operating characteristic curve analysis showed that the number of focal lesions
best discriminating for PFS and OS prediction was 4 and 11 for 18F-FDG PET/
CT and 2 in both cases for 99mTc-MIBI, respectively. By Kaplan-Meier analysis
and log-rank testing, PFS and OS at follow-up were significantly better in pa-
tients showing a number of focal lesions at 18F-FDG PET/CT or 99mTc-MIBI
lower than the respective cutoff (P = 0.03, P = 0.004, and P < 0.0001, respec-
tively). Finally, PFS was significantly better in patients showing absent/faint dif-
fuse 99mTc-MIBI uptake than in those having moderate/intense diffuse uptake
(P = 0.0012).
Conclusions: 18F-FDG PET/CT and 99mTc-MIBI may be useful in predicting
PFS and OS in myeloma patients.
KeyWords:multiple myeloma, 18F-FDG PET/CT, 99mTc-MIBI,MRI, prognosis
(Clin Nucl Med 2015;40: 303–308)
M ultiple myeloma (MM) is a malignant hematologic disorder char-acterized by proliferation of clonal plasma cells in the bone mar-
row. Disease expression is very heterogeneous including diffuse bone
marrow infiltration, focal bone lesions, or extramedullary lesions.1 As
a consequence, the clinical course and outcome of disease can be quite
variable ranging from few months up to 10 years also due to treatment
improvements achieved in the last decades.2 In this, setting is crucial to
identify reliable prognostic factors to estimate the individual patient's
outcome. A variety of clinical and hematological parameters, imaging
findings, and more recently cytogenetic tests have been used in the
effort to obtain a reliable evaluation of clinical status and prognosis of
patients with MM.3 The majority of these parameters have been in-
cluded in the main 3 staging systems that are currently used in the man-
agement and prognostic assessment ofMM, namely, Durie and Salmon,
Durie and Salmon PLUS, and International Staging System (ISS).4
Although ISS is based exclusively on the values of serum albumin
and β2-microglobilin, in the other 2 systems, imaging plays a very im-
portant role because it is used to evaluate the extent of disease at diag-
nosis, which represents one of the most important prognostic factors in
MM patients.5 In the Durie and Salmon system, osteolytic bone lesions
are detected by skeletal radiography. However, the prognostic value of
this imaging methodology may be controversial because it can signifi-
cantly underestimate the extent of bone and bone marrow involvement,
especially at the onset of disease.6 Therefore, the system has been up-
dated in Durie and Salmon PLUS by adding more advanced imaging
modalities such as whole-body 18F-FDG PET/CT and/or MRI of the
spine and pelvis in the effort to improve the assessment of the extent
and severity of disease and also the prognostic stratification of patients.
In fact, these techniques have proved to be reliable for predicting the
outcome in various series of MM patients, both at diagnosis and after
treatment.7–9
A further imaging methodology, 99mTc-MIBI scintigraphy, has
been successfully used in the evaluation of MM extent showing high
sensitivity and specificity in detecting sites of active disease and bone
lesions at diagnosis or follow-up.10–17 Moreover, focal or combined
focal/diffuse patterns of 99mTc-MIBI uptake have been shown to indi-
cate significantly worse prognosis with shorter overall survival (OS)
than normal or diffuse tracer patterns.18–21
Therefore, the aim of our studywas to evaluate the role and com-
pare the relative contribution of whole-body 18F-FDG PET/CT, whole-
body 99mTc-MIBI, and MRI of the spine and pelvis in the prediction of
progression-free survival (PFS) and OS of myeloma patients.
PATIENTS AND METHODS
Patients
We evaluated the PFS and OS in 27 MM patients (7 women,
20 men; mean age, 62 ± 11 years), belonging to a series of 33 newly
diagnosed untreated MM patients formerly studied by our group,
that had been prospectively evaluated by whole-body 18F-FDG PET/CT,
whole-body 99mTc-MIBI, and spine and pelvis MRI within a
period of 10 days.22 The 27 patients included in the present study
were then subjected to follow-up for a mean period of 58 months
(range, 1–104 months; median, 66 months). The 6 remaining patients
of the original series were lost at follow-up aswas not possible to collect
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any further clinical data about them. The study has been approved by
the institutional review board, and all subjects signed awritten informed
consent form before their inclusion in the study.
Clinical characteristics of the 27 patients studied such as age, sex,
type of myeloma, bone lesions, performance status, Durie and Salmon
stage, and ISS (available on 22 patients) are reported in Table 1. All pa-
tients were treated according to therapeutic regimens containing novel
agents such as thalidomide, lenalidomide, or bortezomib and/or con-
ventional agents and followed, in 12 of them, by autologous bone mar-
row transplantation. At reevaluation, patients were considered to have
progressive disease when showing a greater than or equal to 25% in-
crease in diffuse bone marrow plasma cell infiltration and/or in the
M-protein or new bone lesions; patients were considered to have partial
remission when the M-protein decreased more than 50% and complete
remission when the percentage of diffuse bone marrow plasma cell in-
filtration was less than 5% and M-protein was absent.3
Imaging Studies
18F-FDG PET/CT, 99mTc-MIBI, and MRI scans were performed
in MM patients at diagnosis as described in the previous study.22
Briefly, whole-body 18F-FDG PET/CT scans were acquired af-
ter fasting for 8 hours 60 to 90 minutes after IV injection of 18F-FDG
(370 MBq) in patients with glucose level less than 120 mg/dL by using
a combined PET/CT Discovery LS scanner (GE Healthcare).
99mTc-MIBI imaging studies were performed by acquiring
planar anterior and posterior whole-body scans 10 minutes after IV
injection of 99mTc-MIBI (555 MBq) by using a dual-head γ-camera
(ECAM, Siemens).
MRI studies were performed at 1.5 T (Achieva, Philips Medical
Systems, the Netherlands) along sagittal planes covering the whole
spine with 3 partly overlapping slabs and along coronal planes for the
study of the pelvis. The sequence parameters (TR/TE/echo train length)
used for the spine were as follows: 477/13/4 for T1-weighted images,
3500/120/43 for T2-weighted images. The sequence parameters used
for the pelvis were as follows: 550/14/5 for T1-weighted images,
3500/120/43 for T2-weighted images with spectral pre-saturation with
inversion-recovery fat suppression.
18F-FDG PET/CT, 99mTc-MIBI, and MRI were read and inter-
preted blindly by 2 independent nuclear medicine physicians and/or
2 independent radiologists who were unaware of the imaging results.
The number of eventual focal lesions and/or the presence or absence
of diffuse bonemarrow involvement assessed by each imaging method-
ology were recorded by analyzing the imaging findings of 18F-FDG
PET/CT, 99mTc-MIBI, and MRI as previously described.10,22,23
Statistical Analysis
Statistical analysis was performed using SPSS software (IBM
SPSS Inc, Chicago, Ill). Univariate and multivariate analyses of clinical
and imaging variables were performed using Cox proportional hazards
regression. Variables that were found to be predictive of PFS and OS by
univariate analysis were included in the multivariate analysis. Receiver
operating characteristic (ROC) curve analysis was performed to esti-
mate the best discriminative value of independent prognostic variables
between dead and survivors as well as between patients with and with-
out progression. Survival analysis was carried out using Kaplan-Meier
method and log-rank tests. Survivors were censored at the time of
the last clinical control. A probability value P < 0.05 was considered
statistically significant.
RESULTS
Imaging findings obtained at diagnosis in the 27MMpatients si-
multaneously analyzed with 18F-FDG PET/CT, 99mTc-MIBI, and MRI
in the previous study are reported in Table 2. Briefly, whole-body
18F-FDG PET/CT was positive in 26 patients (14 had focal uptake,
2 had diffuse uptake, and 10 combined focal and diffuse uptake).
Whole-body 99mTc-MIBI resulted positive in 24 patients (3 had focal
uptake, 8 diffuse uptake, and 13 combined focal and diffuse uptake).
Spine and pelvis MRI was positive in 22 patients (5 showed focal pat-
tern, 10 diffuse pattern, and 7 combined focal and diffuse pattern of dis-
tribution). By analyzing the number and sites of focal lesions detected,
we found a total of 185 focal lesions by 18F-FDG PET/CT—70 in the
spine and pelvis (34 and 36, respectively) and 115 in other districts,
whereas 99mTc-MIBI visualized a total of 56 focal lesions—1 in
the spine, 6 in the pelvis, and 49 in other districts. Fourteen of the focal
lesions visualized by 18F-FDG PET/CT and 3 of those detected by
99mTc-MIBI were localized in soft tissues. Finally, MRI detected a total
of 39 focal lesions, 28 in the spine and 11 in the pelvis.
After a mean follow-up period of 58 months, 9 patients had pro-
gressive disease (7 of which died of MM), 10 showed partial remission,
and 9 showed complete remission. For survival analysis, patients show-
ing progressive disease or subsequently dead (n = 9) were compared
with patients in complete or partial remission (n = 18). Similarly, pa-
tients showing progressive disease, partial remission, or complete re-
mission were grouped as survivors (n = 20) and compared with those
who were dead (n = 7).
TABLE 1. Patients Characteristics
Characteristics Value
Age (range), y 62 ± 11 (32–84)
Sex
Female 7 (26%)
Male 20 (74%)
Type of myeloma
IgG 20 (74%)
IgA 6 (22%)
Nonsecretory 1 (4%)
Bone lesions
<4 lesions 11 (41%)
≥4 lesions 16 (59%)
Performance status
≤70% 9 (33%)
80% 8 (30%)
90% 10 (37%)
Stage
IA 8 (30%)
IIA 4 (15%)
IIIA 15 (55%)
ISS
I 14 (64%)
II 5 (23%)
III 3 (13%)
TABLE 2. Imaging Findings of Whole-Body 18F-FDG PET/CT,
Whole-Body 99mTc-MIBI, and MRI of the Spine and Pelvis
Performed on 27 MM Patients at Diagnosis, According to the
Presence of Normal, Diffuse, Focal, or Focal and Diffuse Pattern
of Bone Marrow Involvement
Normal Diffuse Focal Focal + Diffuse
Whole-body 18F-FDG PET/CT 1 (3%) 2 (7%) 14 (51%) 10 (37%)
Whole-body 99mTc-MIBI 3 (11%) 8 (29%) 3 (11%) 13 (48%)
MRI of the spine and pelvis 5 (18%) 10 (37%) 5 (18%) 7 (25%)
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Univariate analysis showed that 18F-FDG PET/CT focal uptake
(χ2 = 8.773; P = 0.0031), 99mTc-MIBI focal uptake (χ2 = 4.633; P =
0.0314), 99mTc-MIBI diffuse uptake (χ2 = 7.368; P = 0.0066),MRI dif-
fuse distribution (χ2 = 4.321; P = 0.0376), hemoglobin (χ2 = 8.007;
P = 0.0047), β2-microglobulin (χ2 = 4.468; P = 0.0345), and stage
(χ2 = 5.532; P = 0.0187) were all predictive of PFS (Table 3). When
these variables were entered in the multiple regression model, only
3 of them were retained, one derived form 18F-FDG PET/CT (ie, focal
uptake) and 2 derived from 99mTc-MIBI (ie, focal and diffuse uptake)
(χ2 = 17.205;P = 0.0006). Receiver operating characteristic curve anal-
ysis showed that the number of focal lesions that best discriminate be-
tween patients in progression and remission was 4 (area under the
curve [AUC], 0.799) by 18F-FDG PET/CT scan and 2 (AUC, 0.716)
by 99mTc-MIBI scintigraphy, respectively. Progression-free survival
curve estimated by Kaplan-Meier method and log-rank test, in fact,
was significantly prolonged in patients with 4 lesions or fewer com-
pared with patients with more than 4 lesions on 18F-FDG PET/CT
(χ2 = 4.6684; P = 0.0307) as well as in patients with 2 lesions or more
compared with patients with more than 2 lesions on 99mTc-MIBI (χ2 =
20.4759; P < 0.0001) (Fig. 1). In addition, PFS curve by Kaplan-Meier
method and log-rank test was significantly prolonged in patients show-
ing absent or faint diffuse 99mTc-MIBI uptake than in those having
moderate or intense diffuse uptake (χ2 = 10.5020; P = 0.0012; Fig. 2).
Regarding OS prediction, univariate analysis showed that
18F-FDG PET/CT focal uptake (χ2 = 8.654; P = 0.0033), 99mTc-
MIBI focal uptake (χ2 = 7.596; P = 0.0058), 99mTc-MIBI diffuse up-
take (χ2 = 5.109; P = 0.0238), hemoglobin (χ2 = 4.122; P = 0.0423),
and bone marrow transplantation (χ2 = 4.647; P = 0.0311) were all pre-
dictive of OS. Moreover, β2-microglobulin (χ2 = 3.772; P = 0.0521)
was nearly significant in OS prediction (Table 3). When all these vari-
ables were entered in the multiple regression model, only 2 of them
were retained, namely, 18F-FDG PET/CT focal uptake and 99mTc-
MIBI focal uptake (χ2 = 13.892; P = 0.0010). ROC curve analysis
showed that the number of focal lesions that best discriminate between
patients who had died and survivors was 11 (AUC, 0.807) by 18F-FDG
PET/CT and 2 (AUC, 0.857) by 99mTc-MIBI, respectively. Overall sur-
vival curve estimated by Kaplan-Meier method and log-rank test, in fact,
was significantly prolonged in patientswith 11 lesions or fewer compared
with patients with more than 11 lesions on 18F-FDG PET/CT (χ2 =
7.9696; P = 0.0048) as well as in patients with 2 lesions or fewer com-
pared with patients with more than 2 lesions on 99mTc-MIBI (χ2 =
21.2430; P < 0.0001) (Fig. 3). Representative images of focal and dif-
fuse tracer uptake by whole-body 18F-FDG PET/CT and 99mTc-MIBI
scans performed on the same MM patient are shown in Figure 4.
DISCUSSION
The results of our comparative study show that the number of fo-
cal lesions detected by 18F-FDG PET/CT or 99mTc-MIBI is a predictor
of disease progression and death in patients with MM independently
from other conventional prognostic factors, whereas diffuse 99mTc-
MIBI uptake is an independent predictor of disease progression only.
TABLE 3. Predictors of PFS and OS by Univariate Analysis Based
on Clinical and Imaging Parameters
Univariate Analysis
PFS OS
Variable χ2 P χ2 P
Age, y 0.229 0.6322 0.084 0.7710
Hemoglobin 8.007 0.0047 4.122 0.0423
Plasma cell concentration 0.522 0.4702 0.988 0.3203
M-protein 1.435 0.2309 0.695 0.4043
Albumin 3.396 0.0654 1.022 0.3122
β2-microglobulin 4.468 0.0345 3.772 0.0521
Performance status 0.984 0.3211 0.219 0.6401
Stage 5.532 0.0187 2.983 0.0842
ISS 2.207 0.1374 1.344 0.2463
Bone marrow transplantation 1.929 0.1648 4.647 0.0311
18F-FDG PET/CT focal uptake 8.773 0.0031 8.654 0.0033
18F-FDG PET/CT diffuse uptake 0.639 0.4242 0.444 0.5054
99mTc-MIBI focal uptake 4.633 0.0314 7.596 0.0058
99mTc-MIBI diffuse uptake 7.368 0.0066 5.109 0.0238
MRI focal pattern 0.679 0.4099 0.228 0.6327
MRI diffuse pattern 4.321 0.0376 2.728 0.0986
FIGURE 1. Progression-free survival by Kaplan-Meier analysis
and log-rank test showing significant difference at 104months
follow-up between MM patients according to the number of
focal lesions. A, Patients with 4 focal lesions or fewer or 4 focal
lesions or more on 18F-FDG PET/CT as assessed by ROC curve
analysis (P = 0.0307). B, Patients with 2 focal lesions or fewer
or 2 focal lesions or more on 99mTc-MIBI as assessed by ROC
curve analysis (P < 0.00001).
FIGURE 2. Progression-free survival by Kaplan-Meier analysis and
log-rank test showing significant difference at 104 months
follow-up between MM patients with absent-to-faint as
compared with those with moderate-to-intense diffuse 99m
Tc-MIBI uptake (P = 0.0012).
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Multiple myeloma is a heterogeneous disease with respect to
clinical presentation and course, biologic characteristics, responsive-
ness to therapy, and long-term survival.3 Therefore, various patient-
related, disease-related, and therapy-related characteristics have been
proposed in the effort to predict disease course and outcome.2,3
The definition of prognosis in MM patients is commonly based
on stage. The most widely used staging system for MM, the Durie and
Salmon system, is considered a reliable and reproducible method to es-
timate MM tumor burden. In this system, the extent of bone lesions is
determined by radiographic bone survey.6,24 Bone disease is the hall-
mark of MM, occurring in approximately two thirds of patients at diag-
nosis and in up to 90% of patients during the course of disease. Despite
the substantial advances in MM therapy over the last decades, bone dis-
ease remains a major cause of morbidity and mortality in MM patients.
Moreover, the presence of lytic bone lesions may have prognostic rele-
vance.9,25 From these considerations comes the need to estimate as ac-
curately as possible the extent of bone disease, yet conventional skeletal
survey is able to detect lytic lesions only when more than 30% of bone
substance has been lost leading to a significant underestimation of bone
disease.4 Therefore newer imaging techniques such as 18F-FDG PET/
CT and MRI of the spine and pelvis were included in the Durie and
Salmon PLUS staging system. In fact, these advanced imaging method-
ologies can detect intramedullary focal lesions before anatomic changes
occur and are also able to detect the diffuse bone marrow infiltration
component of MM.26,27
In particular, 18F-FDG PET/CTallows to explore thewhole body
including the skeleton in a single examination session detecting myelo-
matous lesions with a sensitivity in the order of 90%.1 A previous study
by our group showed that 18F-FDG PET/CT can give a significant con-
tribution in the evaluation of MM patients by detecting more focal le-
sions than MRI of the spine and pelvis due to the consistent number
of lesions outside this anatomic district.22 In the present study, we
FIGURE 3. OS by Kaplan-Meier analysis and log-rank test
showing significant difference at 104 months follow-up
between MM patients according to the number of focal lesions.
A, Patients with 11 focal lesions or fewer or 11 focal lesions or
more on 18F-FDG PET/CT as assessed by ROC curve analysis
(P = 0.0048). B, Patients with 2 focal lesions or fewer or 2 focal
lesions or more on 99mTc-MIBI as assessed by ROC curve
analysis (P < 0.00001).
FIGURE 4. Whole-body 18F-FDG PET/CT and 99mTc-MIBI scans performed on the same MM patient showing diffuse tracer uptake
and focal lesions in the axis, acromion processes, humeri, left clavicle, sternum, ribs, right ilium, and femuri. A, MIP view. B, Sagittal
CT, PET, and fusion images of whole-body 18F-FDG PET/CT. C, Anterior and posterior whole-body 99mTc-MIBI.
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showed that 18F-FDG PET/CT can also play a role in the prognosis of
MM patients. Several studies showed that imaging parameters related
to tumor burden such as the number of focal lesions, the intensity of
tracer activity by the lesions, the value of metabolic tumor volume, or
the presence of extramedullary disease affect survival outcomes.9,28,29
In particular, the presence of more than 3 FDG-avid focal lesions on
baseline examination was the leading independent parameter adversely
affecting PFS and OS.28 Also in our study, among all the variables
tested, the number of focal lesions on 18F-FDG PET/CTwas shown to
be one of the independent factors predicting survival. In fact, the pres-
ence of more than 4 and 11 focal lesions was associated with worst
PFS and OS, respectively. Conversely, the number of focal lesions on
MRI was not predictive of PFS or OS. In a previous study, the presence
of more than 7 focal lesions on the initial MRI was associated with
inferior outcome.30 This apparent discrepancy could be explained by
the different characteristics of patient population showing at MRI
a mean number of focal lesions per patient of 9.9 as compared with
1.4 in our series.
Previous studies by our and other groups showed that focal
99mTc-MIBI uptake in MM patients indicates active and advanced dis-
ease stage10–16 and affects prognosis.18,19,21 In our study, the prognostic
cutoff threshold for 99mTc-MIBI was lower as compared with that of
18F-FDG PET/CT; in fact, the presence of few lesions at 99mTc-MIBI
(ie, >2) was able to predict both disease progression and death despite
the fact that the number of focal lesions detected by 99mTc-MIBI
scan was less than one third of those detected by 18F-FDG PET/CT. No-
tably, both 99mTc-MIBI and 18F-FDG PET/CT focal uptake are inde-
pendent predictors of PFS and OS therefore providing complementary
prognostic information.
In a former study by our group, diffuse 99mTc-MIBI uptake was
graded as low, moderate, or intense according to extension and intensity
criteria.10 Using this score, diffuse uptake correlated with both clinical
status and disease stage, and intense diffuse uptake indicates high tumor
burden and poor prognosis.10,21 Accordingly, the present study showed
that PFS was significantly prolonged in patients with absent or faint
diffuse 99mTc-MIBI uptake as compared with those having moderate
or intense diffuse uptake. Conversely, MRI diffuse bone marrow in-
volvement, despite its significance at univariate analysis in PFS predic-
tion, was not retained in the model at multivariate analysis, although
previous studies reported its influence on the prognosis of MM when
used as the sole imagingmodality.31,32 Furthermore, in agreementswith
other studies,33 our results indicate that 18F-FDG PET/CT diffuse bone
marrow uptake in MM patients does not provide useful information for
prognosis in our series of patients.
In this study, a classic prognostic factor such as β2-microglobulin
was found to be significant at univariate analysis, but it was not retained
in the model at multivariate analysis in both PFS and OS prediction.
The measurement of β2-microglobulin and serum albumin levels is
the basis of the ISS, which is created to standardize the classification
of myeloma using more widely available measures of disease.3,24 How-
ever, cutoff levels for these variables are controversial because in
advanced disease, the increase in β2-microglobulin levels could be
due to both tumor burden or renal failure. Moreover, a recent study sug-
gested that ISS is strongly dependent from age-related comorbidity bur-
den lacking specificity for MM.34 Moreover, with the introduction of
new drugs for treatingMM, its prognostic significance should probably
be redefined.5
In recent years, cytogenetic abnormalities have been reported to
predict prognosis in hematologic malignancies, especially in acute leu-
kemias.31 Inmyeloma, translocation t(4;14), t(14;16), or deletion of 17p
by fluorescence in situ hybridization; deletion of 13 or 13q, t(4;14); or
deletion of 17p by conventional cytogenetic were reported to identify
high-risk MM patients.2,35–37 At the time of diagnosis of our patients,
cytogenetic tests were not included in the standard workup of MM at
our institution; therefore, the available cytogenetic data did not allow
an accurate statistical analysis. In MM, however, data from genetic al-
terations obtained by conventional cytogenetic or fluorescence in situ
hybridization are not yet considered adequate enough to suggest their
routine use in MM prediction due to technical challenges related to
the low proliferation rate of malignant plasma cells and their potential
low proportion in bioptic samples.2,35,36 Moreover, outcome heteroge-
neity has been observed even in high-risk MM subgroups defined by
cytogenetic tests.35
However, the main focus of the present study was to compare
imaging modalities such as 18F-FDG PET/CT, 99mTc-MIBI, and MRI
of the spine and pelvis in the prediction of prognosis in MM patients,
and to the best of our knowledge, it is the first to provide such compar-
ison. The number of focal lesions at 18F-FDG PET/CT or 99mTc-MIBI
scan is an independent predictor of both PFS and OS in myeloma pa-
tients therefore providing complementary information on the prognosis
of these patients. Moreover, diffuse 99mTc-MIBI uptake is an indepen-
dent predictor of disease progression. Conversely, neither focal nor dif-
fuse MRI pattern of distribution independently predicted PFS or OS.
18F-FDG PET/CT and 99mTc-MIBI resulted to be more accurate in
predicting disease outcome than spine and pelvis MRI likely because
of their wider whole-body FOV that allows them to detect the consis-
tent number of lesions occurring outside the spine and pelvis in MM
patients.
In conclusion, among all imaging and conventional clinical var-
iables tested, 18F-FDG PET/CTand 99mTc-MIBI provided independent
prognostic parameters that can improve prognostic stratification and
therapeutic strategies in MM patients. Therefore, it is advisable to per-
form at least one of these techniques at baseline in every newly diagnosed
patient because the presence of 18F-FDG PET/CT or 99mTc-MIBI focal
uptake can be of aid in identifying patients with poor prognosis who
may benefit from more aggressive treatments.
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LETTER TO THE EDITOR
Salvage therapy with pegylated liposomial doxorubicin-
based regimen in relapsed/refractory multiple myeloma:
comments to the article by Romano et al.
To the Editor:
Romano A. et al. have recently published an interesting
study on the efﬁcacy of a salvage regimen with pegylated
liposomial doxorubicin, cyclophosphamide, and dexametha-
sone in relapsed/refractory multiple myeloma patients
(rrMM). As the authors clearly demonstrated, this regimen
can be really effective and safe also for rrMM patients previ-
ously treated with novel agents (median of previous lines: 2,
range: 1–6), with clinical response in 12 patients (50%),
29% of which being Very Good Partial Response (VGPR)
or better, with 8.7 months Progression Free Survival (PFS)
and 21.5 months Overall Survival (OS) (range: 2–
44 months), after a median follow-up of 21.5 months (1).
Since 2009, in our Institution, some patients affected by
multiple myeloma, relapsed and refractory to most of the
available therapeutic options (2–7), have been treated with
courses of pegylated liposomial doxorubicin (35 mg/sqm,
day 1), cyclophosphamide (800 mg/sqm, day 1), and
dexamethasone (20 mg days 1–4), with pegﬁlgrastim at day
+4, every 28 d (Caelyx, Endoxan, Dexamethasone (CED)
regimen), until progression of disease.
So far, 31 patients (16 women, 12 men), with median age
63.4 yr (range: 43–84), affected by relapsed and progressive
multiple myeloma, whose median number of previous treat-
ments was six (range: 2–11), have been treated with CED
schedule (median number of courses: 4.3, range: 2–17). Avail-
able results refer to 31 patients completing at least two courses
of CED, whereas four patients who received only one cycle
were excluded from analysis. Tolerability proﬁle of CED was
satisfactory: hematological toxicity was present in all patients,
but grade 3 transfusion-dependent anemia or neutropenia was
veriﬁed in 37% and 46% of cases, without necessity of hospi-
talization. No severe extrahematologic toxicity was observed:
grade 1 gastrointestinal side effect (nausea) in the majority of
patients and two grade 3 extrahematological events: acute
renal failure in a patient and bradycardia in another patient,
both of them not requiring hospitalization. According to Inter-
national Myeloma Working Group (IMWG) response criteria,
after a median follow-up of 6 months of treatment (range: 2–
17+), overall response ratio (ORR) was 51% (2 Complete
Response (CR), 2 VGPR, 8 Partial Response (PR), 4 Minimal
Response (MR)) with 10 disease progressions and ﬁve
patients in stable disease. Median OS from start of CED was
5.9 months (range: 2–17). These effects appear impressive in
patients so far lacking available therapeutic options. Together
to Romano’s results, our observations underline the efﬁcacy
of pegylated liposomial doxorubicin, which seems to give a
contribution in a particular severe setting of patients, without
signiﬁcant side effects.
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Dear Editor,
Febrile neutropenia (FN) is a serious side effect of chemothera-
py, and even when it does not result in significant morbidity,
mortality, and costs, it normally leads to a delay in subsequent
chemotherapy treatments [1]. Suboptimal delivery of chemo-
therapy and reduced relative dose intensity (RDI) adversely af-
fects long-term cancer outcome and survival [2]. FN is a surro-
gate marker for infections during chemotherapy and is charac-
terized by an absolute neutrophil count (ANC) <1000/mmc and
a single body temperature of >38.3 °C or a sustained tempera-
ture of ≥38 °C for more than 1 h [1, 3]. Risk of FN is dependent
on both patient-specific factors (e.g., type of cancer, disease
stage, co-morbid conditions, and age) and the myelotoxicity of
the chemotherapy regimen. Once an episode of FN occurs, the
risk of FN increases in subsequent chemotherapy cycles [4].
Recombinant granulocyte colony-stimulating factors (G-
CSFs) have been developed to stimulate proliferation and dif-
ferentiation of neutrophils in patients receiving chemotherapy.
The American Society of Clinical Oncology (ASCO) and
the National Comprehensive Cancer Network (NCCN) rec-
ommend the use of G-CSF as primary prophylaxis (PP) when
the overall FN risk is greater than 20 % following myelosup-
pressive chemotherapy, and secondary prophylaxis (SP) fol-
lowing FN or a dose-limiting neutropenic events [4, 5].
Pegfilgrastim is a pegylated long-acting recombinant form
of G-CSF which extends the half-life, requiring less frequent
dosing than non-pegylated G-CSF [6]. It is indicated to de-
crease the incidence of infection, as manifested by FN, in
patients with non-myeloid malignancies receiving myelosup-
pressive chemotherapy associated with a clinically significant
incidence of FN [5]. Pegfilgrastim is cleared via a neutrophil-
mediated system and requires only a single dose administered
subcutaneously once per chemotherapy cycle [6–8].
Multiple myeloma (MM) in advanced phases of disease may
be managed by regimens combining agents not frequently
employed in early phases of treatment (e.g., anthracyclines,
alkylating agents, etc), which have significant myelotoxicity.
Bendamustine is a bifunctional alkylating agent that produces
both single and double strand breaks in DNA, which has shown
good results in association with bortezomib and dexamethasone
in heavily pretreated patients [9], but in this schedule
myelotoxicity is themainexpectedsideeffect [10]. In thiscontext,
G-CSFs are often necessary to warrant an effective treatment,
counteracting the risks of febrile neutropenia. Their use is bound
to frequent evaluation of neutrophil counts which may not be
easily performed by patients in home care. Avoiding severe neu-
tropenia by prophylactic long-acting G-CSF, as pegfilgrastim,
seems particularly useful in this setting of patients.
The objective of this retrospective study was to evaluate the
efficacy and safety of pegfilgrastim in relapsed and refractory
MM patients, in treatment with courses of bendamustine-
bortezomib-dexamethasone (BVD), in order to determine
whether primary prophylaxis with pegfilgrastim is more effec-
tive than that with filgrastim [6, 11–13] in terms of incidence
of chemotherapy disruptions due to FN, days of hospitaliza-
tion, and G-CSF-related extra-hematological side effects.
Methods
FromDecember 2012 to February 2016, 47 patients have been
considered (25 male and 22 female) with a median age of
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61.3 years (range 37–83) affected by relapsed and refractory
MM, treated with several lines of treatments (median 6, r. 2–
11), and refractory to the drugs previously received, who were
treated with monthly courses of BVD (bendamustine 90 mg/
sqm i.v. days 1 and 2; bortezomib 1 mg/sqm s.c. days 1, 4, 8,
and 11; and dexamethasone 20 mg per os days 1, 2, 4, 5, 8, 9,
11, and 12, until progression).
All treatments were performed in our outpatient unit.
Twenty-four consecutive patients received pegfilgrastim
(6 mg) subcutaneously with a single administration on day
+4, as primary prophlyaxis, and they were compared to a
historical group of twenty-three consecutive patients in which
filgrastim (5 μg/kg/day for at least 3 days) had been given, as
primary prophylaxis Bon demand,^ if neutrophils count was
<1000 × 109 cells/L.
All patients performed blood counts twice weekly and re-
ceived, from day +8 to day +19, considering Bday +1^ the day
in which the chemotherapy protocol starts, prophylactic oral
quinolones and anti-fungal drugs.
Results
In filgrastim group, twenty-three consecutive patients, previ-
ously treated with several lines of treatments (median 6, r. 3–
11) with a median age of 60.7 years (r. 37–78) have been
considered. Nadir neutropenia was registered after a median
of 9.1 days (r.8–15), with maximum duration of 13 days (me-
dian 9.4 days, r. 7–13); median of nadir neutrophil count was
1.15 × 109 cells/L (range 0.3–1.5 × 109 cells/L). Median num-
ber of filgrastim administrations was 4.2 (r. 3–6). Patients have
been evaluated after at least three courses of therapy (r. 3–6).
Filgrastim was well tolerated in all patients; main side effects
were mild fever and bone pain (6/23, 26 %), treated success-
fully with paracetamol. Three hospitalizations for pneumonia
were needed during filgrastim (median days of hospitalization
15, range 8–19); the patients received intravenous antibiotic
treatment with resolution of infectious episodes. Four patients
(4/23, 17.3 %) disrupted chemotherapy schedules because of
neutropenia.
In pegfilgrastim group, twenty-four consecutive patients,
previously treated with several lines of treatments (median 6,
r. 2–10) with a median age of 62.1 years (r. 43–83) have been
considered. Nadir neutropenia, registered at day +11, was
1.484 × 109 cells/L (range 1.04–2.33 × 109 cells/L). During
pegfilgrastim, neutropenia, when present, was shorter than
during filgrastim treatment, never longer than 8 days (median
5.9 days, r. 4–8), with a consequent reduction of neutropenia-
related infections. Only four patients (16.6 %) needed, after
pegfilgrastim, a supplement of three administrations of
filgrastim. Patients have been evaluated after at least three
courses of therapy (r. 3–6). Apart from the advantage of
mono-administration, pegfilgrastim was well tolerated in all
patients; main side effects were mild fever and bone pain
(3/24, 12.5 %), treated successfully with paracetamol.
Moreover, no hospital izat ion was needed during
pegfilgrastim. Only two patients (2/24, 8.3 %) disrupted che-
motherapy schedules because of neutropenia.
In Italy, the cost of filgrastim 30-MU vial is 95.18–127.95
euro (depending from producer), while the cost of
pegfilgrastim 6 mg is 1.489.50 euro. However, this cost has
to be considered together with that of hospitalizations, antibi-
otic usage, and disruptions of scheduled chemotherapy
treatments.
Thus, pegfilgrastim was significantly associated with fewer
incidence rate of FN-related chemotherapy disruptions
(17.3 % in filgrastim group vs. 8.3 % in pegfilgrastim group,
p = 0.3534 by χ2 test), fewer days of hospitalization due to
FN (median number 15 days in filgrastim group vs. 0 in the
pegfilgrastim group), and fewer G-CSF-related extra-
hematological side effects (26 % in filgrastim group vs.
12.5 % in pegfilgrastim group, p = 0.2987 by χ2 test), with
consequent improvement of quality of life. However, statisti-
cal comparison of the two groups (by χ2 test) was not prop-
erly feasible because of the very small sample size.
Conclusions
In conclusions, in patients affected by relapsed and refractory
MM, treated with bendamustine-bortezomib-dexamethasone,
primary prophylaxis with pegfilgrastim seems to reduce the
incidence of chemotherapy disruptions due to FN, and the
days of hospitalization. Moreover, it is better tolerated and
may increase the opportunity tomaintain the planned schedule
of treatment. These results make pegfilgrastim and advanta-
geous option in most cases, both in terms of cost-effectiveness
and of quality of life. These preliminary observations need to
be validated by controlled clinical trials, involving a larger
number of patients.
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Abstract
Background In this prospective study, the impact of granulo-
cyte colony-stimulating factors (G-2 CSF) administered dur-
ing induction treatment with bendamustine plus rituximab for
indolent non- Hodgkin Llymphoma (NHL) was evaluated by
comparing patients who received secondary prophylaxis with
filgrastim (control group) versus. patients who received
pegfilgrastim as primary prophylaxis (peg-group). The pri-
mary endpoint was the incidence rate of febrile neutropenia
(FN)- related chemotherapy disruptions (regarding dose-
dense and/or dose-intensity of schedule). The Ssecondary
endpoint included days of hospitalization due to FN, and G-
CSF-related side effects (grade ≥3 WHO toxicity criteria) in
each group.
Methods One hundred twenty-two: 122 consecutive patients,
with untreated indolent NHL, were referred to our outpatient
unit for remission induction immuno-chemotherapy with
bendamustine-rituximab. During the first period, 61 patients
received secondary prophylaxis with filgrastim, given “on de-
mand” if ANCwas <1000/mm3. During the second period, 61
patients received primary prophylaxis with pegfilgrastim in a
single administration.
Results Pegfilgrastim was significantly associated with fewer
incidence rate of FN-related chemotherapy disruptions (11.4%
in the control group vs. 1.6% in the peg-group, p = 0.04) and
fewer days of hospitalization due to FN (median number 18
days in the control group vs. 6 in the peg-group, p = 0.04). In
terms of G-CSF-related extra-hematological grade III side ef-
fects, no significant difference has been found in the two
groups (9.8% in the control group vs. 11.5% in the peg-group,
p = 0.77). Only one patient stopped the treatment in the peg-
group due to intolerance.
Conclusions In patients with indolent NHL, in front-line treat-
ment with bendamustine plus rituximab, primary prophylaxis
with pegfilgrastim seems to reduce the incidence of chemo-
therapy disruptions due to FN, and the days of hospitalization.
Moreover, it is well- tolerated and may increase the opportu-
nity to maintain the planned schedule of treatment. These
results make pegfilgrastim an advantageous option in most
cases both in terms of cost-effectiveness and quality of life.
These preliminary observations need to be validated by con-
trolled clinical trials.
Introduction
Bendamustine is a bifunction alkylating agent that produces
both single- and double-strand breaks in deoxyribonucleic
acid. It is frequently used in association with rituximab as a
frontline treatment of indolent (follicular and non-follicular)
non-Hodgkin lymphoma (NHL). With this schedule,
myelotoxicity, in particular severe neutropenia, is the main
expected side effect [1, 2]. Febrile neutropenia (FN) is one
of the most important clinical signs of infection during che-
motherapy and is characterized by an absolute neutrophil
count (ANC) <1000/mm3 and at least one temperature
* Claudio Cerchione
claudiocerc@hotmail.com
1 Hematology, Department of Clinical Medicine and Surgery, Azienda
Ospedaliera Universitaria Federico II, Via Pansini 5,
80131 Naples, Italy
2 Department of Advanced Biomedical Science, Azienda Ospedaliera
Universitaria Federico II, Via Pansini 5, 80131 Naples, Italy
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measuring of ≥38 °C [3]. Once an episode of FN occurs, the
risk of FN increases in subsequent chemotherapy courses
[4–6]. FN may lead to a disruption of chemotherapy program,
with delay of cytotoxic agent administration and/or reduction
of relative dose intensity, adversely affecting long-term pa-
tients’ outcome [4–6]. The American Society of Clinical
Oncology and the National Comprehensive Cancer Network
recommend the use of granulocyte colony-stimulating factors
(G-CSF), which have been developed to stimulate the prolif-
eration and differentiation of neutrophils in patients receiving
cytotoxic agent treatments [7, 8]. The routine use of G-CSF
from the first cycle of myelosuppressive chemotherapy, i.e.,
primary prophylaxis, is indicated when the overall FN risk is
greater than 20% [6, 7]. In the other cases (≤ 20% of risk), it is
suggested a secondary prophylaxis, which consists of post-
chemotherapy G-CSF administration Bon demand^ if ANC
is <1000/mm3 [6, 7]. Another important issue is the type of
G-CSF to employ [9–11]. Filgrastim is a non-pegylated form
of G-CSF, used at the daily dose of 5 μg/kg, until the end of
neutropenia, according to the myelosuppressive chemothera-
py schedules [7]. Pegfilgrastim is a pegylated long-acting re-
combinant form of G-CSF which extends the half-life, requir-
ing less frequent administrations than non-pegylated G-CSF
[9]. Pegfilgrastim is cleared via a neutrophil-mediated system
and requires only a single dose administered once per chemo-
therapy cycle [9–11]. It is indicated to decrease the incidence
of infections in patients with non-myeloid malignancies, re-
ceiving myelosuppressive chemotherapy [6]. However, data
on the optimal G-CSF strategy, i.e., primary vs. secondary
prophylaxis and/or non-pegylated vs. pegylated form, are
scanty in the setting of patients with NHL undergoing front-
line treatment with immuno-chemotherapy schedule [1, 2].
In this prospective study, the impact of G-CSF admin-
istered during induction treatment with bendamustine
plus rituximab for indolent NHL was evaluated by com-
paring patients who received secondary prophylaxis with
filgrastim (control group) to patients who received
pegfilgrastim as primary prophylaxis (peg-group). The
primary endpoint was the incidence rate of FN-related
chemotherapy disruptions (regarding dose dense and/or
dose intensity of schedule). Secondary endpoints includ-
ed days of hospitalization due to FN and G-CSF-related
side effects (grade ≥3 WHO toxicity criteria) in each
group.
Patients and methods
Study design
From March 2013 to February 2016, 264 patients with histo-
logically diagnosed and untreated indolent NHL (including
grade 1 or 2 follicular lymphoma, lymphoplasmocitic lym-
phoma, small lymphocytic lymphoma, and marginal zone
lymphoma), age ≥18 years, and WHO performance score 0–
2 were screened for enrollment. Eligible criteria were features
requiring to start immuno-chemotherapy treatment, i.e., Ann
Arbor stage III or IV, and impaired hemopoiesis (hemoglobin
<10 g/dL, ANC <1500/mm3 , or platelet count <100 × 109/L),
presence of B symptoms, large tumor burden (three areas
>5 cm, or one area >7.5 cm), bulky disease with impingement
on internal organs, progressive disease (defined as a more than
50% increase of tumor mass within 6 months), and/or a hy-
perviscosity syndrome [12]. Only patients who received
bendamustine plus rituximab regimen were included in the
study (Fig. 1).
Ninety-nine patients were excluded: 79 because they
underwent to other chemo-immunotherapy regimens, while
20 because of severe cardiac disease or previous malignancy,
inadequate hepatic, renal, or cardiac function, or infection
with HIVor hepatitis B (HbsAg positivity) (Fig. 1).
All patients underwent standard pretreatment screening,
including a physical examination, complete blood count, as-
sessment of serum chemistry, serum immune-electrophoresis,
measurement of immunoglobulin concentrations, chest radio-
graph, CT scans of the chest, abdomen, and pelvis, sonogra-
phy of the abdomen, and bone marrow aspiration and biopsy.
The protocol was approved by the local ethics committee;
the study complied with the Declaration of Helsinki and its
amendments. It was done in accordance with the Good
Clinical Practice guidelines. All patients gave written in-
formed consent.
Strategies of prophylaxis with G-CSF
All patients received frontline immune-chemotherapy courses
in our outpatient unit. Treatment included intravenous
bendamustine (90 mg/m2 given over 30–60 min on days 1
and 2 of each cycle) plus rituximab (375 mg/m2 on day 1 of
each cycle), every 4 weeks for up to 6 cycles [1].
Patients were divided into two groups of G-CSF prophy-
lactic strategy. From March 2013 to August 2014 (first peri-
od), 61 patients received secondary prophylaxis with
filgrastim (5 μg/kg/day s.c. for at least 3 days) given on de-
mand if ANC was <1000/mm3. Since July 2014 (second pe-
riod), the use of primary prophylaxis with pegfilgrastim
(Neulasta®; Amgen) became in our division a standard prac-
tice during frontline treatment for NHL with bendamustine
plus rituximab. Thus, during the second period, 61 patients
received primary prophylaxis with pegfilgrastim (6 mg,
injected subcutaneously in a single administration on day 4,
from the first course of immuno-chemotherapy).
All neutropenic patients underwent antimicrobial prophy-
laxis with quinolones and azoles, as elsewhere reported [13].
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Study endpoints
Wedefined as Bdisrupted chemotherapy^whenwe delayed treat-
ment cycles for at least 1 week if the leukocyte count was less
than 2000/mm3 before a scheduled cycle (Btime-disruption^), or
if we noted a leukocyte count less than 1000/mm3 on two con-
secutive days between cycles, the dose of bendamustine was
decreased to 70 mg/m2 (Bdose-disruption^) [1].
During the study period, as part of our Institutional
guidelines for post-chemotherapy supportive care, in pa-
tients with FN, i.e., an ANC <1000/mm3 and at least one
temperature measuring of ≥38 °C, blood cultures were
performed every 24–48 h: the Vitek 2 automated system
(bioMérieux, Marcy l’Etoile, France) was used for blood-
stream isolate identification and antimicrobial susceptibil-
ity testing. Minimum inhibitory concentrations (MICs)
were evaluated by using E-test (BioMerieux) strips and
classified according to the European Committee on
Antimicrobial Susceptibility Testing [14]. If respiratory
symptoms or signs appeared, sputum culture and chest
radiography or thorax computed tomography (CT) scans
were performed. Serum CMV DNA screening was per-
formed in case of neutropenic fever or in patients with
fever even in the absence of neutropenia.
We used WHO’s toxicity criteria to assess treatment-
related toxic effects [3]. Complete blood counts, including
differential counts, and physical examination were done
twice a week.
Statistical analysis
For the statistical evaluations, the χ2 test was performed to com-
pare proportions for clinical characteristics and complication rate,
and the t test was used to compare the quantitative variables of
clinical characteristics, disruptions, and hospitalization times be-
tween the two groups. p values less than 0.05 were considered to
indicate a significant difference.
Results
During the study period, among 264 patients with diagnosis of
indolent NHL, 122 consecutive patients (63 males and 59 fe-
males), older than 18 years (median age, 45.3 years; range, 31–
77) with untreated indolent NHL (histological subtypes: follicu-
lar, n = 83; marginal zone, n = 32; small lymphocytic, n = 4; and
lymphoplasmocytic, n = 3), met the inclusion criteria and were
included in the final analysis (Table 1). All patients underwent to
first-line immuno-chemotherapy with bendamustine plus
rituximab.
Findings in the control group
In the 366 cycles of immuno-chemotherapy performed in the
control group, the median number of the vials of filgrastim
administered was 3 (range, 0–5), started in mean from the
second course (range, 1–3). The mean of nadir of ANC was
Fig. 1 Flow chart shows patient selection during the study. *Other immuno-chemotherapy regimens included R-CHOP, R-CVP, and R-FC [15].
**Immuno-chemotherapy with rituximab plus bendamustine was conducted according to Rummel et al. study [1]
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1220/mm3 (range, 300–1700) for a mean duration of 9 days
(range, 7–11).
Overall, 7/61 patients (11.5%) disrupted chemotherapy
schedules due to FN. Of them, three were time-disruptions
and four were dose-disruptions (Table 2).
Five patients (5/61, 8.1%) were hospitalized for pneumonia
(median days of hospitalization 18, with a range of 6–22) and
received intravenous antibiotic treatment with resolution of
infectious episodes (Table 3). Extra-hematological toxicity
of grade ≥III (bone pain) was observed in six patients
(9.8%), treated successfully with paracetamol. No patient
had to stop the immuno-chemotherapy because of filgrastim-
related side effects.
Findings in the peg-group
In the peg-group, pegfilgrastim was administered at day 4 for
each of the 366 cycles of immuno-chemotherapy performed.
The mean of nadir of ANC was 1734/mm3 (range, 880–2110)
for a mean duration of 5 days (range, 3–9).
Overall, only 1/61 patients (1.6%) disrupted chemotherapy
schedules due to FN (time-disruption; Table 2).
Three patients (3/61, 4.9%) were hospitalized for pneu-
monia (median days of hospitalization 6, range 1–21) and
received intravenous antibiotic treatment with resolution of
infectious episodes. No patient died during pegfilgrastim.
Apart from the advantage of mono-administration,
pegfilgrastim was well tolerated in all patients. Extra-
hematological toxicity of grade III (bone pain) was
observed in 7/61 patients (11.5%), managed successfully
with paracetamol. Extra-hematological toxicity of grade IV
(bone pain) was observed only in one patient (1.6%), who
had to stop the treatment.
Peg-group vs. control group
Thus, pegfilgrastim was significantly associated with
fewer incidence rate of FN-related chemotherapy disrup-
tions (11.4% in the control group vs. 1.6% in the
peg-group, p = 0.04) and fewer days of hospitalization
due to FN (median number 18 days in the control group
Table 1 Baseline characteristics
of patients in the two study groups Control group Peg-group p
value
Total patients 61 61
Sex
Male 32 (52.4) 31 (50.8) 0.85
Female 29 (47.6) 30 (49.2)
Age, years
Median (range) 45.1 (31–76) 45.4 (33–77) 0.59
Histology [15]
Follicular 41 (67.2) 42 (68.8) 0.85
Marginal zone 17 (27.9) 15 (24.6) 0.68
Small lymphocytic 2 (3.3) 2 (3.3) 1.00
Lymphoplasmocytica 1 (1.6) 2 (3.3) 0.56
Stage
II 3 (4.9) 2 (3.3) 0.65
III 12 (19.7) 11 (18.0) 0.81
IV 46 (75.4) 48 (78.7) 0.66
B symptoms 22 (36.1) 19 (31.1) 0.56
Bone marrow involved 40 (65.6) 42 (68.9) 0.69
Extra-nodal involved sites ≥1 46 (75.4) 45 (73.8) 0.84
LDH >240 U/L 22 (36.1) 21 (34.4) 0.85
Prognostic groups according to FLIPI
Low risk (0–1 risk factor) 5 (12.1) 5 (11.9) 0.96
Intermediate risk (2 risk factors) 15 (36.6) 13 (31.0) 0.59
Poor risk (3–5 risk factors) 21 (51.2) 24 (57.1) 0.58
Unless otherwise indicated, data are number of patients, with percentage in parentheses
FLIPI Follicular Lymphoma International Prognostic Index [16]
aWaldenström’s macroglobulinemia
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vs. 6 in the peg-group, p = 0.04). In terms of G-CSF-
related extra-hematological grade III side effects, no
significant difference has been found in the two groups
(9.8% in the control group vs. 11.5% in the peg-group,
p = 0.77). Only one patient was obliged to stop the treat-
ment in the peg-group due to intolerance.
Discussion
Immuno-chemotherapy treatment with rituximab-
bendamustine has been approved as a frontline treatment for
indolent NHL. It has been demonstrated to be non-inferior to
rituximab in combination with cyclophosphamide,
Table 3 Clinical characteristics
of neutropenic episodes in the two
study groups
Characteristic Control group
(N = 61)
Peg-group
(N = 61)
p
value
Neutropenic episodes without infectious symptoms 20 (32.8) 7 (11.5) 0.04
Febrile neutropenia of unknown origin 10 (16.4) 2 (3.3) 0.04
Febrile neutropenia with clinically documented infection 17 (27.8) 5 (8.2) 0.005
Site/source of infection
Moutha 7 (11.5) 1 (1.6) 0.03
Upper respiratory tract 3 (4.9) 1 (1.6) 0.31
Lower respiratory tract 5 (8.2) 3 (4.9) 0.46
Urinary tract 2 –
Radiological signs of infectionb 5 (8.2) 3 (4.9) 0.46
Febrile neutropenia with microbiologically documented
infections
7 (11.5) 4 (6.6) 0.34
Bacteremia 2 (3.3) – 0.15
Gram-positive 2 (3.3) – 0.15
Enterococcus spp. 1 (1.6) – 0.31
Staphylococcus spp. 1 (1.6) – 0.31
Gram-negative – – 1.00
Positive sputum culture 2 (3.3) 1 (1.6) 0.56
Gram-positive 1 (1.6) 1 (1.6) 1.00
Staphylococcus spp. 1 (1.6) – 0.31
Gram-negative 1 (1.6) – 0.31
Pseudomonas spp. 1 (1.6) – 0.31
Serum CMV DNA positivity 3 (4.9) 3 (4.9) 1.00
Hospitalization required for FN complications 5 (8.1) 3 (4.9) 0.46
Hospitalization days
Median (range) 18 (6–22) 6 (1–21) 0.04
ICU recovery 2 (3.3) – 0.15
Unless otherwise indicated, data are number of patients, with percentage in parentheses
a It refers to stomatitis
b Chest radiography or CT scans suspected for pneumonia
Table 2 Modification of
immune-chemotherapy schedule
with rituximab plus bendamustine
according to Rummel et al. [1]
due to neutropenia in the two
study groups
Control group
(N = 61)
Peg-group
(N = 61)
p
value
Overall chemotherapy disruption 7 (11.5) 1 (1.6) 0.028
Time disruption 3 (4.9) 1 (1.6) 0.31
Median days (range) 16 (6–21) 5a 0.04
Dose disruption 4 (6.6) – 0.04
Percentage 22.3 – <0.001
Unless otherwise indicated, data are number of patients, with percentage in parentheses
a Data are from the only patient in the peg-group obliged to delay chemotherapy due to FN
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doxorubicin, vincristine, and prednisone (R-CHOP) in terms
of efficacy, but better tolerated. Indolent NHL is characterized
by a chronic relapsing-remitting disease course, with patients
usually exposed to several successive treatment courses.
In this scenario, a reduction of treatment-related toxicities
and an improvement of quality of life should be considered so
important as clinical results.
In this prospective study, the impact of G-CSF adminis-
tered during induction treatment with bendamustine plus ri-
tuximab for indolent NHL was evaluated by comparing pa-
tients who received secondary prophylaxis with filgrastim
(control group) vs. patients who received pegfilgrastim as pri-
mary prophylaxis (peg-group).
In this study, we observed a lower rate of febrile neutrope-
nia with clinical signs of infection in the peg-group compared
with control group (8.2 vs. 27.8%; p = 0.005): in particular, we
observed an increased number of stomatitis in the control
group compared with the peg-group (11.5 vs. 1.6%; p = 0.03).
Conversely, no difference was found between the two
groups regarding microbiological documented infection, both
for bacterial infection than for those CMV-related. The com-
mon prophylaxis to the two study groups with quinolone is
likely able to reduce the rate of documented bacterial infec-
tions regardless of neutropenia, although the number of pa-
tients is probably too low to state this statement with certainty.
At the same time, the number of CMV-related infections is
equal in the two groups (3 vs. 3), being this type of viral
infection non-controllable merely by neutrophils. Indeed, the
number of hospitalization required for FN complications was
similar in the two study groups (8.1% in the control group vs.
4.9% in the peg-group), being influenced by the CMV-
induced pneumonia; while the median hospitalization time
was lower in the peg-group, probably due to a more rapid
recovery of neutrophil counts.
Moreover, pegfilgrastim demonstrated a reduction of
the incidence rate of FN-related chemotherapy disruptions
(regarding dose-dense and/or dose-intensity of schedule),
of days of hospitalization due to FN, with no differences
in G-CSF-related side effects (grade ≥3 WHO toxicity
criteria), such as bone and back pain. No clinical signifi-
cant changes in laboratory parameters or vital signs were
observed.
This gives an advantage in pegfilgrastim’s group also in
terms of quality of life, which should be always considered
in this setting of patients.
In conclusion, in patients affected by newly diagnosed in-
dolent NHL, in treatment with bendamustine plus rituximab,
primary prophylaxis with pegfilgrastim seems to reduce the
incidence of chemotherapy disruptions due to FN, and of the
days of hospitalization, with no differences in G-CSF-related
side effects. Moreover, it is well-tolerated and may increase
the opportunity to maintain the planned schedule of treatment.
These results make pegfilgrastim an advantageous option in
most cases both in terms of cost-effectiveness and of quality of
life. These preliminary observations need to be validated by
controlled clinical trials.
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The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily
pretreated and fragile patients are tough clinical issues for clinicians. In advanced phases of disease, the choice of available therapies
becomes very poor, and the retreatment with previously adopted and effective therapy, although unpredictable, could be an effective
option. In this report, we describe the clinical history of a patient, previously treatedwith 9 lines of therapy, refractory to bortezomib
and IMIDs, for whom the retreatment with bendamustine resulted in a stable disease with good quality of life.
1. Introduction
In advanced multiple myeloma, the choice of the treatment
can be difficult, as therapeutic options decrease over time.
Both new combinations of previously used drugs and retreat-
ment with a previously adopted and effective therapy can
be taken into consideration in patients showing persistent
chemosensitivity. In this report, we describe the case of
a heavily pretreated patient, refractory to bortezomib and
IMIDs, with clinical benefit after retreatment with ben-
damustine.
2. Case Presentation
In June 2009, this male patient was 67 years old and
was diagnosed with IgG 𝜆 stage IIIA multiple myeloma
(MM). FISH analysis was performed at diagnosis, and it
showed negativity for the most frequent alterations (t(11;
14), t(4; 14), del13q, and del17p). First-line therapy was 7
cycles of thalidomide-dexamethasone (TD), followed by
radiotherapy on T2. In March 2010 progressive bone dis-
ease was detected by MRI of the spine showing multiple
cervical and dorsal osteolytic lesions. Thus, second line of
bortezomib-desametasone (VD), together with zoledronic
acid, was performed for 5 cycles, obtaining a partial response.
A first ASCT, preceded by thiotepa/melphalan conditioning
regimen, was performed in December 2010 leading to a
partial response. After a period with stable clinical con-
ditions, in April 2011, disease progression was documented
by the increase of the serum monoclonal component (sMC):
the patient was treated with 4 courses of lenalidomide-
dexamethasone (RD), but the disease progressed. Therefore,
a combination of melphalan-lenalidomide-dexamethasone
(MRD) was performed for 3 cycles in September 2011, again
followed by disease progression, determined by sMC increase.
At the same time, PET/CT performed for neck pain revealed
multiple osteolytic lesions: the most dangerous (C2) was
treated with tomotherapy (40Gy total). Thus, 2 cycles of
cyclophosphamide-doxorubicin-dexamethasone (CED) reg-
imen were attempted (1), but the disease was still refractory.
Hence, a bendamustine-bortezomib-dexamethasone (BVD)
regimenwas administered (bendamustine 90mg/sqm at days
1 and 2, bortezomib 1.3mg/sqm at days 1, 4, 8, and 11,
dexamethasone 20mg at days 1, 2, 4, 5, 8, 9, 11, and 12, and
pegfilgrastim 6mg at day + 4) (2, 3, and 4) for 6 cycles,
resulting in a partial response, followed by a second ASCT,
preceded by thiotepa/melphalan conditioning regimen. In
February 2014, a further sMC increase suggested disease
progression, and the patient was treated with bortezomib-
lenalidomide-dexamethasone (VRD) for 6 cycles with the
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Table 1: Patient’s history.
Line Regimen Cycle (n∘) Responses
1 Thalidomide-dexamethasone + RT 7 Progressive disease
2 Bortezomib-dexamethasone 5 Partial response
3 First auto-BMT (thiotepa-melphalan) / Stable disease
4 Lenalidomide-dexamethasone 4 Progressive disease
5 Melphalan-lenalidomide-dexamethasone 3 Progressive disease
6 Doxorubicin-cyclophosphamide-dexamethasone 2 Progressive disease
7 Bendamustine-bortezomib-dexamethasone 6 Partial response
8 Second auto-BMT (thiotepa-melphalan) / Stable disease
9 Bortezomib-lenalidomide-dexamethasone 6 Progressive disease
10 Bendamustine-bortezomib-dexamethasone 7 Stable disease
11 Pomalidomide-dexamethasone 4 Progressive disease
result of progressive disease. In November 2014, for disease
progression confirmed also by PET/CT scan (Table 1), even
considering cardiovascular comorbidities, BVD-retreatment
was chosen as tenth line. The patient switched to a stable
disease status and clinical conditions were relatively fit for
more than one year.The treatmentwaswell tolerated: the only
toxicities were grade 2 anemia and grade 3 thrombocytope-
nia, while severe neutropenia was effectively prevented with
pegfilgrastim prophylaxis (6mg at day + 4 of every courses).
No extrahematological side effects were revealed.
Due to further sMC increase, in December 2015, 4 courses
of pomalidomide-dexamethasone were attempted, in a pal-
liative intent, but the patient died in July 2016.
3. Discussion
After the advent of proteasome inhibitors, international
guidelines agree on first-line treatment strategy for ASCT-
eligible and noneligible patients [1–3]. However, selecting
and managing the correct therapy for a patient with rrMM
it is still a tough task for the hematologist, as, after many
relapses, available therapeutic options are scanty. A com-
monly adopted strategy consists in retreating the patient
with the same molecules used previously, choosing those
which showed the best response or considering new drug
combinations, even if in previous administrations single drugs
showed to be ineffective [4–9].
This strategy seems particularly successful in patients
who show persistent chemosensitivity, as in our case, who
obtained an overall survival longer than 7 years, which can
be considered as an impressive result in a 67-year-old patient
affected by MM.
Bendamustine is a well-tolerated agent with a double
mechanism of action, alkylating and antimetabolite, with
proved effectiveness in treatment of relapsed/refractory [10,
11] and newly diagnosed multiple myeloma [12, 13] and in
a relapsing/refractory setting [14–19]. In rrMM it can be
used as single agent combined to dexamethasone, but a
synergistic effect has been demonstrated when associated
with bortezomib.
Bendamustine showed significant efficacy also in a
selected setting of patients, such as those who became
refractory to bortezomib and IMIDs or multirelapsed after
single or double ASCT, demonstrating also an effective
opportunity as a bridge to ASCT [10]. To the best of our
knowledge, BVD-retreatment for relapsing/refractory MM
is still not consolidated, but, as in our case, it could be
considered an effective choice in heavily pretreated patients
without significant therapeutic options, in a context of a well-
tolerated palliative treatment with good quality of life.
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Introduction 
Myelodysplastic syndromes (MDS) are a 
heterogeneous group of clonal disorders of 
haematopoietic stem cells, characterised by ineffective 
haematopoiesis leading to peripheral cytopenias and 
hypercellular bone marrow, with increased propensity to 
progression to acute myeloid leukaemia. Anaemia is the 
most common symptom: it may precipitate symptoms 
in patients with cardiac disorders, thus affecting the 
patients' outcome.
Approved therapies, such as erythropoiesis-
stimulating agents, azacitidine, decitabine and 
lenalidomide are now available for patients who are 
ineligible for potentially curative haematopoietic stem 
cell transplantation. These former options can produce 
haematological improvement and enhance the quality 
of life of patients who previously would have received 
only supportive care.
In this context, supportive red blood cell transfusions 
represent a life-saving treatment for patients with chronic 
anaemia, in particular for those who do not respond or 
have a poor response to available treatments1. However, 
transfusions lead to iron overload, with an increased risk 
of associated comorbidity and mortality, independently 
of the underlying haematological disease, in relation to 
iron toxicity to cardiac, hepatic and endocrine cells. The 
management of iron overload is problematic because 
humans lack effective means to excrete excess iron.
Retrospective studies revealed that transfusion-
related iron toxicity is associated with reduced survival 
in MDS patients2. This is a particularly relevant problem 
in low-risk MDS patients, because of these patients' 
otherwise long-life expectancy. Adequate iron chelation 
therapy can, however, improve survival and may delay 
transformation into acute myeloid leukaemia3-6.
Iron chelation therapy is recommended in MDS to 
manage iron overload when the patient has, at least, 
elevated serum ferritin (SF), evidence of iron-related 
organ dysfunction or is receiving chronic red blood cell 
(RBC) transfusions. Guidelines from the Italian Society 
of Haematology recommend iron chelation therapy 
with deferasirox for the treatment of MDS patients with 
low/intermediate-1 risk (according to the International 
Prognostic Scoring Scale, IPSS) after they have received 
at least 20 units of packed RBC5.
It is evident from controlled clinical trials, and 
confirmed by real-life experience7, that iron overload in 
many MDS patients is often not adequately managed4.
Iron chelation therapy should be considered in all 
patients who require long-term RBC transfusions while 
it may not be needed in patients with MDS or other 
acquired refractory anaemias who have an estimated 
survival of less than 1 year.
Ideally, chelation therapy should be initiated 
prophylactically, before clinically significant iron 
accumulation has occurred. Treatment should begin 
when patients have received between 10 and 20 units 
of RBC. Patients who have already undergone repeated 
transfusions without sufficient chelation can also 
be successfully treated, but they may require more 
intensive chelating regimens. Iron chelation therapy 
is recommended by several treatment guidelines for 
patients who have a low or intermediate-1 IPSS risk 
and SF >1,000-2,000 ng/mL, depending on transfusion 
requirements.
Evaluation of the patient before the initiation or 
adjustment of iron chelation therapy should include 
a detailed characterisation of the underlying disorder, 
with thorough documentation of the transfusion and 
chelation history, determination of body iron load by 
measurement of hepatic iron and SF, estimation of the 
rate of transfusional iron loading, and assessment of 
cardiac iron deposition8. 
Until recently, desferoxamine and deferiprone were 
the only drugs available for iron chelation therapy and 
neither was well tolerated by patients. 
Deferoxamine was developed more than 40 years 
ago and, due to its pharmakokinetic properties, in order 
to be effective, must be administered subcutaneously 
or intravenously, usually with a portable pump, as a 
slow infusion over 8-12 hours/day, 5-7 days/week, 
often resulting in poor compliance. Subcutaneous 
administration is preferred, except in patients 
with severe cardiac iron deposition, for whom 
continuous intravenous deferoxamine is recommended. 
This regimen is contraindicated in patients with 
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thrombocytopenia and the inconvenience often results 
in low compliance9-11.
Deferiprone is not approved or recommended for 
MDS, as it can cause neutropenia and agranulocytosis.
Deferasirox is a once-daily orally administered iron 
chelator, with established dose-dependent efficacy, 
approved for the treatment of transfusional iron overload 
in both adult and paediatric patients with transfusion-
dependent anaemia. The initial dose of 10 mg/kg can 
be increased to 20-30 mg/kg based on the degree of 
iron load, concentration of SF and extent of iron-related 
organ damage12. The efficacy and safety of deferasirox 
have been evaluated in patients with β-thalassaemia 
and a wide range of other disorders, including MDS, 
sickle cell disease, aplastic anaemia, Diamond-Blackfan 
anaemia, and other rare anaemias13. In vivo studies in 
acute myeloid leukaemia and MDS cell lines showed 
that deferasirox is a potent nuclear factor-kB inhibitor, 
which may partly explain the reports regarding its ability 
to produce haematological improvements14,15. In addition 
to reducing key indicators of total body iron level (SF, 
liver iron concentration, and toxic labile plasma iron), 
deferasirox has also been shown to remove cardiac iron 
and prevent further cardiac iron accumulation. It has an 
acceptable safety profile: the most commonly reported 
side effects have been non-progressive changes in serum 
creatinine levels, gastrointestinal disturbances and skin 
rashes, with significant increases in alanine transaminase 
value after 12 months of treatment being possible, in direct 
correlation with the dose administered7. Because of its 
potential hepatotoxicity, it is usually not recommended 
for patients with known liver disease.
Nowadays, most patients requiring iron chelation 
therapy opt for deferasirox because of the convenience 
of its oral administration, while deferoxamine, which 
has been proven to reverse iron-induced heart disease 
and increase long-term survival16, may be indicated if 
deferasirox is ineffective, and it may be favoured for 
severe iron overload, especially with cardiac involvement. 
Deferasirox may be better in patients who are unable 
to tolerate subcutaneous infusions of deferoxamine 
and it may also be an alternative to deferoxamine after 
successful clearance of cardiac iron. 
To our knowledge, the possibility of iron chelation 
therapy with a combination of deferasirox and 
deferoxamine has been reported only in patients with 
β-thalasssaemia17-20. There do not appear to be any data 
on the use of this combination in MDS patients with liver 
disease. We describe here the first patient affected by 
MDS and chronic liver disease in whom combined iron 
chelation therapy was successfully employed.
Case report
A 62-year old Caucasian man was first seen in our 
Division for anaemia. He was diagnosed as having 
MDS-refractory anaemia (low IPSS risk), and hepatitis 
C virus-correlated liver cirrhosis (Child-Pugh class B) 
with signs of portal hypertension (portal vein 14.6 mm, 
splenic vein 14 mm, normal mesenteric vein), and severe 
splenomegaly (longitudinal diameter 205 mm). Liver 
function tests at the diagnosis of MDS were: serum 
albumin 3.2 g/dL, normal coagulation profile, total/
direct bilirubin 1.01/0.69; aspartate transaminase 38 
U/L (normal values <40 U/L), alanine transaminase 60 
U/L (normal values <40 U/L). The patient was initially 
treated with an erythropoiesis-stimulating agent (30,000 
U/week), without success for 6 months, which was then 
withdrawn, and he continued treatment with only RBC 
transfusions, requiring two packs/month. Iron chelation 
therapy was started when he had a SF of 700 ng/mL 
(normal values 30-400 ng/mL): deferoxamine was given 
(starting dose 15 mg/kg/day, for 5 days/week, increased 
up to 25 mg/kg/day, for 5 days/week), in consideration 
of the patient's pre-existing hepatic disease. However, 
the patient was unable to take the drug correctly and 
his transfusion needs increased to two packs of RBC/
week, with his SF exceeding 6,000 ng/mL (Figure 1), 
after 12 months of transfusion treatment. At that time, 
Figure 1 - Time course of serum ferritin (normal values: 30-400 ng/dL) and haemoglobin concentrations.
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Deferasirox plus deferoxamine in iron overload in MDS
deferasirox was started (Table I) at the dose of 10 mg/
kg/day, after a thorough investigation of the patient's 
hepatic, renal and cardiac function. After 3 months, 
neither SF nor other biochemical parameters had 
changed. The dose of deferasirox was then gradually 
increased to 30 mg/kg/die after 2 months, without 
evidence of liver damage. After 5 months of a full 
dose of deferasirox, the patient's SF concentration was 
5,098 ng/mL.
Taking into consideration all risks related to secondary 
haemochromatosis, after informed consent, combined 
iron chelation therapy with deferasirox (30 mg/kg/die) 
and deferoxamine (25 mg/kg/day for 5 days/week) was 
started. After 3 months the patient's SF had decreased 
to 3,000 ng/mL. In the meantime, his haemoglobin 
concentration decreased significantly, so he had to be given 
two packs of RBC/week. After 2 years of combined therapy, 
his SF concentration was stable under 3,000 ng/mL and his 
transfusion requirements gradually decreased (Figure 1). 
No adverse events were observed and regular monitoring 
of hepatic (Figure 2), renal and cardiac function did not 
show any alterations. After 4 years of transfusions and 
combined iron chelation therapy, the patient died from 
acute respiratory distress syndrome.
Discussion 
Supportive care of MDS patients is based on RBC 
transfusions, with management of iron overload being 
an essential, but sometimes overlooked, part of the 
treatment. In recent years, better understanding of the 
biological consequences of secondary haemosiderosis 
in MDS has suggested that iron chelation therapy should 
be started promptly to prevent serious clinical sequelae 
in patients with a long life-expectancy. Retrospective 
analyses indicated that iron overloading has an impact on 
the outcome of MDS patients and suggested that chelation 
therapy could improve patients' overall survival.
Until recently, desferoxamine and deferiprone were 
the only drugs available for the treatment of transfusional 
iron overload, but deferasirox is changing the clinical 
scenario of iron chelation therapy.
Deferasirox is a once-daily orally administered iron 
chelator, with established dose-dependent efficacy, 
approved for the treatment of transfusional iron overload 
in both adult and paediatric patients with transfusion-
dependent anaemia. The drug has an acceptable safety 
profile, with the most common side effects reported 
being non-progressive changes in serum creatinine 
levels, gastrointestinal disturbances, and skin rash, and 
dose-related hepato-toxicity. 
Deferasirox may allow effective iron chelation 
therapy in patients intolerant to subcutaneous infusions 
of deferoxamine.
In our case, the combination of deferasirox and 
deferoxamine had significant effects on iron overload, 
Figure 2 -  Time course of liver function parameters: aspartate transaminase (AST, normal values <40 U/L) and alanine 
transaminase (ALT, normal values <40 U/L).
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Table I - Characteristics of deferoxamine and deferasirox8.
Variable Deferoxamine Deferasirox 
Chelator-iron 
complex
Hexadentate, 
1:1 complex
Tridentate, 
2:1 complex
Usual dose 25-50 mg/kg/day 20-40 mg/kg/day
Administration Subcutaneous or 
intravenous, 8-10 h/day, 
5-7 days/week
Oral, once daily
Plasma half-life 20-30 min 8-16 hr
Route of 
elimination
Biliary and urinary Predominantly biliary
Regulatory 
approval
Approved in USA, 
Canada, Europe and 
other countries
Approved in USA, 
Canada, Europe and 
other countries
Indication Transfusional iron 
overload
Transfusional iron 
overload
Adverse effects Irritation at the infusion 
site, ocular and auditory 
disturbances, growth 
retardation and skeletal 
changes, allergy, 
respiratory distress 
syndrome with higher-
than-recommended doses
Gastrointestinal 
disturbances, rash, 
increase in serum 
creatinine level; 
potential foetal renal 
and hepatic impairment 
or failure, gastrointestinal 
haemorrhage
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and proved to be safe in a patient with hepatitis C virus-
correlated liver cirrhosis. The patient complied well with 
the treatment, had a good quality of life, had no side 
effects and did not require hospitalisation. Moreover, 
as reported in literature, deferasirox can also improve 
haematological parameters: our patient had a decrease in 
transfusional needs during treatment, which could have 
been related to the deferasirox treatment2,6,14. 
In our opinion, if deferasirox alone is not able to 
reduce iron overload rapidly, combined treatment with 
deferoxamine should be considered a safe and useful 
therapeutic choice, in selected patients, although our 
preliminary observations need to be validated by 
controlled clinical trials. 
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Dear Editor,
We would like to thank Kenneth Rolston for his com-
ments regarding our recent Supportive Care in Cancer
article on chronic disseminated candidiasis (CDC) in pa-
tients with hematological malignancies on the behalf of
SEIFEM (Sorveglianza Epidemiologica Infezioni
Fungine in Ematologia) group [1].
We acknowledge the small sample size (N = 20) and
the retrospective nature of the study, which is probably
not enough capable to lead to significant modifications
of the CDC treatment recommendations. However, we
would like to underline some aspects.
First, the guidelines of the Infectious Diseases Society
of America (IDSA) strongly recommend the first line ther-
apy of CDC with lipid formulation amphotericin B (AmB)
3–5 mg/kg daily [2]. Our data suggest that high-dose
(HD) liposomal AmB (5 mg/kg daily) is the better choice
for the treatment of CDC. This is likely due to the fungi-
cide action of HD liposomal AmB in the liver and spleen
derived from better tissue concentrations (target of liposo-
mal formulation: reticuloendothelial system) than that of
triazoles and echinocandins [3]. In addition, the 5 mg/kg
daily dosage for liposomal AmB may be useful for less
susceptible species, such as Candida glabrata and
Candida krusei [2]. On the other hand, in our series, the ma-
jority of patients were receiving triazoles prophylaxis and thus
had an increased risk of developing infection with a fluconazole-
resistant organism [2]. Moreover, according to the IDSA guide-
lines, fluconazole (6 mg/kg daily) should be administered only
for maintenance therapy [2].
Second, 13/20 (65%) patients received diagnosis of
probable CDC according to standard criteria, i.e., an alka-
line phosphatase increase, hepatic and/or splenic nodules
with typical bull’s eye aspect (seen at imaging tools), and
blood cultures positive for Candida spp. (no polymicrobic
sepsis occurred in our series) [4]. Such patients had neg-
ative serum galactomannan monitoring and negative tho-
rax radiological assessments; three cases had a serum β-
D-glucan assay >80 pg/ml (270, 520, and 370 pg/ml, re-
spectively). Altogether, it is very unlikely that these find-
ings may represent infections due to other organisms, par-
ticularly molds. According to the policy of the SEIFEM
group, when clinically indicated, we performed liver bi-
opsy using a Menghini-type automatic fine-cutting needle
(1.2 mm, 18G) under color ultrasound guidance, as al-
ready reported [5, 6]. In fact, the remaining seven patients
underwent a mini-invasive procedure that was well toler-
ated with no discomfort and provided reliable information
regarding liver histology, leading to the definitive diagno-
sis of CDC.
Third, both cases no. 11 and no. 20 died early as a
result of CDC (before the definitive microbiological re-
sults from blood samples); they were receiving empirical
antifungal treatment, respectively, with fluconazole and
itraconazole.
Finally, no liposomal AmB-related toxicity of grade ≥3,
according to the Common Terminology Criteria for Adverse
Events (CTCAE), occurred in our series [7].
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Abstract The sensitivity of lymph node core-needle biopsy
under imaging guidance requires validation. We employed
power Doppler ultrasonography (PDUS) to select the lymph
nodemost suspected of malignancy and to histologically char-
acterize it through the use of large cutting needle. Institutional
review board approval and informed consent were obtained
for this randomized clinical trial. In a single center between 1
January 2009 and 31 December 2015, patients with lymph
node enlargement suspected for lymphoma were randomly
assigned (1:1) to biopsy with either standard surgery or
PDUS-guided 16-gauge modified Menghini needle. The pri-
mary endpoint was the superiority of sensitivity for the diag-
nosis of malignancy for core-needle cutting biopsy (CNCB).
Secondary endpoints were times to biopsy, complications, and
costs. A total of 376 patients were randomized into the two
arms and received allocated biopsy. However, four patients
undergoing CNCB were excluded for inadequate samples;
thus, 372 patients were analyzed. Sensitivity for the detection
of malignancy was significantly better for PDUS-guided
CNCB [98.8%; 95% confidence interval (CI), 95.9–99.9] than
standard biopsy (88.7%; 95% CI, 82.9–93; P < 0.001). For all
secondary endpoints, the comparison was significantly disad-
vantageous for conventional approach. In particular, estimated
cost per biopsy performed with standard surgery was 24-fold
higher compared with that performed with CNCB. The pres-
ence of satellite enlarged reactive and/or necrotic lymph nodes
may impair the success of an open surgical biopsy (OSB).
PDUS and CNCB with adequate gauge are diagnostic tools
that enable effective, safe, fast, and low-cost routine biopsy for
patients with suspected lymphoma, avoiding psychological
and physical pain of an unnecessary surgical intervention.
Keywords Lymphoma . Power Doppler ultrasonography .
Core-needle cutting biopsy
Introduction
In the case of clinical suspicion of lymphoma, the histological
examination of lymphadenopathy is essential for defining a
correct diagnosis and for developing a proper treatment plan
[1]. An open surgical biopsy (OSB) is still the Bgold
standard,^ owing to the large amount of tissue obtained [2].
Preoperative evaluation includes (1) a careful and through
physical examination, i.e., palpation of superficial lymph node
regions performed by a physician experienced in the manage-
ment of patients with lymphoma; (2) gray-scale ultrasonogra-
phy scans (US), i.e., a technology that is readily available in
clinical practice and is considered to provide sufficient infor-
mation for selecting the node to be biopsied [1, 2]; and (3)
computed tomography (CT), performed to strengthen the sus-
picion of lymphoma [2]. However, the possible presence of
enlarged reactive or necrotic lymph nodes and/or of
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nonpalpable but histologically significant malignant lymph
nodes may impair the success of an OSB. Another limitation
is mostly related to patients whose conditions may be too un-
stable for undergoing general anesthesia and surgical interven-
tion [3]. Thus, a study that has value to decide the primary
interventionist diagnostic tool for suspected lymphoma is a clin-
ically important topic. New mini-invasive approaches to this
procedure based on imaging-guidedmethods are now available.
The introduction of the new generation of ultrasonographic
and biopsy needle devices, which already have been proven
valuable in the management of patients with lymphoma in our
cancer center [4–8], provides the opportunity to develop ef-
fective combined diagnostic strategy. The modern US instru-
ments merge tissue harmonic compound, which generates an
image from multiple imaging lines that strike the target from
different angles [9], with power Doppler (PD) which allows
the study of the angioarchitecture of lymph node tissue [5, 6,
8, 10]. Neoplastic angiogenesis such as vessel proliferation
(endothelial cell migration and proliferation) and abnormal
vascularization (tube formation with stenosis, occlusion,
and/or dilation and/or arteriovenous shunts) is recognized as
being critical for B cell lymphoma pathogenesis [11, 12].
Power Doppler ultrasonography (PDUS) equipment detects
fine flow signals, mimicking an angiography of microvascular
intranodal network. The result is a high-resolution quality ex-
amination that allows better detection of both superficial and
deep-seated malignant lymphadenopathies compared with re-
sults obtained with gray-scale US [13]. Regarding biopsy nee-
dle devices, the latest Menghini needles have ultrathin sharp-
ened cannula with trocar stylet and automatic aspiration with
tiny battery-powered vacuum [14]. These characteristics make
particularly effective the needle devices with large gauge [15].
Under PDUS guidance, the tip of cutting needle can be careful
positioning into the most significant target, obtaining histolog-
ical suction of the core of nodal lesion [14–16]. Nevertheless,
few clear indications for performing such procedure are avail-
able. The Lugano classification for initial evaluation, staging,
and response assessment of Hodgkin and non-Hodgkin lym-
phoma recommend core-needle biopsy when surgical inter-
vention is not possible and to document relapse [2].
However, the existing guidelines are not evidence based, a
uniform program for optimal imaging guidance is lacking,
and the characteristics of biopsy needle, i.e., gauge, length,
tip configurations, and samplingmechanisms, are still a matter
of opinion among experts [1, 14, 16]. Thus, this approach
requires validation with randomized studies.
Our trial was intended to test the efficacy of PDUS-guided
core-needle cutting biopsy (CNCB) compared with OSB as
first-line diagnostic approach for pathologic lymphadenopa-
thies in patients with clinical suspicion of lymphoma. The
primary endpoint of the study was the sensitivity for diagnosis
of malignancy for each of the two interventionist methods,
i.e., percutaneous biopsy by using modified Menghini needle
under modern US guidance and standard excisional biopsy.
Additional endpoints were times to biopsy, rates of biopsy-
related complications, and costs.
Materials and methods
Trial design and participants
Included patients were randomly assigned at 1:1 allocation
ratio to receive lymph node biopsy by using one of two
methods, OSB (standard group) or PDUS-guided CNCB
(core-needle group).
Patients were required to meet the following eligibility
criteria: (a) age ≥14 years, (b) lymph node enlargement clini-
cally suspected for lymphoma, and (c) indication to perform
nodal biopsy. Patients affected by Epstein-Barr virus, cyto-
megalovirus, herpes simplex virus, rubella, toxoplasma, or
tuberculosis infection, as well as abnormalities of coagulation
tests were excluded.
This was a single center study. Eligible patients were reg-
istered at the Hematology Division Office of the BFederico II^
University of Naples, where the trial was designed and ap-
proved by the local Institutional Review Board in the early
2008 (10 January 2008; number of registration, 140/2008).
Interventions
Standard group
In the standard group, all biopsy-related procedures were per-
formed by surgeons experienced in lymph node resection. The
patients underwent physical examination and gray-scale US,
of whom findings were sufficient to account for the region to
be biopsied according to conventional methods [17]. At sur-
geon’s discretion, biopsy was directed to the most superficial
and/or largest lymph node. In a day hospital regimen or as
inpatients, and under local or general anesthesia (according
to the type of intervention scheduled), the lymph nodes were
harvested through skin crease incision obtained by free-hand
methods. Superficial lymphadenopathy was removed by
means of excisional biopsy. Mini-cervicotomy or
mediastinotomy were used for removing lymphadenopathy
in the anterosuperior mediastinum, and abdominal and pelvic
lymphadenopathies were removed by means of laparotomy.
Core-needle group
In the core-needle group, all biopsy-related procedures were
performed by two members of the hematology staff (N.
Pugliese and M. Picardi, with more than 10 years of experi-
ence with interventionist PDUS) [4, 5]. The lymph node to
undergone CNCB was determined by PDUS assessment as
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already reported [8]. In particular, baseline US exploration of all
superficial, anterosuperior mediastinum (clavicular, supra-aor-
tic, and prevascular regions), and abdominal and pelvic lymph
node areas was carried out. Then, any abnormal [for size (long
axis ≥ 2 cm), round shape, hilus absent, and/or hypoechoic
parenchyma] lymph node underwent power Doppler examina-
tion in accordance with methods already described [5, 6, 8],
using a scanner (iU22; Philips Health-care, Bothell, Wash)
equipped with tissue harmonic compound technology
(SonoCT; Philips), power Doppler sonography, and 5–1 MHz
(C5-1 curvilinear; Philips) and 9–3 MHz (L9-3 linear; Philips)
broadband probes. The main criterion to select the node to be
biopsied was the hypervascularization, i.e., intranodal arterial
vessels with high-resistive index value (>0.6) [6, 8]. All CNCB
were carried out under US guidance with a puncture adaptor, an
aseptic technique (sterile cover of the probe and sterile gel), and
cutaneous anesthesia, using a 16-gauge diameter modified
Menghini needle 150 mm in length with automatic aspiration
(Biomol® HS-Hospital; Rome, Italy).
Reference standard
The reference standard for lymph node involvement was his-
topathologic examination. It was performed in a single pathol-
ogy unit by at least three expert hematopathologists (I.
Cozzolino, G. Ciancia, G. Pettinato, P. Zeppa, and/or V.
Varone, with more than 10 years of experience with
hematopathological analysis) [5]. Lymph node samples were
routinely fixed in formalin and embedded in paraffin (FFEP).
The histologic sections were stained according to standard
methods (hematoxylin and eosin, and Giemsa). All cases of
lymphoma were diagnosed by a combination of morphologic,
immunohistochemical and/or molecular analyses and were
classified according to the current WHO criteria [1].
Immunophenotyping was carried out in FFEP slides with an-
tibodies recognizing CD3, CD4, CD8, CD5, CD10, CD15,
CD20, CD23, CD30, CD45RB, CD56, CD79a, bcl-2, bcl-6,
cyclin D1, PAX-5, Mum-1, Ki-67, ALK-1, and TdT. Bcl-2,
Myc, Cyclin D1, and MALT-1 gene translocations were eval-
uated by fluorescent in situ hybridization analysis in FFPE
slides using commercially available kits, whenever deemed
necessary. B or T cell clonality was also investigated by poly-
merase chain reaction. Epithelial metastatic tumors were iden-
tified by monoclonal antibodies to cytokeratin.
Overall, biopsies were categorized as positive for malig-
nancy (samples containing adequate number of cells with
morphologic atypia and evidence of monoclonality), negative
for malignancy (samples containing adequate number of cells
with no evidence of malignancy), or inadequate (specimens
too small to confirm or rule out malignancy). Patients classi-
fied as having histologic results negative for malignancy
underwent strict follow-up by clinicians for the following
months, in order to discovery a malignant disease undetected
at first biopsy.
In 50 patients of the experimental arm, the biopsy speci-
mens of nodal tissue were studied by the three operators: each
one was blinded to the patient’s clinical condition and to the
histologic results of the other hematopathologists (interob-
server reproducibility) [15].
Primary and secondary outcomes
The sensitivity for each arm was defined as the ratio of pa-
tients who showed lymph node positive for malignancy at first
biopsy compared with the total number of patients with ma-
lignancy. In addition, the negative predictive value was de-
fined as the ratio of patients with lymph node negative for
malignancies at first biopsy compared to the total number of
patients with negative results for malignancy during the fol-
low-up. The likelihood ratio of a negative test was also calcu-
lated (1 minus sensitivity divided by specificity).
The waiting time for the performance of biopsy was calcu-
lated as the number of days elapsed between indication to
lymph node biopsy and the execution of the procedure itself.
After biopsy, patients were strictly monitored in order to
look for procedure-related complications. Outpatients were
kept under observation for 1 h and were discharged if there
were no signs or symptoms suggestive of a significant com-
plication. All patients were encouraged to contact their physi-
cians if they developed symptoms after leaving hospital.
Cost analysis for biopsy procedures was performed by
adopting the perspective of the National Healthcare System.
Cost calculations for PDUS-guided CNCB were based on the
tariffs in the Nomenclature for Outpatient Care, provided by
the Italian National Healthcare System (http://www.arsan.
campania.it/documents/10157/01088316-4824-4c7e-8671-
1418af8f3af7). The costs of OSBwere calculated according to
the diagnosis-related group tariffs that are currently used to
fund in patient health services in Italy (http://www.eumed.
it/drg/tariffe_drg.asp).
Sample size
We tested the hypothesis that histological yield obtained with
PDUS-guided CNCB resulted in a higher sensitivity than OSB,
owing to amore significant lymph node tissue biopsied (i.e., the
viable core of malignant lesion was exactly removed). Based on
previous studies, we estimated a sensitivity rate at standard
biopsy of 78% [5] and at PDUS-guided CNCB of 96.5% [14,
18]; hence, a certain number of patients could be
underdiagnosed with OSB approach. To detect more than
10% sensitivity improvement (for the superiority test), 332 pa-
tients were needed, when using a two-sided type I error of 5%
and 99% statistical power. Assuming a dropout rate of 10%, we
set a final sample size of at least 183 patients in each group.
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Randomization
Random allocation sequence was carried out by using a com-
puterized system (generated by the study statistician on the
basis of the procedure outlined elsewhere) [19]. It was based
on a minimization method in which patients were assigned to
the two study groups while ensuring equal distribution on the
basis of sex, age, presence and type of systemic symptoms
(i.e. fever, sweating, and weight loss) and sites of lymph node
enlargement at baseline clinical evaluation.
Patients were asked to sign a consent form before random-
ization, according to the requirements of the Helsinki
declaration.
Statistical analysis
For the statistical evaluations, the χ2 test was performed to
compare proportions for clinical and histological characteris-
tics and complication rate, and the t test was used to compare
the quantitative variables of clinical characteristics, costs, and
waiting times to biopsy between the two groups. P values less
than 0.05 were considered to indicate a significant difference.
Asymptotic 95% confidence intervals for kappa statistic (to
assess the level of agreement in diagnostic opinion among all
three hematopathologists for the 50 samples of the core of
nodal tissue) were computed according to Fleiss et al. [20].
Results
Participants and recruitment
Between 1 January 2009 and 31 December 2015, 376 patients
were randomly assigned either to standard group (N = 187) or
core-needle group (N = 189). All randomized patients re-
ceived allocated biopsy intervention. However, four patients
(2.1%) undergoing PDUS-guided CNCB were excluded for
inadequate samples (thereafter, these cases underwent an
OSB). No other patient was lost to follow-up, nor did any
withdraw their consent to participate in the study when a sec-
ond biopsy was clinically indicated during monitoring. Thus,
a total of 372 patients was analyzed for the primary endpoint
(standard group, N = 187; core-needle group, N = 185).
Twenty-two patients (5.5%) failed during screening. A com-
mon reason for exclusion was contraindications for general
anesthesia (N = 12). Other reasons were the presence of obe-
sity, potential cause of uninterpretable PDUS scans for deep-
seated lymph nodes (N = 6), and refused to participate (N = 4).
A consolidated standard of reporting trials’ (CONSORT) dia-
gram summarizes the study in Figure 1.
Patients in both groups were well-balanced with respect to
clinical characteristics, in particular symptoms suspected for
lymphoma and nodal sites involved at baseline evaluation
(Table 1).
Power Doppler ultrasonographic and core-needle features
The average time required for PDUS examination and core-
needle biopsy was 40 min (range, 30–50 min). Sites of
biopsied lymph nodes were superficial in 140 cases (vs. 160
cases in the standard group) and deep-seated (abdominal or
pelvic regions) in 45 cases (vs. 27 cases in the standard group,
P = 0.02). For each core-needle biopsy, a median of 2 needle
passes (range, 1–4) into the nodal tissue was made. Length of
core-needle specimens varied from 15 to 70 mm (median,
32 mm). Median-estimated volume of acquired tissue was
185 mm3 with a range of 92–430 mm3 (vs. a median volume
of 1458 mm3 with a range of 312–5678 mm3, in the standard
Fig. 1 Flowchart shows patient
selection and follow-up during
the study (CONSORT).
PDUS = power Doppler
ultrasonography
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group). The number of tests (i.e., staining and/or molecular
analyses) performed by pathology on core-needle tissue and
surgical excisional biopsy was similar in the two study groups.
Interobserver reproducibility of histological assessments of
the cores of nodal tissue among the three pathologists had a
kappa score of 0.916 (95%CI: 0.756–1.07). Of the 50 samples
tested for reproducibility, 49 (98%) were classified identically
by the three observers.
Histology
Of the 187 patients undergoing OSB, 149 (80%) cases had
lymph nodes positive for malignancy, and 38 (20%) had
lymph nodes negative for malignancy (described as benign
lymphoid hyperplasia in 37 cases, and sarcoidosis in one case,
with steato-fibrotic and/or necrotic changes in 17 of the cases).
Of the 185 patients undergoing PDUS-guided CNCB (all
with adequate specimens), 172 (93%) cases had lymph nodes
positive for malignancy, and 13 (7%) had lymph nodes nega-
tive for malignancy (benign lymphoid hyperplasia in 10 pa-
tients, Kikuchi-Fujimoto disease in two patients, and sarcoid-
osis in one patient; Table 2).
Overall, the 51 patients with lymph nodes negative for
malignancy (defined as reactive or inflammatory) were ob-
served for a median follow-up of 10 months (range, 1–
24 months). During the follow-up, for 19 of 38 patients in
the standard group, the clinicians required a second lymph
node biopsy, and a malignancy was finally detected. The sec-
ond biopsy, which was performed after a median of 5 months
(range, 1–9 months) from the first biopsy, demonstrated lym-
phoma in 16 patients (five diffuse large B cell lymphomas,
three grade 1 follicular lymphomas, two small lymphocytic
lymphomas, four Hodgkin lymphomas, one mantle cell lym-
phoma, and one nodal marginal zone lymphoma) and meta-
static carcinoma in three patients (Table 3). In contrast, two of
the 13 patients who had had diagnosis of a benign lesion at the
first biopsy in the core-needle group required a second biopsy
(open surgical intervention in both cases) after 6 and 8months,
respectively. Histologic examination showed a malignancy in
both cases (one grade 1 follicular lymphoma and one small
lymphocytic lymphoma) (Table 3).
The definitive histological findings for each case in the two
groups are shown in Tables 2 and 3. Overall, the majority of
patients were suffering from lymphomas (B cell non Hodgkin
lymphoma, 195 cases; Hodgkin lymphoma, 88 cases; T cell
non Hodgkin lymphoma, 12 cases; and metastatic carcinoma,
47 cases).
Accuracy in identifying malignancy
The sensitivity rate of lymph node malignant status was
88.7% [95% confidence interval (CI): 82.9–93] for OSB
(149 of 168 patients with lymph node positive for malignancy
were identified) with a false negative rate of 10.2% (19 of 168
patients with lymph node positive for malignancy were not
identified). By contrast, the sensitivity rate of lymph node
malignant status was 98.8% (95% CI: 95.9–99.9) for PDUS-
guided CNCB (172 of 174 patients with lymph node positive
for malignancy were identified) with a false negative rate of
1.1% (i.e., 2 of 174 patients with lymph node positive for
malignancy were not identified). Therefore, the study objec-
tive to show superiority of PDUS-guided CNCB versus OSB
was achieved, being the sensitivity rate of experimental
Table 1 Baseline characteristics
of patients in the two study groups Standard group Core-needle group P value
Total patients 187 185
Sex
Male 98 (52.4) 86 (46.5) 0.25
Female 89 (47.6) 99 (53.5)
Age, years
Median, (range) 46 (18–79) 42 (17–76) 0.61
Symptoms
Fever 33 (17.6) 31 (16.8) 0.82
Sweat 24 (12.8) 25 (13.5) 0.84
Weight loss 27 (14.4) 26 (14.1) 0.91
Site of clinically suspected lymphadenopathies
Cervical 93 (49.7) 90 (48.6) 0.83
Axillary/pectoral 41 (21.9) 39 (21.1) 0.84
Antero-superior mediastinum 4 (2.1) 3 (1.6) 0.71
Inguinal 28 (15) 30 (16.2) 0.74
Abdomen-pelvic 21 (11.2) 23 (12.4) 0.72
Note: unless otherwise indicated, data are number of patients, with percentage in parentheses
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approach significantly higher than the standard approach
(P < 0.001; Table 4).
Noteworthy, the sensitivity rate of lymph nodes positive for
lymphoma was 98.7% (95%CI: 95.4–99.8) for PDUS-guided
CNCB versus 88.7% (95% CI: 82.3–93.4) for OSB
(P < 0.001). The negative predictive value was 54.3% (95%
CI: 36.6–71.2) for OSB and 84.6% (95% CI: 54.5–98.1) for
PDUS-guided CNCB (P = 0.05). The negative likelihood ratio
was 0.11 (95% CI: 0.07–0.18) for OSB and 0.01 (95% CI:
0.00–0.05) for PDUS-guided CNCB, confirming the value of
the PDUS-guided CNCB for detecting lymphoma.
Waiting time to biopsy
The median waiting time for performance of interventionist
procedure (from biopsy indication to perform itself) in the
core-needle group was 4 days (range, 1–10 days). By contrast,
it was 16 days with a range of 5–34 days in the standard group
(P < 0.001).
Procedure-related complications
Overall, 42 patients, which were in the standard group,
underwent biopsy (cervical-clavicular, 17 cases; medias-
tinum compartments, 4 cases; abdomen-pelvis, 21 cases)
under general anesthesia, with an average hospitalization
of 2.5 days. All other patients underwent biopsy in a
day surgery or outpatient regimen under local
anesthesia.
Patients who received standard biopsy had significantly
more pain, numbness or paresthesia, larger scars,
Table 2 Histologic diagnosis on
lymph node biopsy in the two
study groups
Standard group
(N = 187)
Core-needle group
(N = 185)
B cell neoplasms 84 (44.9) 97 (52.4)
Diffuse large B cell lymphoma 32 (17.1) 38 (20.5)
Follicular lymphoma 25 (13.4) 23 (12.4)
CLL/SLLa 16 (8.6) 18 (9.7)
Mantle cell lymphoma 7 (3.7) 12 (6.5)
Nodal marginal zone lymphoma 3 (1.6) 5 (2.7)
Primary mediastinal (thymic) large B cell lymphoma 1 (0.5) 1 (0.5)
Hodgkin lymphoma 38 (20.3) 46 (24.9)
Nodular sclerosis 25 (13.4) 30 (16.2)
Mixed cellularity 9 (4.8) 11 (5.9)
Nodular lymphocyte predominant 2 (1.1) 2 (1.1)
Lymphocyte-rich 1 (0.5) 1 (0.5)
Lymphocyte-depleted 1 (0.5) 2 (1.1)
T cell neoplasms 4 (2.1) 8 (4.3)
Anaplastic large cell lymphoma, ALK-positive 2 (1.1) 4 (2.2)
T cell lymphoblastic leukemia/lymphoma 1 (0.5) 2 (1.1)
Peripheral T cell lymphoma 1 (0.5) 1 (0.5)
Anaplastic large cell lymphoma, ALK-negative – 1 (0.5)
Metastatic carcinoma 23 (12.3) 21 (11.4)
Nonmalignant findings 38 (20.3) 13 (7)
True-negative 19 (10.1) 11 (5.9)
Benign lymphoid hyperplasia 18 (9.6) 8 (4.3)
Sarcoidosis 1 (0.5) 1 (0.5)
Kikuchi-Fujimoto disease – 2 (1.1)
False-negative 19 (10.1) 2 (1.1)
Benign lymphoid hyperplasiab 19 (10.1) 2 (1.1)
Note: unless otherwise indicated, data are number of patients, with percentage in parentheses
ALK anaplastic lymphoma kinase
a Chronic lymphocytic leukemia/small lymphocytic lymphoma
bWith steato-fibrotic and/or necrotic changes in 17 of the cases
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lymphorrhea, and wound infection than patients who
underwent PDUS-guided CNCB (Table 5).
Cost analysis
The total cost of the biopsy program was much lower for the
core-needle group than that for the standard group. By using
Italian values for direct costs of interventionist procedures, the
cost for one OSB was €10,393 for major surgery and €3056
for minor surgery, whereas it was €171 for one PDUS-guided
CNCB (including the complete US assessment of superficial
and deep-seated lymph node areas). If the cost of additional
surgical biopsies in the 19 patients (false negative results) of
the standard group and in the two patients (false negative
results) of the core-needle group is considered, the total cost
of lymph node biopsy with standard approach was approxi-
mately 25-fold higher than that with PDUS-guided CNCB
(P < 0.001; Table 6). C. Salvatore wrote the section devoted
to cost analysis and produced Table 6.
Table 3 Findings in the patients who underwent a second lymph node biopsy (all open surgical biopsies) in the two study groups
Patient No. No. of months between
the two biopsies
Biopsy site Sample volume
(mm3)
Histologic diagnosis
First Second First Second First Second
1 2 Cervical Axillary 1597 2154 Benign hyperplasiab Diffuse large B cell lymphoma
2 4 Inguinal Mesenteric 1460 2092 Benign hyperplasiab Diffuse large B cell lymphoma
3 3 Cervical Supraclavicular 3200 4230 Benign hyperplasiab Diffuse large B cell lymphoma
4 5 Supraclavicular Axillary 1539 2129 Benign hyperplasia Diffuse large B cell lymphoma
5 6 Inguinal Iliac 5148 2766 Benign hyperplasia Diffuse large B cell lymphoma
6 1 Cervical Supraclavicular 2860 1769 Benign hyperplasiab Nodular sclerosis—HL
7 3 Cervical Cervical 4512 2870 Benign hyperplasiab Nodular sclerosis—HL
8 3 Axillary Supraclavicular 1955 2350 Benign hyperplasiab Nodular sclerosis—HL
9 4 Inguinal Cervical 2766 2020 Benign hyperplasia Nodular sclerosis—HL
10 5 Cervical Cervical 2030 1980 Benign hyperplasia Follicular lymphoma Grade I
11 6 Cervical Axillary 3240 2563 Benign hyperplasia Follicular lymphoma Grade I
12 7 Inguinal Inguinal 1780 1201 Benign hyperplasiab Follicular lymphoma Grade I
13 6 Cervical Supraclavicular 673 1251 Benign hyperplasiab CLL/SLL
14 8 Cervical Inguinal 1840 2560 Benign hyperplasiab CLL/SLL
15 5 Cervical Supraclavicular 790 1300 Benign hyperplasia Mantle cell lymphoma
16 9 Supraclavicular Axillary 1578 3410 Benign hyperplasia Nodal marginal zone lymphoma
17 1 Cervical Supraclavicular 4370 2531 Benign hyperplasia Metastatic carcinoma
18 2 Inguinal Inguinal 3594 1589 Benign hyperplasia Metastatic carcinoma
19 5 Cervical Supraclavicular 1737 2010 Benign hyperplasiab Metastatic carcinoma
20a 6 Supraclavicular Supraclavicular 230 2130 Benign hyperplasia Follicular lymphoma Grade I
21a 8 Inguinal Cervical 310 1867 Benign hyperplasiab CLL/SLL
Note: Unless otherwise indicated, data are number of patients, with percentage in parentheses
HL Hodgkin lymphoma, CLL/SLL Chronic lymphocytic leukemia/small lymphocytic lymphoma
a Patients #20 and #21 had received power Doppler ultrasonography-guided core-needle cutting biopsy as first lymph node biopsy
bWith intranodal steato-fibrotic and necrotic changes
Table 4 Accuracy of standard biopsy and PDUS-guided CNCB for the
diagnosis of malignant lymph nodes
Standard group
(N = 187)
Core-needle group
(N = 185)
P value
Sensitivity
N 149/168 172/174 0.0001
% 88.7 98.8
95% CI 82.9–93.0 95.9–99.9
False-negative
N (%) 19 (10.2) 2 (1.1) 0.0001
Negative predictive value
N 19/38 11/13 0.014
% 50 84.6
95% CI 33.4–66.6 54.5–98.1
Negative likelihood ratio
value 0.11 0.01
95% CI 0.07–0.17 0.00–0.05
CNCB core-needle cutting biopsy, CI confidence interval
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Discussion
Routine biopsy of lymphadenopathies by using core-needle
under imaging guidance in patients with suspicion of lympho-
ma is controversial [1, 2]. Usually, such procedures are re-
served for lymph nodes that are accessible only with surgical
risk or for critical ill patients, and in case of relapse [2]. Most
studies on this issue were retrospective, included an imaging
support based on traditional radiological tools (such as gray-
scale US and CT, which study mostly morphological charac-
teristics, i.e., the dimensional features of lymph node, not
distinguishing between viable tumor and inflammation,
necrosis and/or fibrosis), and have tested the role of
small (≥18-gauge) needle devices with obsolete
Table 5 Biopsy-related
complications in the two study
groups
Standard group
(N = 187)
Core-needle group
(N = 185)
P value
Pain on operated sitea
No 46 (24.6) 130 (70.3) <0.0001
Yes, mild and transient 57 (30.5) 39 (21.1) 0.038
Yes, continuous 84 (44.9) 16 (8.6) <0.0001
Numbness on operated site
No 42 (22.5) 134 (72.4) <0.0001
Yes 145 (77.5) 51 (27.6)
Swelling on operated site
No 50 (26.7) 162 (77.6) 0.0008
Yes 137 (73.3) 23 (12.4)
Esthetic appearance of biopsy scarb
Absent – 185 (100) <0.0001
Acceptable 85 (45.5) –
Unpleasant 102 (54.5) –
Hematomac
No 177 (94.6) 179 (96.8) 0.31
Yes 10 (5.4) 6 (3.2)
Lymphorrhoea
No 178 (85.2) 185 (100) 0.0025
Yes 9 (4.8) –
Wound infection
No 175 (93.6) 185 (100) 0.0005
Yes 12 (6.4) –
Note: unless otherwise indicated, data are number of patients, with percentages in parentheses
a Postoperative pain was evaluated as absent, mild (not requiring analgesia), or continuous (requiring analgesia)
b As judge by the patients themselves 1 month after biopsy
c Temporary hemorrhage, spontaneously resolved
Table 6 Cost analysis of biopsy
procedures Examinations and costs Standard group
(N = 187 patients)
Core-needle group
(N = 185 patients)
Total no. of biopsy procedures 187 185
Unitary cost for biopsy (€)
Major surgerya 10,393 –
Minor surgeryb 3056 –
Complete US assessment of superficial
and deep-seated nodal areas (€)
– 88
US-guided core-needle cutting biopsy (€) – 83
Average cost of biopsy procedure per patient (€) 4115 171
Total cost of additional surgical biopsies due to
false-negative results (€)c
153,445 6112
Total cost of biopsy program (€) 923,016 37,747
aMajor surgery includes mini-cervicotomy, mediastinotomy and laparotomic bioptic procedure
bMinor surgery includes excisional biopsy of superficial lymph nodes
c Total cost of additional surgical biopsies for the four patients randomized in the core-needle group, but excluded
for inadequate samples, was 41,572 €
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configurations [16]. Thus, it is reasonable to investigate
a front line diagnostic combination of new generation
imaging equipment and technologically refined cutting
needle with large gauge [15].
Our randomized study was an examination of two different
interventionist approaches, one surgery-driven (standard arm)
and the other one hematology-driven (experimental arm), in
patients with lymphadenopathies clinically suspected for lym-
phoma. Traditionally, whole lymph nodes are resected when it
is necessary to determine whether a lymphadenopathy is lym-
phoma or some other conditions, such as metastases of a
nonhematological tumor [1, 2]. In our trial, the entire decision
making process for biopsy in the standard arm was left to the
surgeon’s discretion: the selection of the node to be biopsied
was based on physical examination and gray-scale US [17]. In
the daily diagnostic service of our surgery unit, as in others
[21], power Doppler ultrasonographic technology was limited
in its availability for routine clinical practice. In the experi-
mental arm, the selection of the node to be biopsied and
biopsy itself were exclusively based on the expertise of hema-
tologists. In fact, the hematological unit kept a modern US
equipment available and had it run by experienced operators,
who were members of the hematological staff trained in diag-
nostic PDUS [4, 5]. The goal of the study was to maintain
optimal accuracy of the diagnostic work-up of lymphadenop-
athies, while avoiding psychological and physical pain of an
unnecessary surgical intervention.
The primary endpoint in this trial, a greater sensitivity with
the experimental approach, was proven being the comparison
with standard approach significantly advantageous for PDUS-
guided CNCB. The number of cases in which a definite diag-
nosis of malignancy could not be established at first biopsy
Fig. 2 a Inset: low-power image
(H&E, ×1) of a core-needle
biopsy specimen obtained from a
right iliac lymph node: the core-
needles reveal large follicular
nodules closely packed with a
back-to-back arrangement (H&E,
×20). b The neoplastic lymphoid
follicles are composed of a
uniform, small size, cell
population (H&E, ×40). c, d, e
The immunohistochemical stain
strongly highlights CD20 (c),
CD10 (d), and BCL-2 (e) (ABC,
×40). These samples are large
enough to preserve tissue
architecture and to assess the
diagnosis of follicular lymphoma
Fig. 3 a Inset: low-power image (H&E, ×1) of a core-needle biopsy
specimen obtained from a right latero-cervical lymph node: the core-
needle appears fragmented due to an obvious fibrosis (H&E, ×5). b
Higher power views show several Reed-Sternberg cells (H&E, ×40).
The Reed-Sternberg cells are CD30 (c), CD15 (d), and fascin (e)
positive (ABC, ×40). These samples are large enough to preserve tissue
architecture and to assess the diagnosis of nodular sclerosis classical
Hodgkin lymphoma
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was almost 8 times higher on standard tissue specimens than
core-needle material. As a consequence, the clinicians recom-
mended a re-biopsy (OSB) significantly more often in the
standard group than experimental group, also considering
the four patients with inadequate samples randomized in the
core-needle group (19 vs. 6 cases, respectively; P = 0.006).
Not all lymph nodes may be involved by the main disease
entity. There is a risk of removing satellite reactive lymph
nodes, thus missing the primary diagnosis of a malignant dis-
ease present in another node, which is sometimes deeper
seated or even seated in a different anatomic area. An affected
lymph node may also undergo necrosis and/or steato-fibrotic
changes, which could avert the pathologist from the correct
diagnosis. These are all potential sources of inaccuracy in
standard excisional biopsy [5]. In our study, PDUS technology
accurately selected the most suspected target, imaged all nodal
lesion clearly, and simultaneously monitored the entire punc-
ture process (in both superficial and deep-seated regions). The
cutting needle had a diameter of 1.6 mm with ultrathinner tip
and wall, and powered automatic suction. Although the tissue
volume obtained by CNCB was smaller than OSB, the exper-
imental method provided enough tissue for architectural-
morphologic pattern assessment, immunohistochemical stain-
ing, and/or molecular testing (Figs. 2 and 3) [1].
For all secondary endpoints in this trial, the comparison
was significantly disadvantageous for excisional biopsy.
Compared with PDUS-guided CNCB, standard approach
had significantly more waiting time to allocated intervention-
ist procedure, considerably higher amounts of biopsy-related
complications (analgesia required for postoperative pain was
about 5-fold higher), and extraordinarily higher costs for the
National Healthcare System (performance of one biopsy was
24-fold more expensive with standard approach).
Our study suffers from three major limitations. First, this
trial was conducted in one single center. Therefore, studies
from other institutions are needed to assess (1) interobserver
and interequipment PDUS variability; (2) core-needle speci-
men quality reproducibility, e.g., tissue harvested, size and
preservation; and (3) concordance by pathologists in diagnos-
ing and subtyping lymphoma on core-needle material.
Second, a bias error could have been committed due to a more
accurate selection of nodal target to be biopsied in the core-
needle group leading the study toward a better sensitivity for
experimental arm than standard arm. A factor that may have a
strong influence to explain such bias is the high specialization
(derived from long and extensive experience) [4–8] of hema-
tology team to identify the right lymph node and to biopsy it,
as compared to the surgeons. Finally, the rate of failure with
PDUS-guided CNCB was 1.6% (6/376 patients randomly al-
located to core-needle biopsy procedure). In four patients
(those with inadequate samples), stiffened tissue of nodular
sclerosis Hodgkin lymphoma (documented at re-biopsy)
which was seated in subclavicular area (a particular hindered
region) led to the sampling error of CNCB. For the two false
negative results (benign lymphoid hyperplasia), the final di-
agnosis (at second biopsy) was conclusive for small lympho-
cytic indolent non-Hodgkin lymphoma, suggesting that in
some instances, there is a need of a large amount of lymph
node tissue for correct histological assessment.
To the best of our knowledge, this study is the first to
compare in a randomized fashion the sensitivity of imaging-
guided CNCB and OSB in detecting lymphoma. Under opti-
mal study conditions (avoiding patients with obesity), with
modern US equipment and an experienced operator, core-
needle biopsy is a reliable and cost-effective diagnostic pro-
cedure [22]. Histological patterns of lymphoma are recogniz-
able in core material and are useful in diagnosing and
subtyping according to the current WHO classification of tu-
mors of haematopoietic and lymphoid tissues [1, 15]. A 16-
gauge cutting needle is recommended, and at least two passes
yielding two tissue cores, with total length of 30–60 mm
should be taken. CNCB is less traumatic and well tolerated
by patients. It should be recommended as first-line procedure,
for both superficial and deep-seated lymph nodes, for patients
with a suspected lymphoma, and not merely for patients with
poor medical condition when surgical intervention is not pos-
sible or to document relapse.
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Dear Editor,
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN)
whose pathogenesis mainly involves JAK/STAT signaling;
approximately 65% of patients carry V617F-JAK2 mutation
with a gain-of-function mechanism [1, 2]. Hydroxyurea is
recommended as the first-line therapy for MF in low and
intermediate-1 patients, whereas ruxolitinib, an orally avail-
able and selective JAK2-inhibitor, is recommended in
Internat ional Prognost ic Scor ing System (IPSS)
intermediate-2 and high-risk patients as front-line treatment
of symptoms and splenomegaly in non-transplant candidates
[3].
We describe the case of a 57-year-old Caucasian man with
primary MF (PMF). The patient was 166 cm in height and
weighed 60 kg; before diagnosis, he had been in fair physical
condition. At diagnosis (November 2012), his main symp-
toms were early satiety and a sense of fullness in the left upper
abdomen that rapidly deteriorated into cachexia. His blood
count showed anemia and leukocytosis, and a physical exam-
ination revealed splenomegaly (10 cm from costal margin);
size measured by ultrasound scan [4] was 22 cm (longitudinal
diameter) × 14 cm (transverse diameter) with a spleen volume
of 2700 mL. Bone marrow biopsy demonstrated grade 3 fi-
brosis (MF = 3) and the presence of JAK2-V617Fmutation. In
December 2012, cytoreductive therapy with hydroxyurea (1
and 2 capsules daily on alternate days) was started, obtaining a
stable disease for fewmonths. After 3months, systemic symp-
toms and splenomegaly worsened. The patient was cachectic,
his weight had fallen to 47 kg, and his spleen was of hard
consistency and had enlarged, extending to the iliac fossa.
He had lack of appetite, he was having difficulty eating, and
his quality of life had deteriorated badly. The severity of the
patient’s condition led to the consideration of other treatment
options.
The patient refused allogeneic stem cell transplantation af-
ter becoming aware of transplant-related risks and peri-
transplant mortality. Therefore, treatment with ruxolitinib
was initiated, initially at 10 mg twice daily (bid), and reduced
to 5 mg bid in response to grade 3 thrombocytopenia. The
patient experienced only partial relief from symptoms and,
in September 2014, ruxolitinib was discontinued due to severe
leukocytosis and very poor compliance. After hydroxyurea
was reintroduced to control leukocytosis, there was a consid-
erable increase in the need for blood transfusions over subse-
quent months (up to 8 units/month; Fig. 1) and spleen size
increased, reaching 27.8 cm longitudinal diameter. Following
poor compliance with gastroprotective drugs, the patient re-
quired hospitalization in April 2015 for gastric bleeding, and
hydroxyurea therapy was stopped due to severe anemia and
thrombocytopenia (30,000/mm3).
Hydroxyurea was reintroduced with palliative intent after
1 month and, in June 2015, low-dose ruxolitinib (5 mg bid)
rechallenge was undertaken, in combination with hydroxy-
urea (1 and 2 capsules daily on alternate days for 5 days/
week). The ruxolitinib dose was increased to 10 mg bid after
1 month, and after 2 months (September 2015), the patient
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experienced a dramatic reduction in spleen size with substan-
tial relief from symptomatic splenomegaly (longitudinal diam-
eter 15.6 cm), control of anemia and leukocytosis, and im-
proved nutritional status, with an increase in appetite and an
increase in weight to 55 kg. He regained a decent quality of
life and was able to resume routine activities, such as
shopping.
Resolution of cachexia and substantial improvement in
clinical status continued and, as of May 2016, the patient
was continuing combination treatment with ruxolitinib
(10 mg bid) and hydroxyurea.
Single-agent ruxolitinib is effective in improving spleno-
megaly, systemic symptoms, and overall survival, compared
with placebo and standard treatment, in patients with
intermediate-2 or high-risk MF [5, 6]. As with hydroxyurea,
significant anemia and thrombocytopenia are the most com-
mon side effects, often requiring discontinuation [7].
However, despite the combination of ruxolitinib with a
cytoreductive agent, we obtained control of leukocytosis and
anemia with concurrent increase in platelet count to stable nor-
mal values, without the expected synergic cytotoxic effects. Of
interest, the safe and effective use of combination of ruxolitinib
plus hydroxyurea in reducing platelet count and splenomegaly
in a patient with uncontrolled thrombocytosis on ruxolitinib
monotherapy has been described [8]. Furthermore, in addition
to its primary anti-myeloproliferative action via JAK2 inhibi-
tion, ruxolitinib appears to exert a remarkable improvement in
cachexia status [9], as observed in our case.
In conclusion, combined ruxolitinib plus hydroxyurea ef-
fectively controlled myeloproliferation without worsening
anemia, instead leading to a remarkable decrease in the need
for blood transfusions. Our patient’s cachectic status was
reverted, and overall quality of life dramatically improved.
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Key Clinical Message
In this report, we would like to highlight the efficacy of bendamustine in a
heavily pretreated patient, also refractory to pomalidomide. It is conceivable
that different therapy combinations in heavily treated Multiple myeloma (MM)
have to be explored, without “a priori” exclusion of ancient drugs, even after
failure of the ultimate pharmacological options.
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Introduction
Multiple myeloma (MM) is a clonal malignant disorder
derived from an abnormal plasma cell proliferation in the
bone marrow that causes anemia, bones lytic lesions and
renal injury. If the neoplasm is limited to a restricted
area, as bone marrow or soft tissues, it is defined as plas-
macytoma.
The natural history of MM has recurrences of active
disease defined as relapse when salvage treatment is
needed after an off-therapy period, or refractory disease if
nonresponsive during therapy, or progressing within
60 days of last therapy.
In spite of the fact that MM is still an incurable dis-
ease, treatment strategies have improved survival in the
last decades [1], thanks to the availability of novel agents
as proteasome inhibitors (bortezomib, carfilzomib) and
immunomodulatory drugs (IMiDs; thalidomide, lenalido-
mide, and pomalidomide).
In this scenario, the role of many drugs used as sal-
vage therapy after several lines including novel agents in
the relapsing/refractory MM is currently undergoing
evaluation and, although many new molecules appear
promising, their efficacy is still unclear and not always
predictable.
Bendamustine is a nitrogen mustard with both purine-
analogue and alkylating agent mechanisms; it is widely
used in the treatment of chronic lymphocytic leukemia
and low-grade lymphomas, but is also approved in Eur-
ope as single agent and in several combinations with ster-
oid or novel agents (bortezomib, thalidomide, and
lenalidomide) for the treatment of relapsed/refractory
MM, especially in heavily pretreated patients [2].
In this report, we describe the efficacy of bendamustine
combined with bortezomib and dexamethasone (BVD) in
a male patient with a long story of relapsed/refractory
MM, previously treated with all available drugs, also
refractory to pomalidomide, the most recent available
IMiDs [3].
Case Presentation
A 70-year-old man was diagnosed with a scantly secretory
IgA kappa MM in April 2008, evolved by IgA MGUS rec-
ognized 5 years before. At the time of the evaluation,
Durie-Salmon stage was IIIA and ISS was I; PET-CT
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showed several areas of intense focal bone involvement.
Therapy with thalidomide and dexamethasone (TD) was
performed, resulting in a symptomatic stable disease
(SD), with persistent positive PET-CT in the same bone
regions plus a new localization on sternum. Second-line
therapy with bortezomib–dexamethasone (VD) for three
cycles until March 2009 was performed, but a CT showed
heteroplastic tissue wrapping up D2-D3 vertebra; PET-CT
was positive in the same sites. Third-line therapy consist-
ing in lenalidomide/dexamethasone (RD) for five cycles +
radiotherapy on D2-D3 was carried out and was followed,
in September 2009, by autologous stem cell transplanta-
tion after conditioning with high-dose melphalan
(200 mg/m²), and 2 years of interferon (IFN-a2br) main-
tenance therapy in very good partial response (VGPR). In
March 2012, a new relapse in the right shoulder (con-
firmed by PET-CT) led further radiotherapy, and the
patient remained free of disease for more than 3 years
without maintenance. In August 2015, a wide and hard-
consistency lump appeared in the upper-left quadrant of
the abdomen, together with a rising of the Bence-Jones
protein urinary concentration (573 mg/L). Ultrasound
scan showed a vascularized mass surrounding and adher-
ent to the small bowel and mesentery. Fine-needle aspira-
tion cytology (FNAC) was performed on the mass,
showing clonal plasma cells and allowing diagnosis of
extramedullary plasmocytoma. Consequently, salvage
therapy with CED (cyclophosphamide, doxorubicin and
dexamethasone) [4] plus radiotherapy on the mass was
performed in September 2015, but it was interrupted after
the first course due to marrow toxicity (grade III throm-
bocytopenia). Volume and solidity of the mass were
reduced, but Bence-Jonesprotein increased (progressive
disease, PD). Hence, in January 2016, the patient was
switched to pomalidomide and dexamethasone, but, after
the first course, the disease still progressed.
In February 2016, a seventh-line salvage treatment was
performed employing bendamustine, bortezomib, dexam-
ethasone (BVD: bendamustine 90 mg/sqm IV days 1 and
2, bortezomib 1.3 mg/mq s.c. days 1, 4, 8, 11, dexametha-
sone 20 mg oral solution/IV days 1, 2, 4, 5, 8, 9, 11, 12
and pegfilgrastim 6 mg s.c. day 4, every 28 days) [5] with
the unexpected result of a VGPR, achieved after only one
course of treatment, and reduction of more than 90%
of urinary K chain concentration and dramatic shrinkage
of the abdominal tumor mass. Unfortunately, the
patient died before the second course due to progressive
cachexia.
Discussion
Although multiple myeloma is defined as a noncurable
disease, nowadays its prognosis is significantly better
thanks to a wide spectrum of active drugs. Hence, we
often have to face long-survivor patients receiving several
lines of therapy, raising questions on how to combine
different treatments and how to manage sequential
effects.
Nowadays, available treatments for relapsed/refractory
MM are as follows: rechallenge with previously used
agents (bortezomib- or IMID-based treatments), with or
without autologous bone marrow transplantation, new-
generation IMIDs (pomalidomide), bendamustine-based
treatments, or other alkylating agents. Another option,
waiting for new drugs, such as new-generation proteo-
some inhibitors (carfilzomib) and monoclonal antibodies
(daratumumab and elotuzumab), are combinations of
previously used agents, which often demonstrate a syner-
gistic effect also in refractory and heavily pretreated
patients.
In this report, we would like to highlight the efficacy
of bendamustine in a heavily pretreated patient, also
refractory to pomalidomide, the newest available IMiDs.
To our knowledge, this sequence of treatment has never
been reported before. Moreover, it is relevant the clinical
setting where these drugs were administered, as MM
finally progressed to massive extramedullary plasmacy-
toma (intra-abdominal mass), suggesting that changing
in the disease site, hence of disease biology, could have
also affected the response to the therapies, particularly
active in the lymphoma context [6]. It is conceivable
that different therapy combinations in heavily treated
MM have to be explored, without “a priori” exclusion
of ancient drugs, even after failure of the ultimate phar-
macological options.
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